score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.2683	41.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	STAD_MUTECT2	TCGA-BR-7707-01A-11D-2053-08	TCGA-BR-7707-10A-01D-2053-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.3404	47.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	STAD_MUTECT2	TCGA-VQ-A8PU-01A-12D-A410-08	TCGA-VQ-A8PU-10B-01D-A413-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.3333	27.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	STAD_MUTECT2	TCGA-CD-A4MJ-01A-11D-A25D-08	TCGA-CD-A4MJ-10A-01D-A25E-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.3158	76.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	STAD_MUTECT2	TCGA-CG-5727-01A-11D-1600-08	TCGA-CG-5727-11A-01D-1600-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.4762	21.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	STAD_MUTECT2	TCGA-B7-A5TK-01A-12D-A31L-08	TCGA-B7-A5TK-10A-01D-A31J-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12C	0.2273	22.0	0.0	0.0		Putatively Actionable	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12C (Missense)	1	STAD_MUTECT2	TCGA-BR-6802-01A-11D-1882-08	TCGA-BR-6802-10A-01D-1882-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.274	73.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	STAD_MUTECT2	TCGA-SW-A7EA-01A-12D-A34U-08	TCGA-SW-A7EA-10A-01D-A34X-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.0909	55.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	STAD_MUTECT2	TCGA-CD-5798-01A-11D-1600-08	TCGA-CD-5798-10A-01D-1600-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.2333	30.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	STAD_MUTECT2	TCGA-BR-8059-01A-11D-2340-08	TCGA-BR-8059-10A-01D-2340-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.2308	26.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	STAD_MUTECT2	TCGA-BR-7703-01A-11D-2053-08	TCGA-BR-7703-10A-01D-2053-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.25	28.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4118	136.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	STAD_MUTECT2	TCGA-HJ-7597-01A-21D-2201-08	TCGA-HJ-7597-10A-01D-2201-08
Putatively Actionable	Preclinical	Preclinical		Somatic Variant	MAP2K1	Missense	p.C121S	0.2041	98.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Putatively Actionable	Vemurafenib	B-RAF inhibition	Targeted therapy	MEK1 C121S confers resistance to monotherapy with RAF or MEK inhibitors in vitro.	Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-96.	https://doi.org/10.1200/JCO.2010.33.2312										MAP2K1 p.C121S (Missense)	0	STAD_MUTECT2	TCGA-BR-8683-01A-11D-2394-08	TCGA-BR-8683-10A-01D-2394-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.2083	72.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	STAD_MUTECT2	TCGA-HU-A4H3-01A-21D-A25D-08	TCGA-HU-A4H3-10A-01D-A25E-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.1739	46.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	STAD_MUTECT2	TCGA-RD-A8NB-01A-12D-A397-08	TCGA-RD-A8NB-10A-01D-A39A-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.C420R	0.4194	93.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.C420R (Missense)	1	STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.2889	45.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	STAD_MUTECT2	TCGA-FP-7916-01A-11D-2201-08	TCGA-FP-7916-10A-01D-2201-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.2214	140.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	STAD_MUTECT2	TCGA-HU-A4H4-01A-21D-A25D-08	TCGA-HU-A4H4-11A-11D-A25E-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.Y1021C	0.1972	71.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Y1021C (Missense)	1	STAD_MUTECT2	TCGA-BR-6454-01A-11D-1800-08	TCGA-BR-6454-11A-01D-1800-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047Y	0.1264	87.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047Y (Missense)	1	STAD_MUTECT2	TCGA-BR-8081-01A-11D-2340-08	TCGA-BR-8081-10A-01D-2340-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.3455	55.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	STAD_MUTECT2	TCGA-HU-A4GU-01A-11D-A25D-08	TCGA-HU-A4GU-10A-01D-A25E-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.3415	41.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	STAD_MUTECT2	TCGA-VQ-A91E-01A-31D-A410-08	TCGA-VQ-A91E-10A-01D-A413-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.C420R	0.2549	102.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.C420R (Missense)	1	STAD_MUTECT2	TCGA-BR-6455-01A-11D-1800-08	TCGA-BR-6455-10A-01D-1800-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.1402	107.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	STAD_MUTECT2	TCGA-CG-5722-01A-21D-1600-08	TCGA-CG-5722-11A-02D-1600-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.4056	143.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	STAD_MUTECT2	TCGA-CG-4442-01A-01D-1158-08	TCGA-CG-4442-10A-01D-1158-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.3008	123.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	STAD_MUTECT2	TCGA-BR-8360-01A-11D-2340-08	TCGA-BR-8360-10A-01D-2340-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.2326	86.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	STAD_MUTECT2	TCGA-BR-4371-01A-01D-1158-08	TCGA-BR-4371-11A-01D-1158-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.1695	118.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	STAD_MUTECT2	TCGA-BR-4371-01A-01D-1158-08	TCGA-BR-4371-11A-01D-1158-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.5641	78.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	STAD_MUTECT2	TCGA-BR-8676-01A-11D-2394-08	TCGA-BR-8676-10A-01D-2394-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.1684	95.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	STAD_MUTECT2	TCGA-D7-6815-01A-11D-1882-08	TCGA-D7-6815-10A-01D-1882-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.1333	45.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	STAD_MUTECT2	TCGA-D7-A747-01A-22D-A33T-08	TCGA-D7-A747-10A-21D-A33W-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.1447	76.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.1	100.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	STAD_MUTECT2	TCGA-CD-A4MI-01A-21D-A25D-08	TCGA-CD-A4MI-10A-01D-A25E-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.2203	59.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	STAD_MUTECT2	TCGA-CG-4474-01A-02D-1158-08	TCGA-CG-4474-10A-01D-1158-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.1961	102.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	STAD_MUTECT2	TCGA-CG-4305-01A-01D-1158-08	TCGA-CG-4305-10A-01D-1158-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.4091	44.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.4792	48.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	STAD_MUTECT2	TCGA-VQ-AA69-01A-11D-A410-08	TCGA-VQ-AA69-10A-01D-A413-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.3291	79.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	STAD_MUTECT2	TCGA-BR-7851-01A-11D-2201-08	TCGA-BR-7851-10A-01D-2201-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545G	0.1101	109.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545G (Missense)	1	STAD_MUTECT2	TCGA-BR-6802-01A-11D-1882-08	TCGA-BR-6802-10A-01D-1882-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.2	65.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	STAD_MUTECT2	TCGA-HU-A4GX-01A-12D-A25D-08	TCGA-HU-A4GX-10A-01D-A25E-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.383	47.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.25	92.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.C420R	0.2895	190.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.C420R (Missense)	1	STAD_MUTECT2	TCGA-CG-5733-01A-11D-1600-08	TCGA-CG-5733-11A-01D-1600-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.233	103.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.G1049R	0.4231	52.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.G1049R (Missense)	1	STAD_MUTECT2	TCGA-VQ-A91K-01A-11D-A410-08	TCGA-VQ-A91K-10A-01D-A413-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.4239	184.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	STAD_MUTECT2	TCGA-B7-5818-01A-11D-1600-08	TCGA-B7-5818-10A-01D-1600-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.1818	44.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	STAD_MUTECT2	TCGA-VQ-A91W-01A-11D-A410-08	TCGA-VQ-A91W-10A-01D-A413-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.M1043I	0.6357	140.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.M1043I (Missense)	1	STAD_MUTECT2	TCGA-D7-5577-01A-01D-1600-08	TCGA-D7-5577-10A-01D-1600-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.0833	120.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	STAD_MUTECT2	TCGA-D7-5578-01A-01D-1600-08	TCGA-D7-5578-10A-01D-1600-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.4519	104.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	STAD_MUTECT2	TCGA-BR-6707-01A-11D-1882-08	TCGA-BR-6707-10A-01D-1882-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.4048	42.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	STAD_MUTECT2	TCGA-VQ-AA6K-01A-11D-A410-08	TCGA-VQ-AA6K-10A-01D-A413-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.3895	95.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	STAD_MUTECT2	TCGA-HF-A5NB-01A-11D-A31L-08	TCGA-HF-A5NB-10A-01D-A31J-08
Putatively Actionable	Preclinical			Somatic Variant	AKT1	Missense	p.E17K	0.1042	48.0	0.0	0.0		Putatively Actionable	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.E17K (Missense)	0	STAD_MUTECT2	TCGA-BR-6852-01A-11D-1882-08	TCGA-BR-6852-10A-01D-1882-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.M550I	0.5909	88.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.M550I (Missense)	1	STAD_MUTECT2	TCGA-VQ-AA68-01A-11D-A410-08	TCGA-VQ-AA68-10A-01D-A413-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.A305V	0.2944	197.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.A305V (Missense)	1	STAD_MUTECT2	TCGA-CG-4465-01A-01D-1158-08	TCGA-CG-4465-10A-01D-1158-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.D594N	0.1083	120.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.D594N (Missense)	1	STAD_MUTECT2	TCGA-HF-7131-01A-11D-2053-08	TCGA-HF-7131-10A-01D-2053-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.M517V	0.2099	81.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.M517V (Missense)	1	STAD_MUTECT2	TCGA-MX-A5UJ-01A-11D-A31L-08	TCGA-MX-A5UJ-10A-01D-A31J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.G469A	0.275	80.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.G469A (Missense)	1	STAD_MUTECT2	TCGA-VQ-A8PO-01A-11D-A410-08	TCGA-VQ-A8PO-10A-01D-A413-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.G563C	0.32	50.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.G563C (Missense)	1	STAD_MUTECT2	TCGA-HU-A4G9-01A-11D-A24D-08	TCGA-HU-A4G9-10A-01D-A24F-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.H568D	0.1972	71.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.H568D (Missense)	1	STAD_MUTECT2	TCGA-F1-A448-01A-11D-A24D-08	TCGA-F1-A448-10A-01D-A24F-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.A762V	0.1007	407.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.A762V (Missense)	1	STAD_MUTECT2	TCGA-BR-8059-01A-11D-2340-08	TCGA-BR-8059-10A-01D-2340-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.K601T	0.1605	81.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.K601T (Missense)	1	STAD_MUTECT2	TCGA-BR-8366-01A-11D-2340-08	TCGA-BR-8366-10A-01D-2341-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.A712T	0.197	132.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.A712T (Missense)	1	STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.T638M	0.2923	65.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.T638M (Missense)	1	STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.R224H	0.1117	179.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.R224H (Missense)	1	STAD_MUTECT2	TCGA-VQ-A8PX-01A-12D-A410-08	TCGA-VQ-A8PX-10A-01D-A413-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.G239S	0.1	150.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.G239S (Missense)	1	STAD_MUTECT2	TCGA-RD-A7BT-01A-11D-A33T-08	TCGA-RD-A7BT-10A-01D-A33W-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.R252H	0.32	125.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.R252H (Missense)	1	STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P644L	0.3333	63.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P644L (Missense)	1	STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Nonsense	p.R531*	0.2818	330.0	0.0	0.0		Investigate Actionability	Afatinib	EGFR inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions.	Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.R531* (Nonsense)	1	STAD_MUTECT2	TCGA-CG-5726-01A-11D-1600-08	TCGA-CG-5726-11A-01D-1600-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.I351V	0.1325	151.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.I351V (Missense)	1	STAD_MUTECT2	TCGA-CD-A4MI-01A-21D-A25D-08	TCGA-CD-A4MI-10A-01D-A25E-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.F1151L	0.55	40.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.F1151L (Missense)	1	STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.R252H	0.377	122.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.R252H (Missense)	1	STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P937L	0.2034	59.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P937L (Missense)	1	STAD_MUTECT2	TCGA-BR-7851-01A-11D-2201-08	TCGA-BR-7851-10A-01D-2201-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.V85M	0.0625	144.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.V85M (Missense)	1	STAD_MUTECT2	TCGA-D7-6521-01A-11D-1800-08	TCGA-D7-6521-10A-01D-1800-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Nonsense	p.R1068*	0.2609	46.0	0.0	0.0		Investigate Actionability	Afatinib	EGFR inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions.	Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.R1068* (Nonsense)	1	STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.A920S	0.2869	122.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.A920S (Missense)	1	STAD_MUTECT2	TCGA-B7-A5TI-01A-11D-A31L-08	TCGA-B7-A5TI-10A-01D-A31J-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.R324H	0.4318	44.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.R324H (Missense)	1	STAD_MUTECT2	TCGA-FP-7829-01A-11D-2053-08	TCGA-FP-7829-10A-01D-2053-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.T430I	0.2405	79.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.T430I (Missense)	1	STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.A895T	0.25	80.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.A895T (Missense)		STAD_MUTECT2	TCGA-HU-A4GU-01A-11D-A25D-08	TCGA-HU-A4GU-10A-01D-A25E-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.S43I	0.7368	19.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.S43I (Missense)		STAD_MUTECT2	TCGA-HU-A4H5-01A-21D-A25D-08	TCGA-HU-A4H5-11A-11D-A25E-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.V64A	0.2941	85.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.V64A (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.E386K	0.3423	111.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.E386K (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.E740K	0.4737	19.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.E740K (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.V845A	0.0526	152.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.V845A (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.S251R	0.0612	49.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.S251R (Missense)		STAD_MUTECT2	TCGA-BR-8486-01A-31D-2394-08	TCGA-BR-8486-10A-01D-2394-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.V20I	0.1458	48.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.V20I (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.R608Q	0.2586	58.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.R608Q (Missense)		STAD_MUTECT2	TCGA-VQ-A8E3-01A-11D-A397-08	TCGA-VQ-A8E3-10A-01D-A39A-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.E53G	0.2466	73.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.E53G (Missense)		STAD_MUTECT2	TCGA-BR-8687-01A-11D-2394-08	TCGA-BR-8687-10A-01D-2394-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.D439H	0.2667	45.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.D439H (Missense)		STAD_MUTECT2	TCGA-BR-8683-01A-11D-2394-08	TCGA-BR-8683-10A-01D-2394-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.M662T	0.1236	89.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.M662T (Missense)		STAD_MUTECT2	TCGA-CG-4305-01A-01D-1158-08	TCGA-CG-4305-10A-01D-1158-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Frameshift	p.F711Lfs*24	0.1172	128.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.F711Lfs*24 (Frameshift)		STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.R5C	0.439	41.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.R5C (Missense)		STAD_MUTECT2	TCGA-HU-A4G9-01A-11D-A24D-08	TCGA-HU-A4G9-10A-01D-A24F-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.A219G	0.0833	48.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.A219G (Missense)		STAD_MUTECT2	TCGA-RD-A8MW-01A-11D-A364-08	TCGA-RD-A8MW-10A-01D-A362-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.Y362C	0.4028	72.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.Y362C (Missense)		STAD_MUTECT2	TCGA-CG-5733-01A-11D-1600-08	TCGA-CG-5733-11A-01D-1600-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.K642N	0.12	75.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.K642N (Missense)		STAD_MUTECT2	TCGA-BR-8059-01A-11D-2340-08	TCGA-BR-8059-10A-01D-2340-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.R18C	0.0903	277.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.R18C (Missense)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	FDA-Approved			Somatic Variant	MET	Nonsense	p.R547*	0.4824	170.0	0.0	0.0		Investigate Actionability	Capmatinib	MET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Revised May 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf																	MET p.R547* (Nonsense)		STAD_MUTECT2	TCGA-HU-A4H3-01A-21D-A25D-08	TCGA-HU-A4H3-10A-01D-A25E-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.V277M	0.25	36.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.V277M (Missense)		STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.A265V	0.3103	29.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.A265V (Missense)		STAD_MUTECT2	TCGA-BR-8360-01A-11D-2340-08	TCGA-BR-8360-10A-01D-2340-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.V329A	0.3019	53.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.V329A (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.L752F	0.3333	15.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.L752F (Missense)		STAD_MUTECT2	TCGA-3M-AB46-01A-11D-A410-08	TCGA-3M-AB46-10A-01D-A413-08
Investigate Actionability	FDA-Approved			Somatic Variant	MET	Nonsense	p.C1319*	0.4433	97.0	0.0	0.0		Investigate Actionability	Capmatinib	MET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Revised May 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf																	MET p.C1319* (Nonsense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.G549R	0.1143	35.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.G549R (Missense)		STAD_MUTECT2	TCGA-VQ-A8E3-01A-11D-A397-08	TCGA-VQ-A8E3-10A-01D-A39A-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.A569V	0.1833	60.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.A569V (Missense)		STAD_MUTECT2	TCGA-CG-4444-01A-01D-1158-08	TCGA-CG-4444-10A-01D-1158-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.V73A	0.4286	56.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.V73A (Missense)		STAD_MUTECT2	TCGA-VQ-A8PB-01A-11D-A397-08	TCGA-VQ-A8PB-10A-01D-A39A-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.D580N	0.201	209.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.D580N (Missense)		STAD_MUTECT2	TCGA-MX-A5UJ-01A-11D-A31L-08	TCGA-MX-A5UJ-10A-01D-A31J-08
Investigate Actionability	FDA-Approved			Somatic Variant	MET	Splice Site	p.X1211_splice	0.2326	43.0	0.0	0.0		Investigate Actionability	Capmatinib	MET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Revised May 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf																	MET p.X1211_splice (Splice Site)		STAD_MUTECT2	TCGA-BR-6566-01A-11D-1800-08	TCGA-BR-6566-10A-01D-1800-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E141K	0.3073	192.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E141K (Missense)	0	STAD_MUTECT2	TCGA-BR-4362-01A-01D-1158-08	TCGA-BR-4362-11A-01D-1158-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.T134M	0.2639	144.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.T134M (Missense)	0	STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.V743A	0.2936	109.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.V743A (Missense)	0	STAD_MUTECT2	TCGA-HU-A4GU-01A-11D-A25D-08	TCGA-HU-A4GU-10A-01D-A25E-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.V1084M	0.0559	161.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.V1084M (Missense)	0	STAD_MUTECT2	TCGA-BR-8676-01A-11D-2394-08	TCGA-BR-8676-10A-01D-2394-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.I449V	0.3137	102.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.I449V (Missense)	0	STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.L506I	0.3521	71.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.L506I (Missense)	0	STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.A612T	0.3851	161.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.A612T (Missense)	0	STAD_MUTECT2	TCGA-CG-5726-01A-11D-1600-08	TCGA-CG-5726-11A-01D-1600-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.G313V	0.1183	93.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.G313V (Missense)	0	STAD_MUTECT2	TCGA-D7-8572-01A-11D-2340-08	TCGA-D7-8572-10A-01D-2341-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.G729V	0.449	49.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.G729V (Missense)	0	STAD_MUTECT2	TCGA-HU-A4H8-01A-11D-A25D-08	TCGA-HU-A4H8-10A-01D-A25E-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.D154Y	0.1447	76.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.D154Y (Missense)	0	STAD_MUTECT2	TCGA-R5-A7ZE-01B-11D-A34U-08	TCGA-R5-A7ZE-10A-01D-A34X-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.V282A	0.2025	79.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.V282A (Missense)	0	STAD_MUTECT2	TCGA-HF-7132-01A-11D-2053-08	TCGA-HF-7132-10A-01D-2053-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.G430E	0.1806	72.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.G430E (Missense)	0	STAD_MUTECT2	TCGA-BR-8382-01A-11D-2394-08	TCGA-BR-8382-10A-01D-2394-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.1667	18.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	STAD_MUTECT2	TCGA-HU-A4H3-01A-21D-A25D-08	TCGA-HU-A4H3-10A-01D-A25E-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.25	40.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	STAD_MUTECT2	TCGA-BR-4201-01A-01D-1126-08	TCGA-BR-4201-11A-01D-1126-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.A59T	0.25	52.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.A59T (Missense)	1	STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.4516	31.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.3684	19.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	STAD_MUTECT2	TCGA-BR-4368-01A-01D-1158-08	TCGA-BR-4368-11A-01D-1158-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.A59T	0.3103	58.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.A59T (Missense)	1	STAD_MUTECT2	TCGA-VQ-A91E-01A-31D-A410-08	TCGA-VQ-A91E-10A-01D-A413-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.1724	29.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	STAD_MUTECT2	TCGA-CG-4442-01A-01D-1158-08	TCGA-CG-4442-10A-01D-1158-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.A146T	0.2793	111.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.A146T (Missense)	1	STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.R151T	0.2927	82.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.R151T (Missense)	1	STAD_MUTECT2	TCGA-3M-AB46-01A-11D-A410-08	TCGA-3M-AB46-10A-01D-A413-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.6667	33.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	STAD_MUTECT2	TCGA-BR-8078-01A-11D-2340-08	TCGA-BR-8078-10A-01D-2340-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.3529	34.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	STAD_MUTECT2	TCGA-BR-8368-01A-11D-2340-08	TCGA-BR-8368-10A-01D-2341-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12S	0.5455	44.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12S (Missense)	1	STAD_MUTECT2	TCGA-BR-A4CQ-01A-12D-A25D-08	TCGA-BR-A4CQ-10A-01D-A25E-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12S	0.32	25.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12S (Missense)	1	STAD_MUTECT2	TCGA-BR-8687-01A-11D-2394-08	TCGA-BR-8687-10A-01D-2394-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.Q61H	0.284	81.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.Q61H (Missense)	1	STAD_MUTECT2	TCGA-BR-8370-01A-11D-2340-08	TCGA-BR-8370-10A-01D-2341-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.3333	12.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	STAD_MUTECT2	TCGA-BR-4257-01A-01D-1126-08	TCGA-BR-4257-11A-01D-1126-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.2581	31.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	STAD_MUTECT2	TCGA-EQ-A4SO-01A-11D-A25D-08	TCGA-EQ-A4SO-10A-01D-A25E-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.A59T	0.2131	61.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.A59T (Missense)	1	STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.8667	15.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	STAD_MUTECT2	TCGA-CD-8535-01A-11D-2340-08	TCGA-CD-8535-10A-01D-2341-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.8293	41.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	STAD_MUTECT2	TCGA-VQ-AA69-01A-11D-A410-08	TCGA-VQ-AA69-10A-01D-A413-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.A146T	0.6667	219.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.A146T (Missense)	1	STAD_MUTECT2	TCGA-D7-A74A-01A-11D-A32N-08	TCGA-D7-A74A-10A-21D-A32N-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12S	0.0614	342.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12S (Missense)	1	STAD_MUTECT2	TCGA-BR-8679-01A-11D-2394-08	TCGA-BR-8679-10A-01D-2394-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.75	28.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	STAD_MUTECT2	TCGA-BR-4267-01A-01D-1126-08	TCGA-BR-4267-11A-01D-1126-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.3088	68.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	STAD_MUTECT2	TCGA-VQ-A94T-01A-11D-A410-08	TCGA-VQ-A94T-10A-01D-A413-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.A146T	0.2988	164.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.A146T (Missense)	1	STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12S	0.45	20.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12S (Missense)	1	STAD_MUTECT2	TCGA-B7-A5TJ-01A-11D-A31L-08	TCGA-B7-A5TJ-10A-01D-A31J-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.Q61H	0.4615	65.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.Q61H (Missense)	1	STAD_MUTECT2	TCGA-BR-8366-01A-11D-2340-08	TCGA-BR-8366-10A-01D-2341-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.2174	23.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	STAD_MUTECT2	TCGA-BR-4280-01A-01D-1126-08	TCGA-BR-4280-11A-01D-1126-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.R135T	0.0481	478.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.R135T (Missense)	1	STAD_MUTECT2	TCGA-BR-6705-01A-12D-1882-08	TCGA-BR-6705-10A-01D-1882-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.5625	16.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	STAD_MUTECT2	TCGA-HF-A5NB-01A-11D-A31L-08	TCGA-HF-A5NB-10A-01D-A31J-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.Q1500*	0.3937	254.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.Q1500* (Nonsense)		STAD_MUTECT2	TCGA-BR-6454-01A-11D-1800-08	TCGA-BR-6454-11A-01D-1800-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.E343Rfs*5	0.2881	59.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.E343Rfs*5 (Frameshift)		STAD_MUTECT2	TCGA-RD-A8MV-01A-11D-A364-08	TCGA-RD-A8MV-10A-01D-A362-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.T1745Dfs*4	0.4783	23.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.T1745Dfs*4 (Frameshift)		STAD_MUTECT2	TCGA-D7-8575-01A-11D-2340-08	TCGA-D7-8575-10A-01D-2341-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.R329Kfs*8	0.1169	77.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R329Kfs*8 (Frameshift)		STAD_MUTECT2	TCGA-BR-4370-01A-01D-1158-08	TCGA-BR-4370-11A-01D-1158-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R2598*	0.2308	39.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R2598* (Nonsense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R2763*	0.2258	217.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R2763* (Nonsense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.S1403Afs*3	0.2667	45.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.S1403Afs*3 (Frameshift)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.I1581Nfs*5	0.1176	170.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.I1581Nfs*5 (Frameshift)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.K1904Nfs*13	0.375	48.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.K1904Nfs*13 (Frameshift)		STAD_MUTECT2	TCGA-BR-8368-01A-11D-2340-08	TCGA-BR-8368-10A-01D-2341-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.K2811Sfs*46	0.1447	76.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.K2811Sfs*46 (Frameshift)		STAD_MUTECT2	TCGA-VQ-AA6D-01A-11D-A410-08	TCGA-VQ-AA6D-10A-01D-A413-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.S214Pfs*16	0.2222	72.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.S214Pfs*16 (Frameshift)		STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.K2811Vfs*3	0.7571	70.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.K2811Vfs*3 (Frameshift)		STAD_MUTECT2	TCGA-HU-8249-01A-11D-2340-08	TCGA-HU-8249-10A-01D-2341-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.T1399Pfs*3	0.2727	33.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.T1399Pfs*3 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4GX-01A-12D-A25D-08	TCGA-HU-A4GX-10A-01D-A25E-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.K2811Sfs*46	0.1965	173.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.K2811Sfs*46 (Frameshift)		STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Splice Site	p.X2151_splice	0.1056	161.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.X2151_splice (Splice Site)		STAD_MUTECT2	TCGA-CD-5798-01A-11D-1600-08	TCGA-CD-5798-10A-01D-1600-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.K2811Sfs*46	0.4	85.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.K2811Sfs*46 (Frameshift)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.Q2971*	0.1587	63.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.Q2971* (Nonsense)		STAD_MUTECT2	TCGA-BR-A4J7-01A-31D-A25D-08	TCGA-BR-A4J7-10A-01D-A25E-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.S1455Vfs*3	0.4333	90.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.S1455Vfs*3 (Frameshift)		STAD_MUTECT2	TCGA-BR-8361-01A-11D-2340-08	TCGA-BR-8361-10A-01D-2340-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.Q499*	0.2409	137.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.Q499* (Nonsense)		STAD_MUTECT2	TCGA-HF-A5NB-01A-11D-A31L-08	TCGA-HF-A5NB-10A-01D-A31J-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.V706M	0.4	35.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.V706M (Missense)		STAD_MUTECT2	TCGA-CD-A48C-01A-11D-A24D-08	TCGA-CD-A48C-10A-01D-A24F-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.S2695*	0.4924	132.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S2695* (Nonsense)		STAD_MUTECT2	TCGA-IN-A6RL-01A-11D-A32N-08	TCGA-IN-A6RL-10A-01D-A32N-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.T451M	0.2459	183.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.T451M (Missense)		STAD_MUTECT2	TCGA-D7-A4YV-01A-11D-A25D-08	TCGA-D7-A4YV-10A-01D-A25E-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.A793T	0.2034	59.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.A793T (Missense)		STAD_MUTECT2	TCGA-HU-A4GU-01A-11D-A25D-08	TCGA-HU-A4GU-10A-01D-A25E-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.L319F	0.1875	16.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.L319F (Missense)		STAD_MUTECT2	TCGA-BR-8360-01A-11D-2340-08	TCGA-BR-8360-10A-01D-2340-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.P613L	0.25	24.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.P613L (Missense)		STAD_MUTECT2	TCGA-BR-8372-01A-11D-2340-08	TCGA-BR-8372-10A-01D-2341-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.N448S	0.1864	118.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.N448S (Missense)		STAD_MUTECT2	TCGA-VQ-A8E3-01A-11D-A397-08	TCGA-VQ-A8E3-10A-01D-A39A-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.G69D	0.1358	81.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.G69D (Missense)		STAD_MUTECT2	TCGA-FP-8099-01A-11D-2340-08	TCGA-FP-8099-10A-01D-2341-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.K907T	0.2727	22.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.K907T (Missense)		STAD_MUTECT2	TCGA-VQ-A91S-01A-11D-A410-08	TCGA-VQ-A91S-10A-01D-A413-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.R205G	0.125	64.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.R205G (Missense)		STAD_MUTECT2	TCGA-CG-4305-01A-01D-1158-08	TCGA-CG-4305-10A-01D-1158-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.M1009V	0.2614	88.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.M1009V (Missense)		STAD_MUTECT2	TCGA-CG-4305-01A-01D-1158-08	TCGA-CG-4305-10A-01D-1158-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.R721Q	0.1111	117.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.R721Q (Missense)		STAD_MUTECT2	TCGA-BR-A4IU-01A-22D-A25D-08	TCGA-BR-A4IU-10A-01D-A25E-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.N1045S	0.3565	115.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.N1045S (Missense)		STAD_MUTECT2	TCGA-FP-8631-01A-11D-2394-08	TCGA-FP-8631-10A-01D-2394-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.A349V	0.2564	39.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.A349V (Missense)		STAD_MUTECT2	TCGA-HU-A4G8-01A-11D-A25D-08	TCGA-HU-A4G8-10A-01D-A25E-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.R313W	0.225	40.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.R313W (Missense)		STAD_MUTECT2	TCGA-B7-A5TI-01A-11D-A31L-08	TCGA-B7-A5TI-10A-01D-A31J-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.A1046T	0.2453	106.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.A1046T (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.E921D	0.1955	133.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.E921D (Missense)		STAD_MUTECT2	TCGA-VQ-A924-01A-11D-A410-08	TCGA-VQ-A924-10A-01D-A413-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.R231C	0.5	4.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.R231C (Missense)		STAD_MUTECT2	TCGA-BR-8361-01A-11D-2340-08	TCGA-BR-8361-10A-01D-2340-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.A432V	0.3488	86.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.A432V (Missense)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.2471	85.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	STAD_MUTECT2	TCGA-CD-A489-01A-11D-A24D-08	TCGA-CD-A489-10A-01D-A24F-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.E1001D	0.2956	159.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.E1001D (Missense)		STAD_MUTECT2	TCGA-EQ-8122-01A-11D-2340-08	TCGA-EQ-8122-10A-01D-2341-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.A245V	0.1395	43.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.A245V (Missense)		STAD_MUTECT2	TCGA-RD-A8NB-01A-12D-A397-08	TCGA-RD-A8NB-10A-01D-A39A-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.P421Q	0.2432	74.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.P421Q (Missense)		STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.V104M	0.2673	217.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.V104M (Missense)		STAD_MUTECT2	TCGA-BR-4362-01A-01D-1158-08	TCGA-BR-4362-11A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.P306H	0.283	417.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.P306H (Missense)		STAD_MUTECT2	TCGA-BR-4362-01A-01D-1158-08	TCGA-BR-4362-11A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.Q562H	0.2581	31.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.Q562H (Missense)	0	STAD_MUTECT2	TCGA-BR-4362-01A-01D-1158-08	TCGA-BR-4362-11A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.N258Kfs*6	0.1983	116.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.N258Kfs*6 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4H4-01A-21D-A25D-08	TCGA-HU-A4H4-11A-11D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.P39L	0.6875	48.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.P39L (Missense)		STAD_MUTECT2	TCGA-IN-8663-01A-11D-2394-08	TCGA-IN-8663-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.G776V	0.759	83.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.G776V (Missense)		STAD_MUTECT2	TCGA-IN-8663-01A-11D-2394-08	TCGA-IN-8663-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.S236P	0.3439	189.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.S236P (Missense)		STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.G513C	0.3206	131.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.G513C (Missense)		STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.R667S	0.4167	168.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.R667S (Missense)		STAD_MUTECT2	TCGA-BR-6454-01A-11D-1800-08	TCGA-BR-6454-11A-01D-1800-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.K66N	0.1667	24.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.K66N (Missense)	0	STAD_MUTECT2	TCGA-BR-6454-01A-11D-1800-08	TCGA-BR-6454-11A-01D-1800-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.E284K	0.3636	11.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.E284K (Missense)	0	STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.P1518Lfs*21	0.1833	60.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.P1518Lfs*21 (Frameshift)		STAD_MUTECT2	TCGA-BR-4368-01A-01D-1158-08	TCGA-BR-4368-11A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.R631C	0.1111	117.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.R631C (Missense)	0	STAD_MUTECT2	TCGA-HU-A4GN-01A-11D-A25D-08	TCGA-HU-A4GN-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.Q934H	0.0452	221.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.Q934H (Missense)		STAD_MUTECT2	TCGA-BR-4357-01A-01D-1158-08	TCGA-BR-4357-11A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.S652Ifs*13	0.2418	91.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.S652Ifs*13 (Frameshift)		STAD_MUTECT2	TCGA-IN-A6RO-01A-12D-A33T-08	TCGA-IN-A6RO-10A-01D-A33W-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.I279Yfs*4	0.5625	16.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.I279Yfs*4 (Frameshift)		STAD_MUTECT2	TCGA-IN-A6RO-01A-12D-A33T-08	TCGA-IN-A6RO-10A-01D-A33W-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.G128R	0.131	84.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.G128R (Missense)		STAD_MUTECT2	TCGA-EQ-5647-01A-01D-1600-08	TCGA-EQ-5647-10A-01D-1600-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.R511W	0.0857	70.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.R511W (Missense)	0	STAD_MUTECT2	TCGA-VQ-A923-01A-11D-A410-08	TCGA-VQ-A923-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.V653E	0.1405	121.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.V653E (Missense)		STAD_MUTECT2	TCGA-D7-A6EY-01A-21D-A31L-08	TCGA-D7-A6EY-10A-01D-A31J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.F885S	0.0808	99.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.F885S (Missense)		STAD_MUTECT2	TCGA-D7-A6EY-01A-21D-A31L-08	TCGA-D7-A6EY-10A-01D-A31J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.V659D	0.0805	236.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.V659D (Missense)		STAD_MUTECT2	TCGA-D7-A6EY-01A-21D-A31L-08	TCGA-D7-A6EY-10A-01D-A31J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.T862A	0.0583	120.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.T862A (Missense)		STAD_MUTECT2	TCGA-D7-A6EY-01A-21D-A31L-08	TCGA-D7-A6EY-10A-01D-A31J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.A1039T	0.0607	214.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.A1039T (Missense)		STAD_MUTECT2	TCGA-D7-A6EY-01A-21D-A31L-08	TCGA-D7-A6EY-10A-01D-A31J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.A172T	0.3061	49.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.A172T (Missense)	0	STAD_MUTECT2	TCGA-D7-A6EY-01A-21D-A31L-08	TCGA-D7-A6EY-10A-01D-A31J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.V104M	0.1429	224.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.V104M (Missense)		STAD_MUTECT2	TCGA-D7-A4YV-01A-11D-A25D-08	TCGA-D7-A4YV-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.T70M	0.2857	14.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.T70M (Missense)	0	STAD_MUTECT2	TCGA-D7-A4YV-01A-11D-A25D-08	TCGA-D7-A4YV-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.R667H	0.0964	83.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.R667H (Missense)		STAD_MUTECT2	TCGA-VQ-A8P8-01A-11D-A397-08	TCGA-VQ-A8P8-10A-01D-A39A-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.G1128R	0.25	64.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.G1128R (Missense)		STAD_MUTECT2	TCGA-HU-A4GU-01A-11D-A25D-08	TCGA-HU-A4GU-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.M1209Cfs*9	0.1656	151.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.M1209Cfs*9 (Frameshift)		STAD_MUTECT2	TCGA-CG-5728-01A-11D-1600-08	TCGA-CG-5728-11A-01D-1600-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.S128N	0.4055	291.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.S128N (Missense)		STAD_MUTECT2	TCGA-BR-4370-01A-01D-1158-08	TCGA-BR-4370-11A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.R679Q	0.342	231.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.R679Q (Missense)		STAD_MUTECT2	TCGA-CG-4442-01A-01D-1158-08	TCGA-CG-4442-10A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.R557Q	0.8182	22.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.R557Q (Missense)	0	STAD_MUTECT2	TCGA-CG-4442-01A-01D-1158-08	TCGA-CG-4442-10A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R1185*	0.4267	75.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R1185* (Nonsense)		STAD_MUTECT2	TCGA-VQ-A8PT-01A-11D-A410-08	TCGA-VQ-A8PT-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.P583L	0.2655	113.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.P583L (Missense)		STAD_MUTECT2	TCGA-VQ-A8PT-01A-11D-A410-08	TCGA-VQ-A8PT-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.R678Q	0.25	52.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.R678Q (Missense)		STAD_MUTECT2	TCGA-VQ-A8PZ-01A-11D-A410-08	TCGA-VQ-A8PZ-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.V104M	0.1491	161.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.V104M (Missense)		STAD_MUTECT2	TCGA-D7-A4YU-01A-21D-A25D-08	TCGA-D7-A4YU-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.2456	281.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		STAD_MUTECT2	TCGA-BR-8588-01A-11D-2394-08	TCGA-BR-8588-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.A395T	0.2647	136.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.A395T (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.R156Q	0.6471	34.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.R156Q (Missense)	0	STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S974F	0.0269	4455.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S974F (Missense)		STAD_MUTECT2	TCGA-CG-4466-01A-01D-1158-08	TCGA-CG-4466-10A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.K553Rfs*16	0.3101	129.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K553Rfs*16 (Frameshift)		STAD_MUTECT2	TCGA-CD-8536-01A-11D-2340-08	TCGA-CD-8536-10A-01D-2341-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.Y262*	0.2893	159.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y262* (Frameshift)		STAD_MUTECT2	TCGA-CD-8536-01A-11D-2340-08	TCGA-CD-8536-10A-01D-2341-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.L382M	0.2121	99.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.L382M (Missense)	0	STAD_MUTECT2	TCGA-CD-8536-01A-11D-2340-08	TCGA-CD-8536-10A-01D-2341-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Nonsense	p.R477*	0.2529	87.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.R477* (Nonsense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.P306H	0.3874	444.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.P306H (Missense)		STAD_MUTECT2	TCGA-CG-5726-01A-11D-1600-08	TCGA-CG-5726-11A-01D-1600-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.V119I	0.2089	158.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.V119I (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.A440T	0.1724	58.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.A440T (Missense)	0	STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.R293Q	0.2	15.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.R293Q (Missense)	0	STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.M480I	0.25	12.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.M480I (Missense)	0	STAD_MUTECT2	TCGA-KB-A6F7-01A-12D-A32N-08	TCGA-KB-A6F7-10A-01D-A32N-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.V104M	0.1911	157.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.V104M (Missense)		STAD_MUTECT2	TCGA-BR-8078-01A-11D-2340-08	TCGA-BR-8078-10A-01D-2340-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.E228K	0.2857	63.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.E228K (Missense)		STAD_MUTECT2	TCGA-BR-8368-01A-11D-2340-08	TCGA-BR-8368-10A-01D-2341-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.L755S	0.1429	35.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.L755S (Missense)		STAD_MUTECT2	TCGA-VQ-A8PB-01A-11D-A397-08	TCGA-VQ-A8PB-10A-01D-A39A-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.N258Kfs*6	0.4219	64.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.N258Kfs*6 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PS-01A-11D-A410-08	TCGA-VQ-A8PS-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.0476	189.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		STAD_MUTECT2	TCGA-BR-7957-01A-11D-2201-08	TCGA-BR-7957-10A-01D-2201-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.T355I	0.3256	172.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.T355I (Missense)		STAD_MUTECT2	TCGA-HU-A4H8-01A-11D-A25D-08	TCGA-HU-A4H8-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.V842I	0.3281	64.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.V842I (Missense)		STAD_MUTECT2	TCGA-HU-A4H8-01A-11D-A25D-08	TCGA-HU-A4H8-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310Y	0.2083	360.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310Y (Missense)		STAD_MUTECT2	TCGA-MX-A5UJ-01A-11D-A31L-08	TCGA-MX-A5UJ-10A-01D-A31J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S653F	0.203	202.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S653F (Missense)		STAD_MUTECT2	TCGA-MX-A5UJ-01A-11D-A31L-08	TCGA-MX-A5UJ-10A-01D-A31J-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.A395T	0.1793	184.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.A395T (Missense)		STAD_MUTECT2	TCGA-BR-7958-01A-21D-2340-08	TCGA-BR-7958-10A-01D-2340-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.M1539Kfs*7	0.0909	55.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.M1539Kfs*7 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A91S-01A-11D-A410-08	TCGA-VQ-A91S-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.T420M	0.1583	120.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.T420M (Missense)		STAD_MUTECT2	TCGA-BR-8687-01A-11D-2394-08	TCGA-BR-8687-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.A232V	0.1277	47.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.A232V (Missense)		STAD_MUTECT2	TCGA-BR-4257-01A-01D-1126-08	TCGA-BR-4257-11A-01D-1126-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Nonsense	p.R527*	0.1801	322.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.R527* (Nonsense)		STAD_MUTECT2	TCGA-CG-4305-01A-01D-1158-08	TCGA-CG-4305-10A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.V242I	0.2258	62.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.V242I (Missense)	0	STAD_MUTECT2	TCGA-CG-4306-01A-01D-1158-08	TCGA-CG-4306-10A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.M205I	0.0696	115.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.M205I (Missense)		STAD_MUTECT2	TCGA-BR-8380-01A-11D-2340-08	TCGA-BR-8380-10A-01D-2341-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.V104M	0.3333	138.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.V104M (Missense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.R490H	0.413	46.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.R490H (Missense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.A622T	0.283	53.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.A622T (Missense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.A580T	0.4167	24.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.A580T (Missense)	0	STAD_MUTECT2	TCGA-VQ-AA6D-01A-11D-A410-08	TCGA-VQ-AA6D-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.G284R	0.0877	57.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.G284R (Missense)		STAD_MUTECT2	TCGA-VQ-A8PD-01A-11D-A410-08	TCGA-VQ-A8PD-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.R426W	0.0706	85.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.R426W (Missense)		STAD_MUTECT2	TCGA-VQ-A8PD-01A-11D-A410-08	TCGA-VQ-A8PD-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.R678Q	0.2667	60.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.R678Q (Missense)		STAD_MUTECT2	TCGA-VQ-A8PD-01A-11D-A410-08	TCGA-VQ-A8PD-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.L1182V	0.4286	42.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.L1182V (Missense)		STAD_MUTECT2	TCGA-FP-7735-01A-11D-2053-08	TCGA-FP-7735-10A-01D-2053-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.V777M	0.2211	95.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.V777M (Missense)		STAD_MUTECT2	TCGA-BR-6566-01A-11D-1800-08	TCGA-BR-6566-10A-01D-1800-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.K314T	0.1381	268.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.K314T (Missense)		STAD_MUTECT2	TCGA-BR-8381-01A-11D-2394-08	TCGA-BR-8381-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.D769Y	0.1429	35.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.D769Y (Missense)		STAD_MUTECT2	TCGA-BR-8381-01A-11D-2394-08	TCGA-BR-8381-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.R1136H	0.2803	132.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.R1136H (Missense)		STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.V104M	0.1615	130.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.V104M (Missense)		STAD_MUTECT2	TCGA-HU-A4G9-01A-11D-A24D-08	TCGA-HU-A4G9-10A-01D-A24F-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.I279Yfs*4	0.4444	18.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.I279Yfs*4 (Frameshift)		STAD_MUTECT2	TCGA-BR-7851-01A-11D-2201-08	TCGA-BR-7851-10A-01D-2201-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.R678Q	0.1308	107.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.R678Q (Missense)		STAD_MUTECT2	TCGA-BR-6802-01A-11D-1882-08	TCGA-BR-6802-10A-01D-1882-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.I709Ffs*5	0.3134	67.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.I709Ffs*5 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4GX-01A-12D-A25D-08	TCGA-HU-A4GX-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Frameshift	p.K34Nfs*12	0.2778	126.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.K34Nfs*12 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4GX-01A-12D-A25D-08	TCGA-HU-A4GX-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.I671N	0.2072	111.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.I671N (Missense)		STAD_MUTECT2	TCGA-BR-6563-01A-13D-2053-08	TCGA-BR-6563-10A-01D-2053-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.A245V	0.2346	81.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.A245V (Missense)		STAD_MUTECT2	TCGA-SW-A7EA-01A-12D-A34U-08	TCGA-SW-A7EA-10A-01D-A34X-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.F385V	0.3457	188.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.F385V (Missense)		STAD_MUTECT2	TCGA-CG-4469-01A-01D-1158-08	TCGA-CG-4469-10A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.R678Q	0.3721	172.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.R678Q (Missense)		STAD_MUTECT2	TCGA-CG-4469-01A-01D-1158-08	TCGA-CG-4469-10A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.D297Y	0.2394	142.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.D297Y (Missense)		STAD_MUTECT2	TCGA-BR-A4QM-01A-12D-A25D-08	TCGA-BR-A4QM-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.P612H	0.3452	84.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.P612H (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.V104L	0.099	192.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.V104L (Missense)		STAD_MUTECT2	TCGA-BR-6706-01A-11D-1882-08	TCGA-BR-6706-10A-01D-1882-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.H228R	0.2194	155.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.H228R (Missense)		STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.R667H	0.2419	124.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.R667H (Missense)		STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R78*	0.3214	56.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R78* (Nonsense)		STAD_MUTECT2	TCGA-B7-A5TI-01A-11D-A31L-08	TCGA-B7-A5TI-10A-01D-A31J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.T27S	0.2278	79.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.T27S (Missense)		STAD_MUTECT2	TCGA-VQ-A8PH-01A-12D-A410-08	TCGA-VQ-A8PH-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.S1237N	0.0794	63.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.S1237N (Missense)		STAD_MUTECT2	TCGA-BR-8059-01A-11D-2340-08	TCGA-BR-8059-10A-01D-2340-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.L431S	0.0573	157.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.L431S (Missense)		STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.K553Rfs*16	0.0749	187.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K553Rfs*16 (Frameshift)		STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.L1349Wfs*35	0.1961	51.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.L1349Wfs*35 (Frameshift)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.L453M	0.0899	89.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.L453M (Missense)		STAD_MUTECT2	TCGA-VQ-A8DT-01A-11D-A364-08	TCGA-VQ-A8DT-10A-01D-A362-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.A232T	0.2161	236.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.A232T (Missense)		STAD_MUTECT2	TCGA-HF-7132-01A-11D-2053-08	TCGA-HF-7132-10A-01D-2053-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.R444Q	0.1545	110.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.R444Q (Missense)		STAD_MUTECT2	TCGA-HF-7132-01A-11D-2053-08	TCGA-HF-7132-10A-01D-2053-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.A1039T	0.2297	148.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.A1039T (Missense)		STAD_MUTECT2	TCGA-HF-7132-01A-11D-2053-08	TCGA-HF-7132-10A-01D-2053-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.V104M	0.2426	136.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.V104M (Missense)		STAD_MUTECT2	TCGA-VQ-A924-01A-11D-A410-08	TCGA-VQ-A924-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.A330V	0.3077	104.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.A330V (Missense)		STAD_MUTECT2	TCGA-VQ-A924-01A-11D-A410-08	TCGA-VQ-A924-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.L1217I	0.0976	82.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.L1217I (Missense)		STAD_MUTECT2	TCGA-BR-4256-01A-01D-1126-08	TCGA-BR-4256-11A-01D-1126-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.D769Y	0.5517	29.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.D769Y (Missense)		STAD_MUTECT2	TCGA-HU-A4H0-01A-11D-A25D-08	TCGA-HU-A4H0-11A-11D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.P703Afs*20	0.1888	249.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.P703Afs*20 (Frameshift)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.S652Ifs*13	0.2287	293.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.S652Ifs*13 (Frameshift)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.V264A	0.1798	89.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.V264A (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.R282W	0.3333	12.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.R282W (Missense)	0	STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.F378L	0.25	32.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.F378L (Missense)	0	STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.H228R	0.2857	154.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.H228R (Missense)		STAD_MUTECT2	TCGA-CD-8527-01A-11D-2340-08	TCGA-CD-8527-10A-01D-2341-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R1185*	0.25	52.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R1185* (Nonsense)		STAD_MUTECT2	TCGA-BR-8284-01A-11D-2340-08	TCGA-BR-8284-10A-01D-2340-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.A109T	0.1879	165.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.A109T (Missense)		STAD_MUTECT2	TCGA-BR-7703-01A-11D-2053-08	TCGA-BR-7703-10A-01D-2053-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.A441T	0.0779	77.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.A441T (Missense)		STAD_MUTECT2	TCGA-BR-7703-01A-11D-2053-08	TCGA-BR-7703-10A-01D-2053-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.G222C	0.1742	155.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.G222C (Missense)		STAD_MUTECT2	TCGA-BR-6852-01A-11D-1882-08	TCGA-BR-6852-10A-01D-1882-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.N258Mfs*25	0.1029	68.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.N258Mfs*25 (Frameshift)		STAD_MUTECT2	TCGA-BR-8382-01A-11D-2394-08	TCGA-BR-8382-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.V104M	0.1534	163.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.V104M (Missense)		STAD_MUTECT2	TCGA-BR-8382-01A-11D-2394-08	TCGA-BR-8382-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.R453H	0.1415	106.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.R453H (Missense)		STAD_MUTECT2	TCGA-BR-8382-01A-11D-2394-08	TCGA-BR-8382-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Frameshift	p.M18Cfs*8	0.2703	74.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.M18Cfs*8 (Frameshift)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.V104M	0.0685	146.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.V104M (Missense)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.F872Lfs*43	0.6667	27.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.F872Lfs*43 (Frameshift)		STAD_MUTECT2	TCGA-HF-A5NB-01A-11D-A31L-08	TCGA-HF-A5NB-10A-01D-A31J-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.Y346*	0.0732	41.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Y346* (Frameshift)	1	STAD_MUTECT2	TCGA-D7-8570-01A-11D-2340-08	TCGA-D7-8570-10A-01D-2341-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Splice Site	p.X55_splice	0.2021	94.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.X55_splice (Splice Site)	1	STAD_MUTECT2	TCGA-BR-4201-01A-01D-1126-08	TCGA-BR-4201-11A-01D-1126-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.K267Rfs*9	0.2899	69.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.K267Rfs*9 (Frameshift)	1	STAD_MUTECT2	TCGA-BR-4201-01A-01D-1126-08	TCGA-BR-4201-11A-01D-1126-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.N311Qfs*2	0.3208	106.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.N311Qfs*2 (Frameshift)	1	STAD_MUTECT2	TCGA-VQ-A8DL-01A-11D-A364-08	TCGA-VQ-A8DL-10A-01D-A362-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.K267Rfs*9	0.6491	114.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.K267Rfs*9 (Frameshift)	1	STAD_MUTECT2	TCGA-BR-4362-01A-01D-1158-08	TCGA-BR-4362-11A-01D-1158-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.N323Mfs*21	0.4859	142.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.N323Mfs*21 (Frameshift)	1	STAD_MUTECT2	TCGA-VQ-A8PT-01A-11D-A410-08	TCGA-VQ-A8PT-10A-01D-A413-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.N323Mfs*21	0.2404	104.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.N323Mfs*21 (Frameshift)	1	STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.N323Mfs*21	0.0833	108.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.N323Mfs*21 (Frameshift)	1	STAD_MUTECT2	TCGA-BR-8078-01A-11D-2340-08	TCGA-BR-8078-10A-01D-2340-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.K267Rfs*9	0.4773	44.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.K267Rfs*9 (Frameshift)	1	STAD_MUTECT2	TCGA-BR-8368-01A-11D-2340-08	TCGA-BR-8368-10A-01D-2341-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.K164Rfs*3	0.2703	74.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.K164Rfs*3 (Frameshift)	1	STAD_MUTECT2	TCGA-VQ-A8PB-01A-11D-A397-08	TCGA-VQ-A8PB-10A-01D-A39A-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.K267Rfs*9	0.4068	59.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.K267Rfs*9 (Frameshift)	1	STAD_MUTECT2	TCGA-VQ-A8PB-01A-11D-A397-08	TCGA-VQ-A8PB-10A-01D-A39A-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.K267Rfs*9	0.4524	42.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.K267Rfs*9 (Frameshift)	1	STAD_MUTECT2	TCGA-BR-4257-01A-01D-1126-08	TCGA-BR-4257-11A-01D-1126-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.N323Kfs*2	0.2301	113.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.N323Kfs*2 (Frameshift)	1	STAD_MUTECT2	TCGA-CG-4305-01A-01D-1158-08	TCGA-CG-4305-10A-01D-1158-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.T232Hfs*11	0.403	67.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.T232Hfs*11 (Frameshift)	1	STAD_MUTECT2	TCGA-FP-8211-01A-11D-2340-08	TCGA-FP-8211-10A-01D-2341-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.R233*	0.5093	108.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R233* (Nonsense)	1	STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.K267Rfs*9	0.5	26.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.K267Rfs*9 (Frameshift)	1	STAD_MUTECT2	TCGA-HU-A4GT-01A-21D-A25D-08	TCGA-HU-A4GT-10A-01D-A25E-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.R233*	0.3333	84.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R233* (Nonsense)	1	STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.D24Yfs*16	0.0851	47.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.D24Yfs*16 (Frameshift)	1	STAD_MUTECT2	TCGA-RD-A8N1-01A-12D-A364-08	TCGA-RD-A8N1-10A-01D-A362-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.K164Rfs*3	0.1238	105.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.K164Rfs*3 (Frameshift)	1	STAD_MUTECT2	TCGA-BR-4256-01A-01D-1126-08	TCGA-BR-4256-11A-01D-1126-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.K267Rfs*9	0.16	50.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.K267Rfs*9 (Frameshift)	1	STAD_MUTECT2	TCGA-BR-4256-01A-01D-1126-08	TCGA-BR-4256-11A-01D-1126-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.R233*	0.165	103.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R233* (Nonsense)	1	STAD_MUTECT2	TCGA-BR-8284-01A-11D-2340-08	TCGA-BR-8284-10A-01D-2340-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.K267Rfs*9	0.1127	71.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.K267Rfs*9 (Frameshift)	1	STAD_MUTECT2	TCGA-BR-8284-01A-11D-2340-08	TCGA-BR-8284-10A-01D-2340-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.R961P	0.1915	47.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.R961P (Missense)	1	STAD_MUTECT2	TCGA-HU-A4H3-01A-21D-A25D-08	TCGA-HU-A4H3-10A-01D-A25E-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.K395R	0.1989	181.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.K395R (Missense)	1	STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.M837L	0.1979	96.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.M837L (Missense)	1	STAD_MUTECT2	TCGA-D7-A4YV-01A-11D-A25D-08	TCGA-D7-A4YV-10A-01D-A25E-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.G128V	0.1475	61.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.G128V (Missense)	0	STAD_MUTECT2	TCGA-VQ-AA6J-01A-11D-A410-08	TCGA-VQ-AA6J-10A-01D-A413-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.A988D	0.2115	52.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.A988D (Missense)	1	STAD_MUTECT2	TCGA-VQ-A8PX-01A-12D-A410-08	TCGA-VQ-A8PX-10A-01D-A413-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.V224M	0.3617	47.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.V224M (Missense)	0	STAD_MUTECT2	TCGA-BR-8368-01A-11D-2340-08	TCGA-BR-8368-10A-01D-2341-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.G583S	0.127	63.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.G583S (Missense)	1	STAD_MUTECT2	TCGA-CG-4444-01A-01D-1158-08	TCGA-CG-4444-10A-01D-1158-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.G583S	0.25	36.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.G583S (Missense)	1	STAD_MUTECT2	TCGA-HU-A4H8-01A-11D-A25D-08	TCGA-HU-A4H8-10A-01D-A25E-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.L177M	0.1032	126.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.L177M (Missense)	0	STAD_MUTECT2	TCGA-BR-6566-01A-11D-1800-08	TCGA-BR-6566-10A-01D-1800-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.L601P	0.098	51.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.L601P (Missense)	1	STAD_MUTECT2	TCGA-BR-A4PF-01A-11D-A25D-08	TCGA-BR-A4PF-10A-01D-A25E-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.A80V	0.3028	109.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.A80V (Missense)	1	STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.L177M	0.2247	178.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.L177M (Missense)	0	STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.L63I	0.1463	82.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.L63I (Missense)	1	STAD_MUTECT2	TCGA-R5-A7ZI-01A-11D-A34U-08	TCGA-R5-A7ZI-10A-01D-A34X-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.K347N	0.2	20.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.K347N (Missense)	1	STAD_MUTECT2	TCGA-HF-7132-01A-11D-2053-08	TCGA-HF-7132-10A-01D-2053-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.Y457C	0.2239	402.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.Y457C (Missense)	1	STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.E203K	0.3649	222.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.E203K (Missense)	0	STAD_MUTECT2	TCGA-D7-5577-01A-01D-1600-08	TCGA-D7-5577-10A-01D-1600-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.G798R	0.2195	41.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.G798R (Missense)	1	STAD_MUTECT2	TCGA-BR-7703-01A-11D-2053-08	TCGA-BR-7703-10A-01D-2053-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.A943T	0.2268	97.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.A943T (Missense)		STAD_MUTECT2	TCGA-HU-A4GU-01A-11D-A25D-08	TCGA-HU-A4GU-10A-01D-A25E-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.S350L	0.2627	118.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.S350L (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.A1564V	0.2365	148.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.A1564V (Missense)		STAD_MUTECT2	TCGA-VQ-A8E3-01A-11D-A397-08	TCGA-VQ-A8E3-10A-01D-A39A-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.Q491P	0.0446	112.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.Q491P (Missense)		STAD_MUTECT2	TCGA-KB-A93J-01A-11D-A397-08	TCGA-KB-A93J-10A-01D-A39A-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.P1398L	0.3061	49.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.P1398L (Missense)		STAD_MUTECT2	TCGA-VQ-AA6A-01A-11D-A410-08	TCGA-VQ-AA6A-10A-01D-A413-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.N787S	0.0645	93.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.N787S (Missense)		STAD_MUTECT2	TCGA-F1-A448-01A-11D-A24D-08	TCGA-F1-A448-10A-01D-A24F-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.R136Q	0.3333	12.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.R136Q (Missense)		STAD_MUTECT2	TCGA-F1-A448-01A-11D-A24D-08	TCGA-F1-A448-10A-01D-A24F-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.A1479T	0.2788	165.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.A1479T (Missense)		STAD_MUTECT2	TCGA-HU-A4GX-01A-12D-A25D-08	TCGA-HU-A4GX-10A-01D-A25E-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.K330R	0.3495	103.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.K330R (Missense)		STAD_MUTECT2	TCGA-CG-4469-01A-01D-1158-08	TCGA-CG-4469-10A-01D-1158-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.A206V	0.35	40.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.A206V (Missense)		STAD_MUTECT2	TCGA-CD-8531-01A-11D-2340-08	TCGA-CD-8531-10A-01D-2341-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.V1471M	0.1065	169.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.V1471M (Missense)		STAD_MUTECT2	TCGA-CD-5813-01A-11D-1600-08	TCGA-CD-5813-10A-01D-1600-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.S754F	0.0877	57.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.S754F (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.E343Q	0.5738	61.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.E343Q (Missense)		STAD_MUTECT2	TCGA-D7-6528-01A-11D-1800-08	TCGA-D7-6528-10A-01D-1800-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G640E	0.2406	133.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G640E (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E600K	0.1132	53.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E600K (Missense)	1	STAD_MUTECT2	TCGA-CD-5800-01A-11D-1600-08	TCGA-CD-5800-10A-01D-1600-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.N345K	0.1471	102.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.N345K (Missense)	1	STAD_MUTECT2	TCGA-BR-7196-01A-11D-2053-08	TCGA-BR-7196-10A-01D-2053-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R108H	0.234	94.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R108H (Missense)	1	STAD_MUTECT2	TCGA-D7-A4YV-01A-11D-A25D-08	TCGA-D7-A4YV-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R88Q	0.2705	122.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R88Q (Missense)	1	STAD_MUTECT2	TCGA-BR-8591-01A-11D-2394-08	TCGA-BR-8591-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.C378R	0.2809	89.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.C378R (Missense)	1	STAD_MUTECT2	TCGA-BR-8591-01A-11D-2394-08	TCGA-BR-8591-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R88Q	0.113	230.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R88Q (Missense)	1	STAD_MUTECT2	TCGA-CG-5728-01A-11D-1600-08	TCGA-CG-5728-11A-01D-1600-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.G118D	0.25	52.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.G118D (Missense)	1	STAD_MUTECT2	TCGA-D7-A4YX-01A-11D-A25D-08	TCGA-D7-A4YX-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R88Q	0.3704	54.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R88Q (Missense)	1	STAD_MUTECT2	TCGA-BR-8686-01A-11D-2394-08	TCGA-BR-8686-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R93Q	0.418	122.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R93Q (Missense)	1	STAD_MUTECT2	TCGA-F1-6177-01A-11D-1800-08	TCGA-F1-6177-10A-01D-1800-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.Q546H	0.4677	62.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Q546H (Missense)	1	STAD_MUTECT2	TCGA-F1-6177-01A-11D-1800-08	TCGA-F1-6177-10A-01D-1800-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E453K	0.5616	146.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E453K (Missense)	1	STAD_MUTECT2	TCGA-BR-8676-01A-11D-2394-08	TCGA-BR-8676-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R93W	0.2667	120.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R93W (Missense)	1	STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.Y1021H	0.3378	74.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Y1021H (Missense)	1	STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R38H	0.1237	97.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R38H (Missense)	1	STAD_MUTECT2	TCGA-HU-A4G2-01A-11D-A25D-08	TCGA-HU-A4G2-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.K111E	0.1325	83.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.K111E (Missense)	1	STAD_MUTECT2	TCGA-BR-8588-01A-11D-2394-08	TCGA-BR-8588-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.N345K	0.271	107.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.N345K (Missense)	1	STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.Q879R	0.1948	77.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Q879R (Missense)	1	STAD_MUTECT2	TCGA-CD-8536-01A-11D-2340-08	TCGA-CD-8536-10A-01D-2341-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R88Q	0.32	100.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R88Q (Missense)	1	STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.D350N	0.3049	82.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.D350N (Missense)	1	STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E547K	0.0642	109.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E547K (Missense)	1	STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R38C	0.25	60.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R38C (Missense)	1	STAD_MUTECT2	TCGA-VQ-A8PB-01A-11D-A397-08	TCGA-VQ-A8PB-10A-01D-A39A-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.N345K	0.1688	77.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.N345K (Missense)	1	STAD_MUTECT2	TCGA-BR-4253-01A-01D-1126-08	TCGA-BR-4253-11A-01D-1126-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.N345K	0.1586	145.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.N345K (Missense)	1	STAD_MUTECT2	TCGA-HU-8608-01A-11D-2394-08	TCGA-HU-8608-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E365K	0.169	142.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E365K (Missense)	1	STAD_MUTECT2	TCGA-HU-8608-01A-11D-2394-08	TCGA-HU-8608-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.F744I	0.4848	132.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.F744I (Missense)	1	STAD_MUTECT2	TCGA-BR-8589-01A-11D-2394-08	TCGA-BR-8589-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.N345K	0.1459	233.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.N345K (Missense)	1	STAD_MUTECT2	TCGA-CD-5801-01A-11D-1600-08	TCGA-CD-5801-10A-01D-1600-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R93Q	0.2759	116.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R93Q (Missense)	1	STAD_MUTECT2	TCGA-HU-8238-01A-11D-2340-08	TCGA-HU-8238-10A-01D-2341-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E453K	0.1277	141.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E453K (Missense)	1	STAD_MUTECT2	TCGA-BR-6706-01A-11D-1882-08	TCGA-BR-6706-10A-01D-1882-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.S405F	0.15	240.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.S405F (Missense)	1	STAD_MUTECT2	TCGA-D7-A6EZ-01A-11D-A31L-08	TCGA-D7-A6EZ-10A-01D-A31J-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R38H	0.108	250.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R38H (Missense)	1	STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R93Q	0.1882	85.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R93Q (Missense)	1	STAD_MUTECT2	TCGA-HF-7132-01A-11D-2053-08	TCGA-HF-7132-10A-01D-2053-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.G118D	0.125	64.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.G118D (Missense)	1	STAD_MUTECT2	TCGA-BR-8366-01A-11D-2340-08	TCGA-BR-8366-10A-01D-2341-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.Y182H	0.234	94.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Y182H (Missense)	1	STAD_MUTECT2	TCGA-BR-8366-01A-11D-2340-08	TCGA-BR-8366-10A-01D-2341-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.Q546R	0.1852	54.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Q546R (Missense)	1	STAD_MUTECT2	TCGA-VQ-A924-01A-11D-A410-08	TCGA-VQ-A924-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E453K	0.3718	78.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E453K (Missense)	1	STAD_MUTECT2	TCGA-VQ-A91K-01A-11D-A410-08	TCGA-VQ-A91K-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.N380S	0.15	40.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.N380S (Missense)	1	STAD_MUTECT2	TCGA-HU-A4H0-01A-11D-A25D-08	TCGA-HU-A4H0-11A-11D-A25E-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.G364R	0.281	121.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.G364R (Missense)	1	STAD_MUTECT2	TCGA-VQ-A91W-01A-11D-A410-08	TCGA-VQ-A91W-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.K111E	0.175	160.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.K111E (Missense)	1	STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.K948E	0.1765	170.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.K948E (Missense)	1	STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R88Q	0.332	241.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R88Q (Missense)	1	STAD_MUTECT2	TCGA-D7-5577-01A-01D-1600-08	TCGA-D7-5577-10A-01D-1600-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.D1850Tfs*33	0.3153	111.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1850Tfs*33 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4H3-01A-21D-A25D-08	TCGA-HU-A4H3-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.T1348Afs*129	0.2211	190.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.T1348Afs*129 (Frameshift)		STAD_MUTECT2	TCGA-BR-A4PE-01A-31D-A25D-08	TCGA-BR-A4PE-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.A591Ifs*27	0.0837	263.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.A591Ifs*27 (Frameshift)		STAD_MUTECT2	TCGA-BR-7196-01A-11D-2053-08	TCGA-BR-7196-10A-01D-2053-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1095*	0.141	78.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1095* (Nonsense)		STAD_MUTECT2	TCGA-BR-7196-01A-11D-2053-08	TCGA-BR-7196-10A-01D-2053-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P1349Lfs*132	0.2407	162.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1349Lfs*132 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.I620T	0.3333	78.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.I620T (Missense)		STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.R2158*	0.0891	101.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R2158* (Nonsense)		STAD_MUTECT2	TCGA-HU-A4G3-01A-11D-A24D-08	TCGA-HU-A4G3-10A-01D-A24F-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.G1157*	0.299	97.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G1157* (Nonsense)		STAD_MUTECT2	TCGA-BR-4362-01A-01D-1158-08	TCGA-BR-4362-11A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.K1072Nfs*21	0.2041	49.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.K1072Nfs*21 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4H4-01A-21D-A25D-08	TCGA-HU-A4H4-11A-11D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.S1807*	0.3521	71.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1807* (Frameshift)		STAD_MUTECT2	TCGA-MX-A663-01A-11D-A31L-08	TCGA-MX-A663-10A-01D-A31J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.L2281Ffs*104	0.1605	81.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.L2281Ffs*104 (Frameshift)		STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Y551Tfs*68	0.0793	290.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Y551Tfs*68 (Frameshift)		STAD_MUTECT2	TCGA-BR-7707-01A-11D-2053-08	TCGA-BR-7707-10A-01D-2053-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q473Tfs*150	0.2385	457.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q473Tfs*150 (Frameshift)		STAD_MUTECT2	TCGA-BR-4368-01A-01D-1158-08	TCGA-BR-4368-11A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q758Rfs*75	0.1818	143.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q758Rfs*75 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4GN-01A-11D-A25D-08	TCGA-HU-A4GN-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P1898Hfs*25	0.1143	105.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1898Hfs*25 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4GN-01A-11D-A25D-08	TCGA-HU-A4GN-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.H415Pfs*9	0.3433	67.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.H415Pfs*9 (Frameshift)		STAD_MUTECT2	TCGA-IN-AB1X-01A-11D-A397-08	TCGA-IN-AB1X-10E-01D-A39A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1512*	0.2451	102.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1512* (Nonsense)		STAD_MUTECT2	TCGA-FP-7998-01A-11D-2201-08	TCGA-FP-7998-10A-01D-2201-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q594*	0.4286	98.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q594* (Nonsense)		STAD_MUTECT2	TCGA-VQ-A923-01A-11D-A410-08	TCGA-VQ-A923-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.D1850Tfs*33	0.4098	122.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1850Tfs*33 (Frameshift)		STAD_MUTECT2	TCGA-D7-A4YV-01A-11D-A25D-08	TCGA-D7-A4YV-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.E1776*	0.1042	48.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E1776* (Nonsense)		STAD_MUTECT2	TCGA-VQ-A8P8-01A-11D-A397-08	TCGA-VQ-A8P8-10A-01D-A39A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P1468Lfs*13	0.1034	58.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1468Lfs*13 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PX-01A-12D-A410-08	TCGA-VQ-A8PX-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.W2049Cfs*86	0.223	139.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.W2049Cfs*86 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4GU-01A-11D-A25D-08	TCGA-HU-A4GU-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q766Sfs*67	0.406	133.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q766Sfs*67 (Frameshift)		STAD_MUTECT2	TCGA-CG-4465-01A-01D-1158-08	TCGA-CG-4465-10A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.W1973*	0.1918	73.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.W1973* (Nonsense)		STAD_MUTECT2	TCGA-VQ-A91E-01A-31D-A410-08	TCGA-VQ-A91E-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.M1634*	0.2	115.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.M1634* (Frameshift)		STAD_MUTECT2	TCGA-CG-5728-01A-11D-1600-08	TCGA-CG-5728-11A-01D-1600-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q1519Rfs*8	0.1743	218.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1519Rfs*8 (Frameshift)		STAD_MUTECT2	TCGA-BR-4370-01A-01D-1158-08	TCGA-BR-4370-11A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.V1491Afs*9	0.5185	189.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.V1491Afs*9 (Frameshift)		STAD_MUTECT2	TCGA-D7-A4YX-01A-11D-A25D-08	TCGA-D7-A4YX-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.D1850Tfs*33	0.381	63.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1850Tfs*33 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PT-01A-11D-A410-08	TCGA-VQ-A8PT-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.F2141Sfs*59	0.4138	116.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.F2141Sfs*59 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PT-01A-11D-A410-08	TCGA-VQ-A8PT-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P726Lfs*12	0.1481	27.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P726Lfs*12 (Frameshift)		STAD_MUTECT2	TCGA-BR-8291-01A-11D-2340-08	TCGA-BR-8291-10A-01D-2340-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q1333Afs*5	0.2323	99.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1333Afs*5 (Frameshift)		STAD_MUTECT2	TCGA-BR-7722-01A-31D-2201-08	TCGA-BR-7722-10A-01D-2201-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.L818Cfs*15	0.3043	23.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.L818Cfs*15 (Frameshift)		STAD_MUTECT2	TCGA-BR-8686-01A-11D-2394-08	TCGA-BR-8686-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.S617Qfs*2	0.3721	86.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S617Qfs*2 (Frameshift)		STAD_MUTECT2	TCGA-F1-6177-01A-11D-1800-08	TCGA-F1-6177-10A-01D-1800-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.K1072Nfs*21	0.5455	55.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.K1072Nfs*21 (Frameshift)		STAD_MUTECT2	TCGA-F1-6177-01A-11D-1800-08	TCGA-F1-6177-10A-01D-1800-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.G801Vfs*32	0.3158	114.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G801Vfs*32 (Frameshift)		STAD_MUTECT2	TCGA-F1-6874-01A-11D-1882-08	TCGA-F1-6874-10A-01D-1882-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.F2141Sfs*59	0.2595	158.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.F2141Sfs*59 (Frameshift)		STAD_MUTECT2	TCGA-F1-6874-01A-11D-1882-08	TCGA-F1-6874-10A-01D-1882-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.D1850Tfs*33	0.4909	55.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1850Tfs*33 (Frameshift)		STAD_MUTECT2	TCGA-BR-4292-01A-01D-1126-08	TCGA-BR-4292-11A-01D-1126-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.L2106Efs*34	0.1707	164.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.L2106Efs*34 (Frameshift)		STAD_MUTECT2	TCGA-CG-4437-01A-01D-1800-08	TCGA-CG-4437-10A-01D-1800-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q673*	0.2	155.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q673* (Nonsense)		STAD_MUTECT2	TCGA-CD-8536-01A-11D-2340-08	TCGA-CD-8536-10A-01D-2341-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.K1072Nfs*21	0.1724	87.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.K1072Nfs*21 (Frameshift)		STAD_MUTECT2	TCGA-CD-8536-01A-11D-2340-08	TCGA-CD-8536-10A-01D-2341-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q766Sfs*67	0.5905	105.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q766Sfs*67 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.I786F	0.3971	68.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.I786F (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q605*	0.1156	147.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q605* (Nonsense)		STAD_MUTECT2	TCGA-CD-5803-01A-11D-1600-08	TCGA-CD-5803-10A-01D-1600-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Y551Lfs*72	0.3302	212.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Y551Lfs*72 (Frameshift)		STAD_MUTECT2	TCGA-CG-5726-01A-11D-1600-08	TCGA-CG-5726-11A-01D-1600-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.G801Vfs*32	0.1121	107.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G801Vfs*32 (Frameshift)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.D1850Tfs*33	0.5478	115.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1850Tfs*33 (Frameshift)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.I293F	0.0977	133.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.I293F (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q586*	0.4578	225.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q586* (Nonsense)		STAD_MUTECT2	TCGA-KB-A6F7-01A-12D-A32N-08	TCGA-KB-A6F7-10A-01D-A32N-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q1519Rfs*8	0.325	80.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1519Rfs*8 (Frameshift)		STAD_MUTECT2	TCGA-BR-8078-01A-11D-2340-08	TCGA-BR-8078-10A-01D-2340-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P1326Rfs*155	0.18	50.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1326Rfs*155 (Frameshift)		STAD_MUTECT2	TCGA-BR-4363-01A-01D-1158-08	TCGA-BR-4363-11A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P1468Lfs*13	0.3411	129.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1468Lfs*13 (Frameshift)		STAD_MUTECT2	TCGA-BR-4363-01A-01D-1158-08	TCGA-BR-4363-11A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.A1522Pfs*5	0.2615	65.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.A1522Pfs*5 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8E3-01A-11D-A397-08	TCGA-VQ-A8E3-10A-01D-A39A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.D1850Gfs*4	0.339	59.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1850Gfs*4 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8E3-01A-11D-A397-08	TCGA-VQ-A8E3-10A-01D-A39A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Y551Lfs*72	0.2293	157.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Y551Lfs*72 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PB-01A-11D-A397-08	TCGA-VQ-A8PB-10A-01D-A39A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.D1850Tfs*33	0.3871	62.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1850Tfs*33 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PB-01A-11D-A397-08	TCGA-VQ-A8PB-10A-01D-A39A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q802Sfs*15	0.2917	96.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q802Sfs*15 (Frameshift)		STAD_MUTECT2	TCGA-MX-A5UJ-01A-11D-A31L-08	TCGA-MX-A5UJ-10A-01D-A31J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Y850*	0.375	64.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Y850* (Nonsense)		STAD_MUTECT2	TCGA-R5-A804-01A-11D-A364-08	TCGA-R5-A804-10A-01D-A362-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.M924Ifs*6	0.2024	84.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.M924Ifs*6 (Frameshift)		STAD_MUTECT2	TCGA-VQ-AA6F-01A-31D-A410-08	TCGA-VQ-AA6F-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.D1850Tfs*33	0.1654	133.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1850Tfs*33 (Frameshift)		STAD_MUTECT2	TCGA-CG-4305-01A-01D-1158-08	TCGA-CG-4305-10A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P1575Hfs*37	0.2742	124.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1575Hfs*37 (Frameshift)		STAD_MUTECT2	TCGA-CG-4306-01A-01D-1158-08	TCGA-CG-4306-10A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1342*	0.3839	211.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1342* (Nonsense)		STAD_MUTECT2	TCGA-BR-4253-01A-01D-1126-08	TCGA-BR-4253-11A-01D-1126-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.S552*	0.3392	227.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S552* (Nonsense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.L1591Cfs*21	0.4561	57.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.L1591Cfs*21 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q176*	0.3333	18.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q176* (Nonsense)		STAD_MUTECT2	TCGA-HU-8608-01A-11D-2394-08	TCGA-HU-8608-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q2037Pfs*62	0.3143	70.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q2037Pfs*62 (Frameshift)		STAD_MUTECT2	TCGA-BR-4188-01A-01D-1126-08	TCGA-BR-4188-11A-01D-1126-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1741*	0.1524	164.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1741* (Nonsense)		STAD_MUTECT2	TCGA-BR-8589-01A-11D-2394-08	TCGA-BR-8589-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.G276Efs*87	0.4615	13.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G276Efs*87 (Frameshift)		STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.M890Hfs*46	0.1304	69.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.M890Hfs*46 (Frameshift)		STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.R1002W	0.3833	60.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.R1002W (Missense)		STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.S2264*	0.0793	164.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S2264* (Nonsense)		STAD_MUTECT2	TCGA-BR-8381-01A-11D-2394-08	TCGA-BR-8381-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.T294Pfs*69	0.7	10.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.T294Pfs*69 (Frameshift)		STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.F2141Sfs*59	0.1169	248.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.F2141Sfs*59 (Frameshift)		STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P726Sfs*10	0.3125	80.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P726Sfs*10 (Frameshift)		STAD_MUTECT2	TCGA-BR-A4J8-01A-11D-A25D-08	TCGA-BR-A4J8-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q502*	0.1429	378.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q502* (Nonsense)		STAD_MUTECT2	TCGA-BR-A4J5-01A-21D-A25D-08	TCGA-BR-A4J5-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.R1461*	0.3778	90.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1461* (Nonsense)		STAD_MUTECT2	TCGA-BR-7851-01A-11D-2201-08	TCGA-BR-7851-10A-01D-2201-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P728Qfs*87	0.1143	70.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P728Qfs*87 (Frameshift)		STAD_MUTECT2	TCGA-B7-A5TK-01A-12D-A31L-08	TCGA-B7-A5TK-10A-01D-A31J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.A1517Pfs*10	0.1915	94.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.A1517Pfs*10 (Frameshift)		STAD_MUTECT2	TCGA-BR-6456-01A-11D-1800-08	TCGA-BR-6456-10A-01D-1800-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1142*	0.069	87.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1142* (Nonsense)		STAD_MUTECT2	TCGA-BR-6802-01A-11D-1882-08	TCGA-BR-6802-10A-01D-1882-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.R2158*	0.1136	132.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R2158* (Nonsense)		STAD_MUTECT2	TCGA-BR-6802-01A-11D-1882-08	TCGA-BR-6802-10A-01D-1882-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P1898Hfs*25	0.1034	87.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1898Hfs*25 (Frameshift)		STAD_MUTECT2	TCGA-F1-A448-01A-11D-A24D-08	TCGA-F1-A448-10A-01D-A24F-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.F2141Sfs*59	0.3012	166.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.F2141Sfs*59 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4GX-01A-12D-A25D-08	TCGA-HU-A4GX-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.E602*	0.3289	76.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E602* (Nonsense)		STAD_MUTECT2	TCGA-SW-A7EA-01A-12D-A34U-08	TCGA-SW-A7EA-10A-01D-A34X-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Y2254*	0.2313	134.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Y2254* (Nonsense)		STAD_MUTECT2	TCGA-D7-6524-01A-11D-1800-08	TCGA-D7-6524-10A-01D-1800-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P1379Lfs*102	0.5	40.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1379Lfs*102 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4G6-01A-11D-A24D-08	TCGA-HU-A4G6-10A-01D-A24F-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q404*	0.4231	104.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q404* (Nonsense)		STAD_MUTECT2	TCGA-D7-6521-01A-11D-1800-08	TCGA-D7-6521-10A-01D-1800-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.D1850Tfs*33	0.225	80.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1850Tfs*33 (Frameshift)		STAD_MUTECT2	TCGA-R5-A7ZI-01A-11D-A34U-08	TCGA-R5-A7ZI-10A-01D-A34X-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.D1850Tfs*33	0.3604	111.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1850Tfs*33 (Frameshift)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.F2141Sfs*59	0.457	151.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.F2141Sfs*59 (Frameshift)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.E1123D	0.0506	79.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.E1123D (Missense)		STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q1131Lfs*29	0.4091	44.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1131Lfs*29 (Frameshift)		STAD_MUTECT2	TCGA-HF-7134-01A-11D-2053-08	TCGA-HF-7134-10A-01D-2053-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.D1850Tfs*33	0.3041	148.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1850Tfs*33 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4G8-01A-11D-A25D-08	TCGA-HU-A4G8-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.M202T	0.2637	91.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.M202T (Missense)		STAD_MUTECT2	TCGA-HU-A4G8-01A-11D-A25D-08	TCGA-HU-A4G8-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q480*	0.0651	307.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q480* (Nonsense)		STAD_MUTECT2	TCGA-BR-A453-01A-11D-A24D-08	TCGA-BR-A453-10A-01D-A24F-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Y551Tfs*68	0.2706	218.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Y551Tfs*68 (Frameshift)		STAD_MUTECT2	TCGA-CG-5733-01A-11D-1600-08	TCGA-CG-5733-11A-01D-1600-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P1326Rfs*155	0.2273	44.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1326Rfs*155 (Frameshift)		STAD_MUTECT2	TCGA-CG-5733-01A-11D-1600-08	TCGA-CG-5733-11A-01D-1600-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.S1316*	0.6405	153.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1316* (Nonsense)		STAD_MUTECT2	TCGA-D7-A6EZ-01A-11D-A31L-08	TCGA-D7-A6EZ-10A-01D-A31J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.R693*	0.3012	83.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R693* (Nonsense)		STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.F2141Sfs*59	0.321	162.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.F2141Sfs*59 (Frameshift)		STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P1560Lfs*5	0.1667	24.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1560Lfs*5 (Frameshift)		STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1357*	0.0917	360.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1357* (Nonsense)		STAD_MUTECT2	TCGA-D7-8579-01A-11D-2340-08	TCGA-D7-8579-10A-01D-2341-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P1326Rfs*155	0.1034	87.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1326Rfs*155 (Frameshift)		STAD_MUTECT2	TCGA-HF-7132-01A-11D-2053-08	TCGA-HF-7132-10A-01D-2053-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.P757L	0.0899	178.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.P757L (Missense)		STAD_MUTECT2	TCGA-HF-7132-01A-11D-2053-08	TCGA-HF-7132-10A-01D-2053-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P1175Hfs*5	0.2121	66.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1175Hfs*5 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A924-01A-11D-A410-08	TCGA-VQ-A924-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.F2141Sfs*59	0.2261	115.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.F2141Sfs*59 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A924-01A-11D-A410-08	TCGA-VQ-A924-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.H477Qfs*146	0.195	241.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.H477Qfs*146 (Frameshift)		STAD_MUTECT2	TCGA-BR-8365-01A-21D-2340-08	TCGA-BR-8365-10A-01D-2341-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P1115Qfs*46	0.4634	41.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1115Qfs*46 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A91K-01A-11D-A410-08	TCGA-VQ-A91K-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.D1850Tfs*33	0.175	80.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1850Tfs*33 (Frameshift)		STAD_MUTECT2	TCGA-BR-4256-01A-01D-1126-08	TCGA-BR-4256-11A-01D-1126-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.D1850Gfs*4	0.7263	95.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1850Gfs*4 (Frameshift)		STAD_MUTECT2	TCGA-B7-5818-01A-11D-1600-08	TCGA-B7-5818-10A-01D-1600-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q546Rfs*73	0.1925	213.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q546Rfs*73 (Frameshift)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.R1446*	0.2982	114.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1446* (Nonsense)		STAD_MUTECT2	TCGA-D7-5577-01A-01D-1600-08	TCGA-D7-5577-10A-01D-1600-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.I1625Mfs*10	0.4262	122.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.I1625Mfs*10 (Frameshift)		STAD_MUTECT2	TCGA-BR-6707-01A-11D-1882-08	TCGA-BR-6707-10A-01D-1882-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.M890Hfs*46	0.275	40.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.M890Hfs*46 (Frameshift)		STAD_MUTECT2	TCGA-HJ-7597-01A-21D-2201-08	TCGA-HJ-7597-10A-01D-2201-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.D1850Tfs*33	0.2558	172.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1850Tfs*33 (Frameshift)		STAD_MUTECT2	TCGA-HJ-7597-01A-21D-2201-08	TCGA-HJ-7597-10A-01D-2201-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.K1057E	0.4762	42.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.K1057E (Missense)		STAD_MUTECT2	TCGA-HJ-7597-01A-21D-2201-08	TCGA-HJ-7597-10A-01D-2201-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.R542C	0.2885	52.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.R542C (Missense)		STAD_MUTECT2	TCGA-HJ-7597-01A-21D-2201-08	TCGA-HJ-7597-10A-01D-2201-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q766Sfs*67	0.3163	98.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q766Sfs*67 (Frameshift)		STAD_MUTECT2	TCGA-BR-8361-01A-11D-2340-08	TCGA-BR-8361-10A-01D-2340-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.F2141Sfs*59	0.3451	113.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.F2141Sfs*59 (Frameshift)		STAD_MUTECT2	TCGA-BR-8361-01A-11D-2340-08	TCGA-BR-8361-10A-01D-2340-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.D1850Tfs*33	0.2828	145.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1850Tfs*33 (Frameshift)		STAD_MUTECT2	TCGA-BR-6852-01A-11D-1882-08	TCGA-BR-6852-10A-01D-1882-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P1115Qfs*46	0.1385	65.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1115Qfs*46 (Frameshift)		STAD_MUTECT2	TCGA-BR-8382-01A-11D-2394-08	TCGA-BR-8382-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.S795Efs*22	0.5952	126.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S795Efs*22 (Frameshift)		STAD_MUTECT2	TCGA-HF-A5NB-01A-11D-A31L-08	TCGA-HF-A5NB-10A-01D-A31J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.R1721*	0.4398	241.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1721* (Nonsense)		STAD_MUTECT2	TCGA-VQ-A8PF-01A-11D-A410-08	TCGA-VQ-A8PF-10B-01D-A413-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.G283V	0.1887	53.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.G283V (Missense)	0	STAD_MUTECT2	TCGA-RD-A8NB-01A-12D-A397-08	TCGA-RD-A8NB-10A-01D-A39A-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L2561M	0.1014	69.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L2561M (Missense)	1	STAD_MUTECT2	TCGA-RD-A8NB-01A-12D-A397-08	TCGA-RD-A8NB-10A-01D-A39A-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Frameshift	p.M272Cfs*31	0.125	48.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.M272Cfs*31 (Frameshift)		STAD_MUTECT2	TCGA-RD-A8NB-01A-12D-A397-08	TCGA-RD-A8NB-10A-01D-A39A-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.S214P	0.25	56.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.S214P (Missense)	1	STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.V92M	0.1212	99.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.V92M (Missense)		STAD_MUTECT2	TCGA-HU-A4G3-01A-11D-A24D-08	TCGA-HU-A4G3-10A-01D-A24F-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R505C	0.4231	130.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R505C (Missense)		STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.L527R	0.4545	99.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.L527R (Missense)	0	STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.W2491L	0.2611	226.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.W2491L (Missense)	1	STAD_MUTECT2	TCGA-BR-7707-01A-11D-2053-08	TCGA-BR-7707-10A-01D-2053-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R479Q	0.1528	72.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R479Q (Missense)		STAD_MUTECT2	TCGA-HU-A4GN-01A-11D-A25D-08	TCGA-HU-A4GN-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.R269W	0.1081	37.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.R269W (Missense)	0	STAD_MUTECT2	TCGA-HU-A4GN-01A-11D-A25D-08	TCGA-HU-A4GN-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465C	0.1787	207.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465C (Missense)		STAD_MUTECT2	TCGA-D7-A6EY-01A-21D-A31L-08	TCGA-D7-A6EY-10A-01D-A31J-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.A961V	0.2403	258.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.A961V (Missense)	0	STAD_MUTECT2	TCGA-D7-A6EY-01A-21D-A31L-08	TCGA-D7-A6EY-10A-01D-A31J-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.W1461C	0.1887	53.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.W1461C (Missense)	1	STAD_MUTECT2	TCGA-BR-8081-01A-11D-2340-08	TCGA-BR-8081-10A-01D-2340-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R1095G	0.2319	69.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R1095G (Missense)	1	STAD_MUTECT2	TCGA-BR-8591-01A-11D-2394-08	TCGA-BR-8591-10A-01D-2394-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.M2482V	0.2432	74.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.M2482V (Missense)	1	STAD_MUTECT2	TCGA-VQ-A91E-01A-31D-A410-08	TCGA-VQ-A91E-10A-01D-A413-08
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Missense	p.D235G	0.2	40.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.D235G (Missense)	0	STAD_MUTECT2	TCGA-VQ-A91E-01A-31D-A410-08	TCGA-VQ-A91E-10A-01D-A413-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R1466Q	0.2308	104.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R1466Q (Missense)	1	STAD_MUTECT2	TCGA-CG-5728-01A-11D-1600-08	TCGA-CG-5728-11A-01D-1600-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465C	0.3271	269.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465C (Missense)		STAD_MUTECT2	TCGA-CD-A4MJ-01A-11D-A25D-08	TCGA-CD-A4MJ-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465C	0.2545	220.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465C (Missense)		STAD_MUTECT2	TCGA-BR-8360-01A-11D-2340-08	TCGA-BR-8360-10A-01D-2340-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465C	0.2869	251.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465C (Missense)		STAD_MUTECT2	TCGA-BR-8372-01A-11D-2340-08	TCGA-BR-8372-10A-01D-2341-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.P551L	0.1452	62.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.P551L (Missense)		STAD_MUTECT2	TCGA-BR-8686-01A-11D-2394-08	TCGA-BR-8686-10A-01D-2394-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.V419A	0.3684	38.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.V419A (Missense)	0	STAD_MUTECT2	TCGA-F1-6177-01A-11D-1800-08	TCGA-F1-6177-10A-01D-1800-08
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Missense	p.G136E	0.3974	156.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.G136E (Missense)	0	STAD_MUTECT2	TCGA-F1-6177-01A-11D-1800-08	TCGA-F1-6177-10A-01D-1800-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.V57I	0.2466	73.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.V57I (Missense)	0	STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R23Q	0.3721	86.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R23Q (Missense)	1	STAD_MUTECT2	TCGA-BR-4292-01A-01D-1126-08	TCGA-BR-4292-11A-01D-1126-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.A179T	0.2353	51.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.A179T (Missense)	0	STAD_MUTECT2	TCGA-BR-4292-01A-01D-1126-08	TCGA-BR-4292-11A-01D-1126-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R14Q	0.2885	52.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R14Q (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.E871K	0.3939	66.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.E871K (Missense)	1	STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.R402H	0.3617	47.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.R402H (Missense)	0	STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.E7D	0.3125	16.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.E7D (Missense)	0	STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.T323R	0.1207	58.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.T323R (Missense)	0	STAD_MUTECT2	TCGA-CG-4437-01A-01D-1800-08	TCGA-CG-4437-10A-01D-1800-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.H500Q	0.5769	78.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.H500Q (Missense)		STAD_MUTECT2	TCGA-3M-AB46-01A-11D-A410-08	TCGA-3M-AB46-10A-01D-A413-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.H88Y	0.386	57.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.H88Y (Missense)	0	STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R479Q	0.2051	39.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R479Q (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.V1190L	0.3537	82.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.V1190L (Missense)	1	STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.D2090E	0.1605	81.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.D2090E (Missense)	1	STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.R269W	0.4211	19.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.R269W (Missense)	0	STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.F211L	0.3765	162.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.F211L (Missense)	0	STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.Y2398C	0.1163	43.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.Y2398C (Missense)	1	STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Preclinical			Somatic Variant	AKT1	Missense	p.Y417C	0.0814	86.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.Y417C (Missense)	0	STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.D813N	0.1786	112.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.D813N (Missense)	0	STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Preclinical			Somatic Variant	AKT1	Missense	p.I447V	0.2632	38.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.I447V (Missense)	0	STAD_MUTECT2	TCGA-HU-8243-01A-11D-2340-08	TCGA-HU-8243-10A-01D-2341-08
Investigate Actionability	Preclinical			Somatic Variant	AKT1	Missense	p.S475L	0.3529	17.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.S475L (Missense)	0	STAD_MUTECT2	TCGA-VQ-A8PB-01A-11D-A397-08	TCGA-VQ-A8PB-10A-01D-A39A-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.S566N	0.3412	85.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.S566N (Missense)		STAD_MUTECT2	TCGA-HU-A4H8-01A-11D-A25D-08	TCGA-HU-A4H8-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.R117H	0.3636	11.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.R117H (Missense)	0	STAD_MUTECT2	TCGA-HU-A4H8-01A-11D-A25D-08	TCGA-HU-A4H8-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Missense	p.R77C	0.2235	85.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.R77C (Missense)	0	STAD_MUTECT2	TCGA-HU-A4H8-01A-11D-A25D-08	TCGA-HU-A4H8-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465H	0.1403	221.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465H (Missense)		STAD_MUTECT2	TCGA-MX-A5UJ-01A-11D-A31L-08	TCGA-MX-A5UJ-10A-01D-A31J-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.F2410L	0.64	50.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.F2410L (Missense)	1	STAD_MUTECT2	TCGA-BR-A4CQ-01A-12D-A25D-08	TCGA-BR-A4CQ-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.G266S	0.3514	37.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.G266S (Missense)		STAD_MUTECT2	TCGA-VQ-A8PO-01A-11D-A410-08	TCGA-VQ-A8PO-10A-01D-A413-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Nonsense	p.R1093*	0.6121	165.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1093* (Nonsense)		STAD_MUTECT2	TCGA-BR-7704-01A-11D-2053-08	TCGA-BR-7704-10A-01D-2053-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R337C	0.1765	51.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R337C (Missense)	1	STAD_MUTECT2	TCGA-BR-4257-01A-01D-1126-08	TCGA-BR-4257-11A-01D-1126-08
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Missense	p.R191H	0.1959	97.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.R191H (Missense)	0	STAD_MUTECT2	TCGA-CG-4306-01A-01D-1158-08	TCGA-CG-4306-10A-01D-1158-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R479Q	0.1064	47.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R479Q (Missense)		STAD_MUTECT2	TCGA-BR-8380-01A-11D-2340-08	TCGA-BR-8380-10A-01D-2341-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L2890V	0.2388	67.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L2890V (Missense)	1	STAD_MUTECT2	TCGA-CG-4301-01A-01D-1158-08	TCGA-CG-4301-10A-01D-1158-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R674Q	0.3937	127.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R674Q (Missense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.M1040I	0.3265	49.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.M1040I (Missense)	1	STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.D2708N	0.3077	52.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.D2708N (Missense)	1	STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.V6A	0.3	30.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.V6A (Missense)	0	STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.F505C	0.1473	129.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.F505C (Missense)	1	STAD_MUTECT2	TCGA-VQ-A8PC-01A-11D-A397-08	TCGA-VQ-A8PC-10A-01D-A39A-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.T482S	0.2951	61.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.T482S (Missense)		STAD_MUTECT2	TCGA-VQ-AA6D-01A-11D-A410-08	TCGA-VQ-AA6D-10A-01D-A413-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.V464A	0.3	10.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.V464A (Missense)	0	STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R2832C	0.2054	185.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R2832C (Missense)	1	STAD_MUTECT2	TCGA-BR-6566-01A-11D-1800-08	TCGA-BR-6566-10A-01D-1800-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.R403H	0.1522	46.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.R403H (Missense)	0	STAD_MUTECT2	TCGA-BR-8381-01A-11D-2394-08	TCGA-BR-8381-10A-01D-2394-08
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Missense	p.I126F	0.3056	108.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.I126F (Missense)	0	STAD_MUTECT2	TCGA-VQ-A94R-01A-11D-A410-08	TCGA-VQ-A94R-10A-01D-A413-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.A626T	0.2286	35.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.A626T (Missense)		STAD_MUTECT2	TCGA-BR-7851-01A-11D-2201-08	TCGA-BR-7851-10A-01D-2201-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.A244V	0.1556	45.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.A244V (Missense)	1	STAD_MUTECT2	TCGA-BR-7851-01A-11D-2201-08	TCGA-BR-7851-10A-01D-2201-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.P1086Q	0.2289	83.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.P1086Q (Missense)	0	STAD_MUTECT2	TCGA-BR-7851-01A-11D-2201-08	TCGA-BR-7851-10A-01D-2201-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465C	0.0926	162.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465C (Missense)		STAD_MUTECT2	TCGA-F1-A448-01A-11D-A24D-08	TCGA-F1-A448-10A-01D-A24F-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.A190T	0.3065	62.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.A190T (Missense)	0	STAD_MUTECT2	TCGA-HU-A4GX-01A-12D-A25D-08	TCGA-HU-A4GX-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465C	0.1841	391.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465C (Missense)		STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R337C	0.1969	127.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R337C (Missense)	1	STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.I287S	0.5059	85.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.I287S (Missense)	0	STAD_MUTECT2	TCGA-D7-8573-01A-11D-2340-08	TCGA-D7-8573-10A-01D-2341-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.E22G	0.1038	183.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.E22G (Missense)	1	STAD_MUTECT2	TCGA-R5-A7ZI-01A-11D-A34U-08	TCGA-R5-A7ZI-10A-01D-A34X-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R1882Q	0.3409	88.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R1882Q (Missense)	1	STAD_MUTECT2	TCGA-R5-A7ZI-01A-11D-A34U-08	TCGA-R5-A7ZI-10A-01D-A34X-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465H	0.4333	150.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465H (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Splice Site	p.X573_splice	0.4571	105.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.X573_splice (Splice Site)		STAD_MUTECT2	TCGA-D7-6520-01A-11D-1800-08	TCGA-D7-6520-10A-01D-1800-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.R402H	0.0847	59.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.R402H (Missense)	0	STAD_MUTECT2	TCGA-BR-6706-01A-11D-1882-08	TCGA-BR-6706-10A-01D-1882-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.E287V	0.1477	88.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.E287V (Missense)		STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465C	0.2471	433.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465C (Missense)		STAD_MUTECT2	TCGA-CG-5733-01A-11D-1600-08	TCGA-CG-5733-11A-01D-1600-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.K404E	0.8125	96.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.K404E (Missense)		STAD_MUTECT2	TCGA-BR-8678-01A-11D-2394-08	TCGA-BR-8678-10A-01D-2394-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.I1659M	0.1619	105.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.I1659M (Missense)	1	STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.N387D	0.2903	31.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.N387D (Missense)	0	STAD_MUTECT2	TCGA-CD-5804-01A-12D-2053-08	TCGA-CD-5804-10A-01D-2053-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.L48I	0.2958	71.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.L48I (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.R75H	0.1061	66.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.R75H (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.F2686C	0.6	75.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.F2686C (Missense)	1	STAD_MUTECT2	TCGA-CD-8534-01A-11D-2340-08	TCGA-CD-8534-10A-01D-2341-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.R108I	0.1719	64.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.R108I (Missense)	0	STAD_MUTECT2	TCGA-HF-7132-01A-11D-2053-08	TCGA-HF-7132-10A-01D-2053-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465C	0.2267	300.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465C (Missense)		STAD_MUTECT2	TCGA-HF-7132-01A-11D-2053-08	TCGA-HF-7132-10A-01D-2053-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.E437D	0.0761	92.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.E437D (Missense)	0	STAD_MUTECT2	TCGA-IN-A7NR-01A-11D-A34U-08	TCGA-IN-A7NR-10A-01D-A34X-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R479Q	0.172	93.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R479Q (Missense)		STAD_MUTECT2	TCGA-BR-4256-01A-01D-1126-08	TCGA-BR-4256-11A-01D-1126-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.A481V	0.1927	109.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.A481V (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L1408F	0.1391	115.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L1408F (Missense)	1	STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.N2567S	0.1582	158.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.N2567S (Missense)	1	STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R3008C	0.1667	150.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R3008C (Missense)	1	STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R2790K	0.2232	112.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R2790K (Missense)	1	STAD_MUTECT2	TCGA-BR-7717-01A-11D-2053-08	TCGA-BR-7717-10A-01D-2053-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.R25Q	0.1711	76.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.R25Q (Missense)	0	STAD_MUTECT2	TCGA-BR-7703-01A-11D-2053-08	TCGA-BR-7703-10A-01D-2053-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.R40C	0.5	12.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.R40C (Missense)	0	STAD_MUTECT2	TCGA-BR-8361-01A-11D-2340-08	TCGA-BR-8361-10A-01D-2340-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465C	0.1202	208.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465C (Missense)		STAD_MUTECT2	TCGA-BR-6852-01A-11D-1882-08	TCGA-BR-6852-10A-01D-1882-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.R347H	0.134	97.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.R347H (Missense)	0	STAD_MUTECT2	TCGA-BR-8382-01A-11D-2394-08	TCGA-BR-8382-10A-01D-2394-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.G335E	0.0926	54.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.G335E (Missense)	1	STAD_MUTECT2	TCGA-VQ-AA6K-01A-11D-A410-08	TCGA-VQ-AA6K-10A-01D-A413-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.A320V	0.1515	66.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.A320V (Missense)	0	STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.N393K	0.0764	157.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.N393K (Missense)	0	STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.N1100D	0.3058	121.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.N1100D (Missense)	0	STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.R170W	0.3415	41.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.R170W (Missense)	0	STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.V8M	0.4667	30.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.V8M (Missense)		STAD_MUTECT2	TCGA-HF-A5NB-01A-11D-A31L-08	TCGA-HF-A5NB-10A-01D-A31J-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.D225N	0.3636	66.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.D225N (Missense)		STAD_MUTECT2	TCGA-BR-4362-01A-01D-1158-08	TCGA-BR-4362-11A-01D-1158-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.N2117D	0.2143	84.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.N2117D (Missense)		STAD_MUTECT2	TCGA-IN-A6RL-01A-11D-A32N-08	TCGA-IN-A6RL-10A-01D-A32N-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.R507H	0.0974	195.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.R507H (Missense)		STAD_MUTECT2	TCGA-BR-7707-01A-11D-2053-08	TCGA-BR-7707-10A-01D-2053-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.A234T	0.0923	65.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.A234T (Missense)		STAD_MUTECT2	TCGA-BR-4368-01A-01D-1158-08	TCGA-BR-4368-11A-01D-1158-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R1519C	0.2692	26.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R1519C (Missense)		STAD_MUTECT2	TCGA-D7-A6EY-01A-21D-A31L-08	TCGA-D7-A6EY-10A-01D-A31J-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.G2226R	0.24	25.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.G2226R (Missense)		STAD_MUTECT2	TCGA-VQ-A8PX-01A-12D-A410-08	TCGA-VQ-A8PX-10A-01D-A413-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.E1956G	0.3125	48.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.E1956G (Missense)		STAD_MUTECT2	TCGA-HU-A4GU-01A-11D-A25D-08	TCGA-HU-A4GU-10A-01D-A25E-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.R311C	0.4516	31.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.R311C (Missense)		STAD_MUTECT2	TCGA-BR-8591-01A-11D-2394-08	TCGA-BR-8591-10A-01D-2394-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.A613S	0.0847	59.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.A613S (Missense)		STAD_MUTECT2	TCGA-VQ-A91E-01A-31D-A410-08	TCGA-VQ-A91E-10A-01D-A413-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.A186V	0.0494	243.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.A186V (Missense)		STAD_MUTECT2	TCGA-CG-5728-01A-11D-1600-08	TCGA-CG-5728-11A-01D-1600-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.R525W	0.0918	98.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.R525W (Missense)		STAD_MUTECT2	TCGA-CD-8529-01A-11D-2340-08	TCGA-CD-8529-10A-01D-2341-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R847W	0.0612	98.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R847W (Missense)		STAD_MUTECT2	TCGA-CD-A4MJ-01A-11D-A25D-08	TCGA-CD-A4MJ-10A-01D-A25E-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.D1747N	0.2414	87.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.D1747N (Missense)		STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.Y2003C	0.3	80.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.Y2003C (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.V411L	0.3143	245.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.V411L (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.A1778D	0.25	28.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.A1778D (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.T449M	0.3714	105.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.T449M (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.P286L	0.2973	37.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.P286L (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.A1967V	0.4741	135.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.A1967V (Missense)		STAD_MUTECT2	TCGA-CG-5726-01A-11D-1600-08	TCGA-CG-5726-11A-01D-1600-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R1111Q	0.2454	163.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R1111Q (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.S681R	0.0909	99.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.S681R (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.V474I	0.1887	106.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.V474I (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.D316N	0.1176	34.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.D316N (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R821C	0.385	213.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R821C (Missense)		STAD_MUTECT2	TCGA-HU-A4H8-01A-11D-A25D-08	TCGA-HU-A4H8-10A-01D-A25E-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.G324V	0.4444	9.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.G324V (Missense)		STAD_MUTECT2	TCGA-EQ-A4SO-01A-11D-A25D-08	TCGA-EQ-A4SO-10A-01D-A25E-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R2017C	0.2593	54.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R2017C (Missense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R1324C	0.2143	42.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R1324C (Missense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.I728L	0.4167	24.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.I728L (Missense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R1037C	0.1507	73.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R1037C (Missense)		STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.L1388I	0.1558	77.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.L1388I (Missense)		STAD_MUTECT2	TCGA-F1-A448-01A-11D-A24D-08	TCGA-F1-A448-10A-01D-A24F-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.M829V	0.1233	73.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.M829V (Missense)		STAD_MUTECT2	TCGA-R5-A7ZI-01A-11D-A34U-08	TCGA-R5-A7ZI-10A-01D-A34X-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.R126H	0.2319	138.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.R126H (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.E588K	0.2286	35.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.E588K (Missense)		STAD_MUTECT2	TCGA-BR-6706-01A-11D-1882-08	TCGA-BR-6706-10A-01D-1882-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.S805N	0.2286	70.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.S805N (Missense)		STAD_MUTECT2	TCGA-CG-5733-01A-11D-1600-08	TCGA-CG-5733-11A-01D-1600-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.D1948Y	0.1552	58.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.D1948Y (Missense)		STAD_MUTECT2	TCGA-BR-8059-01A-11D-2340-08	TCGA-BR-8059-10A-01D-2340-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R1519H	0.2258	31.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R1519H (Missense)		STAD_MUTECT2	TCGA-BR-8059-01A-11D-2340-08	TCGA-BR-8059-10A-01D-2340-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.Y1865C	0.0583	103.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.Y1865C (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R712C	0.3103	116.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R712C (Missense)		STAD_MUTECT2	TCGA-VQ-A924-01A-11D-A410-08	TCGA-VQ-A924-10A-01D-A413-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.T1738N	0.2373	59.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.T1738N (Missense)		STAD_MUTECT2	TCGA-VQ-A91K-01A-11D-A410-08	TCGA-VQ-A91K-10A-01D-A413-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.A1699D	0.3375	80.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.A1699D (Missense)		STAD_MUTECT2	TCGA-VQ-A91K-01A-11D-A410-08	TCGA-VQ-A91K-10A-01D-A413-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.C112F	0.0889	45.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.C112F (Missense)		STAD_MUTECT2	TCGA-HF-7136-01A-11D-2053-08	TCGA-HF-7136-10A-01D-2053-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R793C	0.1803	61.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R793C (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R665W	0.2581	31.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R665W (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V272M	0.7333	30.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V272M (Missense)		STAD_MUTECT2	TCGA-CD-A48C-01A-11D-A24D-08	TCGA-CD-A48C-10A-01D-A24F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C135F	0.5333	30.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C135F (Missense)		STAD_MUTECT2	TCGA-CD-5800-01A-11D-1600-08	TCGA-CD-5800-10A-01D-1600-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.641	39.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		STAD_MUTECT2	TCGA-CG-4438-01A-01D-1158-08	TCGA-CG-4438-10A-01D-1158-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q317*	0.5347	101.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q317* (Nonsense)		STAD_MUTECT2	TCGA-CG-4436-01A-01D-1158-08	TCGA-CG-4436-10A-01D-1158-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.P152Rfs*18	0.3433	67.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P152Rfs*18 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4H3-01A-21D-A25D-08	TCGA-HU-A4H3-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.V73Wfs*50	0.2867	150.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V73Wfs*50 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4H3-01A-21D-A25D-08	TCGA-HU-A4H3-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.4583	24.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		STAD_MUTECT2	TCGA-VQ-AA6I-01A-11D-A410-08	TCGA-VQ-AA6I-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Q136E	0.6757	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q136E (Missense)		STAD_MUTECT2	TCGA-BR-A4PE-01A-31D-A25D-08	TCGA-BR-A4PE-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.N239Qfs*24	0.225	40.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.N239Qfs*24 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8DL-01A-11D-A364-08	TCGA-VQ-A8DL-10A-01D-A362-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.G266Dfs*79	0.4828	29.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G266Dfs*79 (Frameshift)		STAD_MUTECT2	TCGA-EQ-8122-01A-11D-2340-08	TCGA-EQ-8122-10A-01D-2341-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.1333	30.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		STAD_MUTECT2	TCGA-RD-A8NB-01A-12D-A397-08	TCGA-RD-A8NB-10A-01D-A39A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y220C	0.5405	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y220C (Missense)		STAD_MUTECT2	TCGA-CD-8525-01A-11D-2340-08	TCGA-CD-8525-10A-01D-2341-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V97D	0.2283	92.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V97D (Missense)		STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.L35Cfs*9	0.3043	184.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L35Cfs*9 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V272M	0.3	30.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V272M (Missense)		STAD_MUTECT2	TCGA-CD-8526-01A-11D-2340-08	TCGA-CD-8526-10A-01D-2341-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193R	0.619	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193R (Missense)		STAD_MUTECT2	TCGA-VQ-A922-01A-11D-A410-08	TCGA-VQ-A922-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.619	21.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		STAD_MUTECT2	TCGA-BR-6458-01A-11D-1800-08	TCGA-BR-6458-10A-01D-1800-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.F270L	0.32	25.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F270L (Missense)		STAD_MUTECT2	TCGA-HU-A4H4-01A-21D-A25D-08	TCGA-HU-A4H4-11A-11D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.V73Rfs*76	0.505	200.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V73Rfs*76 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4HD-01A-11D-A25D-08	TCGA-HU-A4HD-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y205H	0.2075	53.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y205H (Missense)		STAD_MUTECT2	TCGA-F1-A72C-01A-21D-A33T-08	TCGA-F1-A72C-10A-01D-A33W-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.*394T	0.0406	197.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.*394T (Frameshift)		STAD_MUTECT2	TCGA-CG-5716-01A-21D-1800-08	TCGA-CG-5716-10A-01D-1800-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179R	0.2188	64.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179R (Missense)		STAD_MUTECT2	TCGA-FP-A9TM-01A-11D-A397-08	TCGA-FP-A9TM-10A-01D-A39A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179R	0.2857	105.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179R (Missense)		STAD_MUTECT2	TCGA-CD-A489-01A-11D-A24D-08	TCGA-CD-A489-10A-01D-A24F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.6136	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		STAD_MUTECT2	TCGA-IN-A6RL-01A-11D-A32N-08	TCGA-IN-A6RL-10A-01D-A32N-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.225	40.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G108S	0.405	121.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G108S (Missense)		STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C141Y	0.3214	28.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C141Y (Missense)		STAD_MUTECT2	TCGA-IN-A6RS-01A-12D-A34U-08	TCGA-IN-A6RS-10A-01D-A34X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.E339Rfs*6	0.4412	34.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E339Rfs*6 (Frameshift)		STAD_MUTECT2	TCGA-CD-A4MH-01A-11D-A25D-08	TCGA-CD-A4MH-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.T125M	0.1603	131.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.T125M (Missense)		STAD_MUTECT2	TCGA-HU-A4GN-01A-11D-A25D-08	TCGA-HU-A4GN-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.7917	24.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		STAD_MUTECT2	TCGA-VQ-A91Z-01A-11D-A410-08	TCGA-VQ-A91Z-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.6385	130.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		STAD_MUTECT2	TCGA-BR-4357-01A-01D-1158-08	TCGA-BR-4357-11A-01D-1158-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.3529	17.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		STAD_MUTECT2	TCGA-VQ-A8E2-01A-11D-A364-08	TCGA-VQ-A8E2-10A-01D-A362-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R306*	0.1782	101.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R306* (Nonsense)		STAD_MUTECT2	TCGA-BR-6457-01A-21D-1800-08	TCGA-BR-6457-10A-01D-1800-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E286G	0.6222	45.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E286G (Missense)		STAD_MUTECT2	TCGA-B7-A5TN-01A-21D-A31L-08	TCGA-B7-A5TN-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.5625	80.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		STAD_MUTECT2	TCGA-VQ-A923-01A-11D-A410-08	TCGA-VQ-A923-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.3684	19.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		STAD_MUTECT2	TCGA-BR-7716-01A-21D-2053-08	TCGA-BR-7716-10A-01D-2053-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.4493	69.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		STAD_MUTECT2	TCGA-BR-8484-01A-11D-2394-08	TCGA-BR-8484-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R306*	0.2333	90.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R306* (Nonsense)		STAD_MUTECT2	TCGA-BR-8682-01A-11D-2394-08	TCGA-BR-8682-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.M237I	0.3796	108.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.M237I (Missense)		STAD_MUTECT2	TCGA-D7-6820-01A-11D-1882-08	TCGA-D7-6820-10A-01D-1882-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.P301Qfs*44	0.1343	67.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P301Qfs*44 (Frameshift)		STAD_MUTECT2	TCGA-BR-8081-01A-11D-2340-08	TCGA-BR-8081-10A-01D-2340-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.7547	53.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		STAD_MUTECT2	TCGA-BR-A4QI-01A-12D-A25D-08	TCGA-BR-A4QI-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.W91*	0.6069	145.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.W91* (Nonsense)		STAD_MUTECT2	TCGA-BR-A4PD-01A-11D-A25D-08	TCGA-BR-A4PD-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.4444	27.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		STAD_MUTECT2	TCGA-IN-7806-01A-11D-2053-08	TCGA-IN-7806-10A-01D-2053-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Q192R	0.1562	32.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q192R (Missense)		STAD_MUTECT2	TCGA-VQ-A8PX-01A-12D-A410-08	TCGA-VQ-A8PX-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R158H	0.4576	59.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R158H (Missense)		STAD_MUTECT2	TCGA-VQ-A8PX-01A-12D-A410-08	TCGA-VQ-A8PX-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.4615	91.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		STAD_MUTECT2	TCGA-CG-4300-01A-01D-1158-08	TCGA-CG-4300-10A-01D-1158-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.M246I	0.3099	71.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.M246I (Missense)		STAD_MUTECT2	TCGA-VQ-A925-01A-11D-A410-08	TCGA-VQ-A925-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X223_splice	0.7368	19.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X223_splice (Splice Site)		STAD_MUTECT2	TCGA-VQ-A925-01A-11D-A410-08	TCGA-VQ-A925-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.08	50.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		STAD_MUTECT2	TCGA-VQ-A91E-01A-31D-A410-08	TCGA-VQ-A91E-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X25_splice	0.4348	69.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X25_splice (Splice Site)		STAD_MUTECT2	TCGA-ZQ-A9CR-01A-11D-A397-08	TCGA-ZQ-A9CR-10A-01D-A39A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X261_splice	0.7778	9.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X261_splice (Splice Site)		STAD_MUTECT2	TCGA-BR-7723-01A-11D-2053-08	TCGA-BR-7723-10A-01D-2053-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.I254S	0.4324	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.I254S (Missense)		STAD_MUTECT2	TCGA-VQ-A8PK-01A-12D-A410-08	TCGA-VQ-A8PK-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.C135Afs*35	0.6818	22.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C135Afs*35 (Frameshift)		STAD_MUTECT2	TCGA-KB-A93H-01A-11D-A397-08	TCGA-KB-A93H-10A-01D-A39A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V272M	0.7273	11.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V272M (Missense)		STAD_MUTECT2	TCGA-VQ-AA6B-01A-11D-A410-08	TCGA-VQ-AA6B-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.F113L	0.6105	95.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F113L (Missense)		STAD_MUTECT2	TCGA-F1-6874-01A-11D-1882-08	TCGA-F1-6874-10A-01D-1882-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.3679	106.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		STAD_MUTECT2	TCGA-IN-7808-01A-11D-2201-08	TCGA-IN-7808-10A-01D-2201-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.L35Cfs*9	0.3412	170.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L35Cfs*9 (Frameshift)		STAD_MUTECT2	TCGA-HU-8604-01A-11D-2394-08	TCGA-HU-8604-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G244C	0.2937	126.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G244C (Missense)		STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P250L	0.56	100.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P250L (Missense)		STAD_MUTECT2	TCGA-CG-4449-01A-01D-1158-08	TCGA-CG-4449-10A-01D-1158-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q192*	0.425	40.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q192* (Nonsense)		STAD_MUTECT2	TCGA-D7-A4YU-01A-21D-A25D-08	TCGA-D7-A4YU-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.2105	19.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		STAD_MUTECT2	TCGA-BR-4292-01A-01D-1126-08	TCGA-BR-4292-11A-01D-1126-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.P152Rfs*18	0.871	93.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P152Rfs*18 (Frameshift)		STAD_MUTECT2	TCGA-CG-4466-01A-01D-1158-08	TCGA-CG-4466-10A-01D-1158-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.D281Gfs*63	0.3684	19.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.D281Gfs*63 (Frameshift)		STAD_MUTECT2	TCGA-3M-AB46-01A-11D-A410-08	TCGA-3M-AB46-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.4242	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.5	76.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P4L	0.4324	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P4L (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.8649	74.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		STAD_MUTECT2	TCGA-D7-6815-01A-11D-1882-08	TCGA-D7-6815-10A-01D-1882-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.P98Afs*51	0.5269	93.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P98Afs*51 (Frameshift)		STAD_MUTECT2	TCGA-BR-8486-01A-31D-2394-08	TCGA-BR-8486-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.P128Lfs*42	0.4651	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P128Lfs*42 (Frameshift)		STAD_MUTECT2	TCGA-HF-7131-01A-11D-2053-08	TCGA-HF-7131-10A-01D-2053-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.P301Qfs*44	0.3562	160.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P301Qfs*44 (Frameshift)		STAD_MUTECT2	TCGA-BR-4363-01A-01D-1158-08	TCGA-BR-4363-11A-01D-1158-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R196*	0.2424	66.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R196* (Nonsense)		STAD_MUTECT2	TCGA-BR-4363-01A-01D-1158-08	TCGA-BR-4363-11A-01D-1158-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.W146*	0.7609	46.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.W146* (Nonsense)		STAD_MUTECT2	TCGA-VQ-A8E3-01A-11D-A397-08	TCGA-VQ-A8E3-10A-01D-A39A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y220C	0.4667	15.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y220C (Missense)		STAD_MUTECT2	TCGA-VQ-AA6G-01A-11D-A410-08	TCGA-VQ-AA6G-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179Y	0.6327	49.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179Y (Missense)		STAD_MUTECT2	TCGA-CG-4444-01A-01D-1158-08	TCGA-CG-4444-10A-01D-1158-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.5682	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		STAD_MUTECT2	TCGA-HU-8243-01A-11D-2340-08	TCGA-HU-8243-10A-01D-2341-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.5294	68.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		STAD_MUTECT2	TCGA-FP-8099-01A-11D-2340-08	TCGA-FP-8099-10A-01D-2341-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E286K	0.5385	26.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E286K (Missense)		STAD_MUTECT2	TCGA-HU-A4GP-01A-11D-A25D-08	TCGA-HU-A4GP-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C176F	0.6627	83.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C176F (Missense)		STAD_MUTECT2	TCGA-BR-A4CQ-01A-12D-A25D-08	TCGA-BR-A4CQ-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H214R	0.2545	55.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H214R (Missense)		STAD_MUTECT2	TCGA-BR-4255-01A-01D-1126-08	TCGA-BR-4255-11A-01D-1126-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.6458	48.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		STAD_MUTECT2	TCGA-IN-A6RI-01A-11D-A32N-08	TCGA-IN-A6RI-10A-01D-A32N-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.6765	34.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		STAD_MUTECT2	TCGA-BR-8077-01A-11D-2340-08	TCGA-BR-8077-10A-01D-2340-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C176F	0.5405	74.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C176F (Missense)		STAD_MUTECT2	TCGA-BR-A452-01A-91D-A25D-08	TCGA-BR-A452-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C238F	0.0909	55.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C238F (Missense)		STAD_MUTECT2	TCGA-BR-8296-01A-11D-2340-08	TCGA-BR-8296-10A-01D-2340-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.C229Yfs*10	0.4773	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C229Yfs*10 (Frameshift)		STAD_MUTECT2	TCGA-CG-5732-01A-11D-1600-08	TCGA-CG-5732-11A-01D-1600-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L265P	0.6957	23.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L265P (Missense)		STAD_MUTECT2	TCGA-VQ-A91S-01A-11D-A410-08	TCGA-VQ-A91S-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.S96Ffs*25	0.1083	120.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S96Ffs*25 (Frameshift)		STAD_MUTECT2	TCGA-D7-A74B-01A-12D-A33T-08	TCGA-D7-A74B-10A-01D-A33W-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q136*	0.3111	45.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q136* (Nonsense)		STAD_MUTECT2	TCGA-SW-A7EB-01A-11D-A34U-08	TCGA-SW-A7EB-10A-01D-A34X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.G226Afs*21	0.383	47.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G226Afs*21 (Frameshift)		STAD_MUTECT2	TCGA-BR-8683-01A-11D-2394-08	TCGA-BR-8683-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.L130Cfs*20	0.72	25.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L130Cfs*20 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8DV-01A-12D-A364-08	TCGA-VQ-A8DV-10A-01D-A362-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273S	0.3721	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273S (Missense)		STAD_MUTECT2	TCGA-D7-8578-01A-21D-2340-08	TCGA-D7-8578-10A-01D-2341-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R158H	0.0833	48.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R158H (Missense)		STAD_MUTECT2	TCGA-BR-A4IU-01A-22D-A25D-08	TCGA-BR-A4IU-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.D281Afs*62	0.4694	49.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.D281Afs*62 (Frameshift)		STAD_MUTECT2	TCGA-D7-6818-01A-11D-1882-08	TCGA-D7-6818-10A-01D-1882-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L130V	0.6571	35.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L130V (Missense)		STAD_MUTECT2	TCGA-HU-A4GF-01A-11D-A24D-08	TCGA-HU-A4GF-10A-01D-A24F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.I195T	0.4054	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.I195T (Missense)		STAD_MUTECT2	TCGA-HU-8244-01A-11D-2340-08	TCGA-HU-8244-10A-01D-2341-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.S241Pfs*6	0.3276	58.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S241Pfs*6 (Frameshift)		STAD_MUTECT2	TCGA-HU-8245-01A-11D-2340-08	TCGA-HU-8245-10A-01D-2341-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X126_splice	0.2203	59.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X126_splice (Splice Site)		STAD_MUTECT2	TCGA-CG-4476-01A-01D-1158-08	TCGA-CG-4476-10A-01D-1158-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G245S	0.6602	103.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245S (Missense)		STAD_MUTECT2	TCGA-FP-8631-01A-11D-2394-08	TCGA-FP-8631-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y220C	0.8235	34.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y220C (Missense)		STAD_MUTECT2	TCGA-CG-5730-01A-11D-1600-08	TCGA-CG-5730-11A-01D-1600-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X261_splice	0.2286	35.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X261_splice (Splice Site)		STAD_MUTECT2	TCGA-VQ-A8PC-01A-11D-A397-08	TCGA-VQ-A8PC-10A-01D-A39A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X261_splice	0.8095	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X261_splice (Splice Site)		STAD_MUTECT2	TCGA-F1-6875-01A-11D-2053-08	TCGA-F1-6875-11A-01D-2053-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R306*	0.8462	52.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R306* (Nonsense)		STAD_MUTECT2	TCGA-CD-8535-01A-11D-2340-08	TCGA-CD-8535-10A-01D-2341-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.T150Afs*16	0.747	83.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.T150Afs*16 (Frameshift)		STAD_MUTECT2	TCGA-IN-A6RR-01A-12D-A32N-08	TCGA-IN-A6RR-10A-01D-A32N-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.6452	31.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		STAD_MUTECT2	TCGA-D7-8576-01A-11D-2340-08	TCGA-D7-8576-10A-01D-2341-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.I195N	0.5897	39.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.I195N (Missense)		STAD_MUTECT2	TCGA-HU-A4GD-01A-11D-A25D-08	TCGA-HU-A4GD-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.P98Lfs*25	0.0549	91.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P98Lfs*25 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PD-01A-11D-A410-08	TCGA-VQ-A8PD-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.E294Sfs*51	0.6667	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E294Sfs*51 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A91N-01A-11D-A410-08	TCGA-VQ-A91N-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P151T	0.7	20.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P151T (Missense)		STAD_MUTECT2	TCGA-CD-8528-01A-11D-2340-08	TCGA-CD-8528-10A-01D-2341-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.5849	53.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		STAD_MUTECT2	TCGA-VQ-A8E7-01B-11D-A410-08	TCGA-VQ-A8E7-10B-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.3929	28.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R158H	0.3077	91.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R158H (Missense)		STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V173M	0.4419	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V173M (Missense)		STAD_MUTECT2	TCGA-FP-7735-01A-11D-2053-08	TCGA-FP-7735-10A-01D-2053-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.3151	73.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		STAD_MUTECT2	TCGA-BR-A4IY-01A-11D-A25D-08	TCGA-BR-A4IY-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.I162F	0.6829	41.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.I162F (Missense)		STAD_MUTECT2	TCGA-HU-A4GH-01A-11D-A24D-08	TCGA-HU-A4GH-10A-01D-A24F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.M237I	0.75	48.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.M237I (Missense)		STAD_MUTECT2	TCGA-D7-A6F2-01A-12D-A31L-08	TCGA-D7-A6F2-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.P153Afs*28	0.2258	31.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P153Afs*28 (Frameshift)		STAD_MUTECT2	TCGA-IN-8462-01A-11D-2340-08	TCGA-IN-8462-10A-01D-2341-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.W53*	0.5541	157.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.W53* (Nonsense)		STAD_MUTECT2	TCGA-KB-A93J-01A-11D-A397-08	TCGA-KB-A93J-10A-01D-A39A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.E221Afs*2	0.25	68.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E221Afs*2 (Frameshift)		STAD_MUTECT2	TCGA-CG-4477-01A-01D-1158-08	TCGA-CG-4477-10A-01D-1158-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y107D	0.3279	61.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y107D (Missense)		STAD_MUTECT2	TCGA-BR-6565-01A-11D-1800-08	TCGA-BR-6565-10A-01D-1800-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.N345Sfs*2	0.7297	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.N345Sfs*2 (Nonsense)		STAD_MUTECT2	TCGA-D7-6526-01A-11D-1800-08	TCGA-D7-6526-10A-01D-1800-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175G	0.1667	66.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175G (Missense)		STAD_MUTECT2	TCGA-D7-6518-01A-11D-1800-08	TCGA-D7-6518-10A-01D-1800-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X261_splice	0.5238	21.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X261_splice (Splice Site)		STAD_MUTECT2	TCGA-VQ-A8P5-01A-11D-A397-08	TCGA-VQ-A8P5-10A-01D-A39A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.F270S	0.6923	13.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F270S (Missense)		STAD_MUTECT2	TCGA-BR-7715-01A-11D-2053-08	TCGA-BR-7715-10A-01D-2053-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X331_splice	0.6098	41.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X331_splice (Splice Site)		STAD_MUTECT2	TCGA-VQ-A94R-01A-11D-A410-08	TCGA-VQ-A94R-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.I195Yfs*14	0.5306	49.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.I195Yfs*14 (Frameshift)		STAD_MUTECT2	TCGA-BR-A4J8-01A-11D-A25D-08	TCGA-BR-A4J8-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.N310Tfs*35	0.2857	35.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.N310Tfs*35 (Frameshift)		STAD_MUTECT2	TCGA-RD-A8N9-01A-12D-A397-08	TCGA-RD-A8N9-10A-01D-A39A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.F270L	0.4318	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F270L (Missense)		STAD_MUTECT2	TCGA-CG-5727-01A-11D-1600-08	TCGA-CG-5727-11A-01D-1600-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P151T	0.3673	49.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P151T (Missense)		STAD_MUTECT2	TCGA-IN-A7NU-01A-22D-A34U-08	TCGA-IN-A7NU-10A-01D-A34X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y220C	0.8788	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y220C (Missense)		STAD_MUTECT2	TCGA-VQ-AA6A-01A-11D-A410-08	TCGA-VQ-AA6A-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193R	0.2571	35.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193R (Missense)		STAD_MUTECT2	TCGA-BR-6456-01A-11D-1800-08	TCGA-BR-6456-10A-01D-1800-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.M237I	0.2182	55.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.M237I (Missense)		STAD_MUTECT2	TCGA-RD-A8MW-01A-11D-A364-08	TCGA-RD-A8MW-10A-01D-A362-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.P82Rfs*41	0.5192	156.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P82Rfs*41 (Frameshift)		STAD_MUTECT2	TCGA-BR-A4PF-01A-11D-A25D-08	TCGA-BR-A4PF-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P72S	0.2817	284.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P72S (Missense)		STAD_MUTECT2	TCGA-HU-A4GX-01A-12D-A25D-08	TCGA-HU-A4GX-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.3803	71.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		STAD_MUTECT2	TCGA-IN-A7NT-01A-21D-A34U-08	TCGA-IN-A7NT-10A-01D-A34X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X307_splice	0.2714	70.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X307_splice (Splice Site)		STAD_MUTECT2	TCGA-HU-A4GC-01A-12D-A25D-08	TCGA-HU-A4GC-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y205C	0.7308	78.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y205C (Missense)		STAD_MUTECT2	TCGA-CD-8533-01A-11D-2340-08	TCGA-CD-8533-10A-01D-2341-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y126D	0.3333	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y126D (Missense)		STAD_MUTECT2	TCGA-MX-A666-01A-11D-A31L-08	TCGA-MX-A666-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L145P	0.3902	41.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L145P (Missense)		STAD_MUTECT2	TCGA-VQ-A8DZ-01A-11D-A364-08	TCGA-VQ-A8DZ-10A-01D-A362-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V173L	0.5155	97.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V173L (Missense)		STAD_MUTECT2	TCGA-R5-A7ZE-01B-11D-A34U-08	TCGA-R5-A7ZE-10A-01D-A34X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X261_splice	0.9048	21.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X261_splice (Splice Site)		STAD_MUTECT2	TCGA-RD-A8N6-01A-11D-A364-08	TCGA-RD-A8N6-10A-01D-A362-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G245S	0.622	82.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245S (Missense)		STAD_MUTECT2	TCGA-BR-8286-01A-12D-2340-08	TCGA-BR-8286-10A-01D-2340-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.M169T	0.1569	51.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.M169T (Missense)		STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R196*	0.5769	26.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R196* (Nonsense)		STAD_MUTECT2	TCGA-VQ-A8PE-01A-11D-A410-08	TCGA-VQ-A8PE-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.5556	45.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		STAD_MUTECT2	TCGA-CG-4469-01A-01D-1158-08	TCGA-CG-4469-10A-01D-1158-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.Y103Tfs*20	0.5368	95.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y103Tfs*20 (Frameshift)		STAD_MUTECT2	TCGA-BR-8679-01A-11D-2394-08	TCGA-BR-8679-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.4516	31.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		STAD_MUTECT2	TCGA-D7-6525-01A-11D-1800-08	TCGA-D7-6525-10A-01D-1800-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.303	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		STAD_MUTECT2	TCGA-D7-6817-01A-11D-1882-08	TCGA-D7-6817-10A-01D-1882-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P151A	0.2727	66.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P151A (Missense)		STAD_MUTECT2	TCGA-VQ-A8PY-01A-11D-A410-08	TCGA-VQ-A8PY-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V173M	0.146	137.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V173M (Missense)		STAD_MUTECT2	TCGA-KB-A93G-01A-11D-A397-08	TCGA-KB-A93G-10A-01D-A39A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.S20Qfs*24	0.125	40.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S20Qfs*24 (Frameshift)		STAD_MUTECT2	TCGA-CG-5734-01A-11D-1600-08	TCGA-CG-5734-11A-01D-1600-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.7759	58.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		STAD_MUTECT2	TCGA-D7-A6EX-01A-11D-A31L-08	TCGA-D7-A6EX-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.F134L	0.88	25.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F134L (Missense)		STAD_MUTECT2	TCGA-VQ-A91V-01A-11D-A410-08	TCGA-VQ-A91V-10B-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X126_splice	0.2368	38.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X126_splice (Splice Site)		STAD_MUTECT2	TCGA-VQ-A8PM-01A-21D-A410-08	TCGA-VQ-A8PM-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q144*	0.4348	69.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q144* (Nonsense)		STAD_MUTECT2	TCGA-BR-8690-01A-11D-2394-08	TCGA-BR-8690-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.2667	75.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.4667	45.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		STAD_MUTECT2	TCGA-D7-6520-01A-11D-1800-08	TCGA-D7-6520-10A-01D-1800-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X125_splice	0.247	166.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X125_splice (Splice Site)		STAD_MUTECT2	TCGA-BR-8369-01A-11D-2340-08	TCGA-BR-8369-10A-01D-2341-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X224_splice	0.2778	18.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X224_splice (Splice Site)		STAD_MUTECT2	TCGA-HU-8238-01A-11D-2340-08	TCGA-HU-8238-10A-01D-2341-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C176W	0.2037	54.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C176W (Missense)		STAD_MUTECT2	TCGA-RD-A8N1-01A-12D-A364-08	TCGA-RD-A8N1-10A-01D-A362-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C242Y	0.4615	39.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C242Y (Missense)		STAD_MUTECT2	TCGA-CD-8531-01A-11D-2340-08	TCGA-CD-8531-10A-01D-2341-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.45	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		STAD_MUTECT2	TCGA-CD-5813-01A-11D-1600-08	TCGA-CD-5813-10A-01D-1600-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E285*	0.2295	61.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E285* (Nonsense)		STAD_MUTECT2	TCGA-B7-A5TI-01A-11D-A31L-08	TCGA-B7-A5TI-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P152L	0.3301	103.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P152L (Missense)		STAD_MUTECT2	TCGA-B7-A5TI-01A-11D-A31L-08	TCGA-B7-A5TI-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C176F	0.6964	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C176F (Missense)		STAD_MUTECT2	TCGA-FP-7829-01A-11D-2053-08	TCGA-FP-7829-10A-01D-2053-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R267G	0.5	22.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R267G (Missense)		STAD_MUTECT2	TCGA-R5-A7O7-01A-11D-A33T-08	TCGA-R5-A7O7-10A-01D-A33W-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.R342Efs*3	0.5714	35.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R342Efs*3 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A91U-01A-11D-A410-08	TCGA-VQ-A91U-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179N	0.5686	51.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179N (Missense)		STAD_MUTECT2	TCGA-D7-A6EV-01A-11D-A31L-08	TCGA-D7-A6EV-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.D259Y	0.5152	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.D259Y (Missense)		STAD_MUTECT2	TCGA-VQ-A8PH-01A-12D-A410-08	TCGA-VQ-A8PH-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.S94*	0.6479	71.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S94* (Nonsense)		STAD_MUTECT2	TCGA-BR-8678-01A-11D-2394-08	TCGA-BR-8678-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E198*	0.28	50.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E198* (Nonsense)		STAD_MUTECT2	TCGA-R5-A7ZF-01A-11D-A34U-08	TCGA-R5-A7ZF-10A-01D-A34X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.K382Nfs*40	0.0591	220.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K382Nfs*40 (Frameshift)		STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.2683	41.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H168R	0.2069	58.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H168R (Missense)		STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R337C	0.4419	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R337C (Missense)		STAD_MUTECT2	TCGA-CD-5804-01A-12D-2053-08	TCGA-CD-5804-10A-01D-2053-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.2788	165.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		STAD_MUTECT2	TCGA-BR-8297-01A-12D-2340-08	TCGA-BR-8297-10A-01D-2340-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.N345D	0.3571	28.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.N345D (Missense)		STAD_MUTECT2	TCGA-BR-8080-01A-11D-2340-08	TCGA-BR-8080-10A-01D-2340-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.C242Afs*5	0.4316	95.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C242Afs*5 (Frameshift)		STAD_MUTECT2	TCGA-CG-4440-01A-01D-1158-08	TCGA-CG-4440-10A-01D-1158-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C176F	0.0778	90.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C176F (Missense)		STAD_MUTECT2	TCGA-CG-5717-01A-11D-1600-08	TCGA-CG-5717-10A-01D-1600-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R196*	0.3243	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R196* (Nonsense)		STAD_MUTECT2	TCGA-VQ-A8DT-01A-11D-A364-08	TCGA-VQ-A8DT-10A-01D-A362-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X126_splice	0.2174	23.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X126_splice (Splice Site)		STAD_MUTECT2	TCGA-HF-7132-01A-11D-2053-08	TCGA-HF-7132-10A-01D-2053-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.1786	28.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		STAD_MUTECT2	TCGA-CD-8524-01A-11D-2340-08	TCGA-CD-8524-10A-01D-2341-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.T284Kfs*61	0.7742	62.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.T284Kfs*61 (Frameshift)		STAD_MUTECT2	TCGA-D7-6822-01A-11D-1882-08	TCGA-D7-6822-10A-01D-1882-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X187_splice	0.1905	21.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X187_splice (Splice Site)		STAD_MUTECT2	TCGA-BR-4183-01A-02D-1126-08	TCGA-BR-4183-11A-01D-1126-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.8182	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		STAD_MUTECT2	TCGA-D7-A6F0-01A-11D-A31L-08	TCGA-D7-A6F0-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.L35Cfs*9	0.6514	175.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L35Cfs*9 (Frameshift)		STAD_MUTECT2	TCGA-D7-6527-01A-11D-1800-08	TCGA-D7-6527-10A-01D-1800-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.9	10.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		STAD_MUTECT2	TCGA-VQ-A8DU-01A-11D-A364-08	TCGA-VQ-A8DU-10A-01D-A362-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.0938	64.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		STAD_MUTECT2	TCGA-IN-A7NR-01A-11D-A34U-08	TCGA-IN-A7NR-10A-01D-A34X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R342*	0.7941	34.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R342* (Nonsense)		STAD_MUTECT2	TCGA-IP-7968-01A-11D-2201-08	TCGA-IP-7968-10A-01D-2201-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L111Q	0.3906	64.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L111Q (Missense)		STAD_MUTECT2	TCGA-CD-8530-01A-11D-2340-08	TCGA-CD-8530-10A-01D-2341-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.1944	36.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		STAD_MUTECT2	TCGA-BR-4256-01A-01D-1126-08	TCGA-BR-4256-11A-01D-1126-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L130F	0.0926	54.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L130F (Missense)		STAD_MUTECT2	TCGA-BR-6803-01A-11D-1882-08	TCGA-BR-6803-10A-01D-1882-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.2	50.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E286K	0.8909	55.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E286K (Missense)		STAD_MUTECT2	TCGA-BR-A4CR-01A-11D-A24D-08	TCGA-BR-A4CR-10A-01D-A24F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.5733	75.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		STAD_MUTECT2	TCGA-CD-5799-01A-11D-1600-08	TCGA-CD-5799-10A-01D-1600-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.P152Wfs*10	0.4737	57.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P152Wfs*10 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4H2-01A-11D-A25D-08	TCGA-HU-A4H2-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.3611	36.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		STAD_MUTECT2	TCGA-BR-7197-01A-11D-2201-08	TCGA-BR-7197-10A-01D-2201-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X125_splice	0.7431	109.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X125_splice (Splice Site)		STAD_MUTECT2	TCGA-BR-8483-01A-31D-2394-08	TCGA-BR-8483-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193Y	0.56	25.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193Y (Missense)		STAD_MUTECT2	TCGA-VQ-A91X-01A-12D-A410-08	TCGA-VQ-A91X-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.4026	77.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		STAD_MUTECT2	TCGA-CD-A487-01A-21D-A24D-08	TCGA-CD-A487-10A-01D-A24F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X126_splice	0.75	20.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X126_splice (Splice Site)		STAD_MUTECT2	TCGA-VQ-A8PJ-01A-11D-A410-08	TCGA-VQ-A8PJ-10A-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q167*	0.8155	103.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q167* (Nonsense)		STAD_MUTECT2	TCGA-BR-4366-01A-01D-1158-08	TCGA-BR-4366-11A-01D-1158-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C242S	0.3333	120.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C242S (Missense)		STAD_MUTECT2	TCGA-BR-A4CS-01A-11D-A24D-08	TCGA-BR-A4CS-10A-01D-A24F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.S392T	0.3774	212.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S392T (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8E0-01A-11D-A410-08	TCGA-VQ-A8E0-10B-01D-A413-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E271K	0.5758	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E271K (Missense)		STAD_MUTECT2	TCGA-D7-5578-01A-01D-1600-08	TCGA-D7-5578-10A-01D-1600-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.T253I	0.4783	92.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.T253I (Missense)		STAD_MUTECT2	TCGA-BR-7703-01A-11D-2053-08	TCGA-BR-7703-10A-01D-2053-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.1739	92.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		STAD_MUTECT2	TCGA-IN-A6RP-01A-21D-A33T-08	TCGA-IN-A6RP-10A-01D-A33W-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.P152Rfs*18	0.4382	89.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P152Rfs*18 (Frameshift)		STAD_MUTECT2	TCGA-HJ-7597-01A-21D-2201-08	TCGA-HJ-7597-10A-01D-2201-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C176Y	0.6471	51.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C176Y (Missense)		STAD_MUTECT2	TCGA-BR-8361-01A-11D-2340-08	TCGA-BR-8361-10A-01D-2340-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R209*	0.625	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R209* (Nonsense)		STAD_MUTECT2	TCGA-VQ-A94U-01A-12D-A410-08	TCGA-VQ-A94U-10A-01D-A413-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.V568M	0.093	215.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.V568M (Missense)		STAD_MUTECT2	TCGA-CG-4436-01A-01D-1158-08	TCGA-CG-4436-10A-01D-1158-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.G250R	0.4302	86.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.G250R (Missense)		STAD_MUTECT2	TCGA-IN-8663-01A-11D-2394-08	TCGA-IN-8663-10A-01D-2394-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.S601R	0.4478	67.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.S601R (Missense)		STAD_MUTECT2	TCGA-KB-A93H-01A-11D-A397-08	TCGA-KB-A93H-10A-01D-A39A-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.E189G	0.3043	69.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.E189G (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.Q447P	0.3234	235.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.Q447P (Missense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.V515I	0.3148	54.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.V515I (Missense)		STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.R616H	0.2903	31.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.R616H (Missense)		STAD_MUTECT2	TCGA-BR-A4PE-01A-31D-A25D-08	TCGA-BR-A4PE-10A-01D-A25E-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.S244A	0.5789	19.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.S244A (Missense)		STAD_MUTECT2	TCGA-VQ-A8P3-01A-11D-A364-08	TCGA-VQ-A8P3-10A-01D-A362-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.K237R	0.5	30.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.K237R (Missense)		STAD_MUTECT2	TCGA-BR-6454-01A-11D-1800-08	TCGA-BR-6454-11A-01D-1800-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.G590E	0.3462	26.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.G590E (Missense)		STAD_MUTECT2	TCGA-IN-A6RS-01A-12D-A34U-08	TCGA-IN-A6RS-10A-01D-A34X-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.H292R	0.2143	14.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.H292R (Missense)		STAD_MUTECT2	TCGA-HU-A4GN-01A-11D-A25D-08	TCGA-HU-A4GN-10A-01D-A25E-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.R280C	0.4756	82.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.R280C (Missense)		STAD_MUTECT2	TCGA-HU-A4GU-01A-11D-A25D-08	TCGA-HU-A4GU-10A-01D-A25E-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.K862R	0.3462	52.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.K862R (Missense)		STAD_MUTECT2	TCGA-KB-A93H-01A-11D-A397-08	TCGA-KB-A93H-10A-01D-A39A-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.F814V	0.4737	38.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.F814V (Missense)		STAD_MUTECT2	TCGA-CD-A4MJ-01A-11D-A25D-08	TCGA-CD-A4MJ-10A-01D-A25E-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.A299T	0.7273	33.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.A299T (Missense)		STAD_MUTECT2	TCGA-BR-8372-01A-11D-2340-08	TCGA-BR-8372-10A-01D-2341-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.C602Y	0.2857	49.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.C602Y (Missense)		STAD_MUTECT2	TCGA-CD-A4MI-01A-21D-A25D-08	TCGA-CD-A4MI-10A-01D-A25E-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.S704N	0.2444	45.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.S704N (Missense)		STAD_MUTECT2	TCGA-MX-A5UJ-01A-11D-A31L-08	TCGA-MX-A5UJ-10A-01D-A31J-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.F814L	0.2366	93.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.F814L (Missense)		STAD_MUTECT2	TCGA-BR-7704-01A-11D-2053-08	TCGA-BR-7704-10A-01D-2053-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.F57V	0.0833	120.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.F57V (Missense)		STAD_MUTECT2	TCGA-CD-5801-01A-11D-1600-08	TCGA-CD-5801-10A-01D-1600-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.L548V	0.717	53.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.L548V (Missense)		STAD_MUTECT2	TCGA-HU-8249-01A-11D-2340-08	TCGA-HU-8249-10A-01D-2341-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.K809N	0.7407	27.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.K809N (Missense)		STAD_MUTECT2	TCGA-VQ-A91V-01A-11D-A410-08	TCGA-VQ-A91V-10B-01D-A413-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.R775H	0.3	120.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.R775H (Missense)		STAD_MUTECT2	TCGA-CD-8531-01A-11D-2340-08	TCGA-CD-8531-10A-01D-2341-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.A270T	0.3673	98.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.A270T (Missense)		STAD_MUTECT2	TCGA-CG-5733-01A-11D-1600-08	TCGA-CG-5733-11A-01D-1600-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.K778T	0.8293	41.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.K778T (Missense)		STAD_MUTECT2	TCGA-VQ-A91K-01A-11D-A410-08	TCGA-VQ-A91K-10A-01D-A413-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.S293P	0.2857	42.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.S293P (Missense)		STAD_MUTECT2	TCGA-D7-6527-01A-11D-1800-08	TCGA-D7-6527-10A-01D-1800-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.N849K	0.2609	46.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.N849K (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.F814V	0.2	40.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.F814V (Missense)		STAD_MUTECT2	TCGA-D7-5578-01A-01D-1600-08	TCGA-D7-5578-10A-01D-1600-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.L389M	0.25	12.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.L389M (Missense)		STAD_MUTECT2	TCGA-BR-8361-01A-11D-2340-08	TCGA-BR-8361-10A-01D-2340-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.T110A	0.32	100.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.T110A (Missense)		STAD_MUTECT2	TCGA-BR-8485-01A-11D-2394-08	TCGA-BR-8485-10A-01D-2394-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.A704T	0.1707	41.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.A704T (Missense)		STAD_MUTECT2	TCGA-RD-A8NB-01A-12D-A397-08	TCGA-RD-A8NB-10A-01D-A39A-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Nonsense	p.R1163*	0.2553	47.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.R1163* (Nonsense)		STAD_MUTECT2	TCGA-BR-7196-01A-11D-2053-08	TCGA-BR-7196-10A-01D-2053-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S944R	0.1605	81.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S944R (Missense)		STAD_MUTECT2	TCGA-D7-A4Z0-01A-22D-A25D-08	TCGA-D7-A4Z0-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.M148Dfs*3	0.4211	76.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.M148Dfs*3 (Frameshift)		STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.V1169I	0.2958	142.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.V1169I (Missense)		STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Frameshift	p.P1621Qfs*53	0.2581	31.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.P1621Qfs*53 (Frameshift)		STAD_MUTECT2	TCGA-BR-7707-01A-11D-2053-08	TCGA-BR-7707-10A-01D-2053-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Frameshift	p.P602Rfs*67	0.0952	105.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.P602Rfs*67 (Frameshift)		STAD_MUTECT2	TCGA-BR-7707-01A-11D-2053-08	TCGA-BR-7707-10A-01D-2053-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Nonsense	p.E644*	0.4333	60.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.E644* (Nonsense)		STAD_MUTECT2	TCGA-CG-4455-01A-01D-1158-08	TCGA-CG-4455-10A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R67W	0.3019	53.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R67W (Missense)		STAD_MUTECT2	TCGA-HU-A4GU-01A-11D-A25D-08	TCGA-HU-A4GU-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Frameshift	p.P1621Qfs*53	0.25	28.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.P1621Qfs*53 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A91E-01A-31D-A410-08	TCGA-VQ-A91E-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R627H	0.2136	103.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R627H (Missense)		STAD_MUTECT2	TCGA-CG-5728-01A-11D-1600-08	TCGA-CG-5728-11A-01D-1600-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Nonsense	p.E946*	0.4091	22.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.E946* (Nonsense)		STAD_MUTECT2	TCGA-BR-6455-01A-11D-1800-08	TCGA-BR-6455-10A-01D-1800-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.G46Afs*25	0.1765	136.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.G46Afs*25 (Frameshift)		STAD_MUTECT2	TCGA-BR-4370-01A-01D-1158-08	TCGA-BR-4370-11A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Frameshift	p.V172Cfs*81	0.3208	106.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.V172Cfs*81 (Frameshift)		STAD_MUTECT2	TCGA-CG-4442-01A-01D-1158-08	TCGA-CG-4442-10A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.C176Vfs*7	0.6891	119.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.C176Vfs*7 (Frameshift)		STAD_MUTECT2	TCGA-CG-4442-01A-01D-1158-08	TCGA-CG-4442-10A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Frameshift	p.G645Vfs*58	0.3571	28.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.G645Vfs*58 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PT-01A-11D-A410-08	TCGA-VQ-A8PT-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Frameshift	p.K1207Nfs*31	0.8077	52.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.K1207Nfs*31 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PT-01A-11D-A410-08	TCGA-VQ-A8PT-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Frameshift	p.L205Wfs*4	0.2706	303.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.L205Wfs*4 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S247T	0.44	125.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S247T (Missense)		STAD_MUTECT2	TCGA-BR-4369-01A-01D-1158-08	TCGA-BR-4369-11A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S1099Y	0.3165	79.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S1099Y (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.T1294A	0.3784	37.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.T1294A (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.A1190T	0.4375	32.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.A1190T (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.A368D	0.3194	72.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.A368D (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.A60V	0.4844	64.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.A60V (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.A486V	0.2885	52.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.A486V (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.A770V	0.0714	42.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.A770V (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R1008H	0.1429	133.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R1008H (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Frameshift	p.P931Tfs*15	0.8636	22.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.P931Tfs*15 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.K134E	0.1275	102.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.K134E (Missense)		STAD_MUTECT2	TCGA-CG-5726-01A-11D-1600-08	TCGA-CG-5726-11A-01D-1600-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R918W	0.1184	76.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R918W (Missense)		STAD_MUTECT2	TCGA-CG-5726-01A-11D-1600-08	TCGA-CG-5726-11A-01D-1600-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.K1437R	0.1463	41.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.K1437R (Missense)		STAD_MUTECT2	TCGA-D7-A747-01A-22D-A33T-08	TCGA-D7-A747-10A-21D-A33W-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.F751I	0.114	114.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.F751I (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.T1308M	0.2436	78.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.T1308M (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Frameshift	p.G1508Afs*60	0.2025	79.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.G1508Afs*60 (Frameshift)		STAD_MUTECT2	TCGA-BR-4363-01A-01D-1158-08	TCGA-BR-4363-11A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R727Q	0.1507	73.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R727Q (Missense)		STAD_MUTECT2	TCGA-CD-A4MI-01A-21D-A25D-08	TCGA-CD-A4MI-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.T852M	0.2	65.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.T852M (Missense)		STAD_MUTECT2	TCGA-FP-8099-01A-11D-2340-08	TCGA-FP-8099-10A-01D-2341-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Frameshift	p.K456Sfs*195	0.2364	110.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.K456Sfs*195 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PB-01A-11D-A397-08	TCGA-VQ-A8PB-10A-01D-A39A-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R1019H	0.2933	75.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R1019H (Missense)		STAD_MUTECT2	TCGA-HU-A4H8-01A-11D-A25D-08	TCGA-HU-A4H8-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.K1437R	0.1972	71.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.K1437R (Missense)		STAD_MUTECT2	TCGA-HU-A4H8-01A-11D-A25D-08	TCGA-HU-A4H8-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.D1015G	0.0648	108.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.D1015G (Missense)		STAD_MUTECT2	TCGA-HU-A4GP-01A-11D-A25D-08	TCGA-HU-A4GP-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.D70Y	0.186	86.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.D70Y (Missense)		STAD_MUTECT2	TCGA-R5-A804-01A-11D-A364-08	TCGA-R5-A804-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.M1060I	0.1786	56.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.M1060I (Missense)		STAD_MUTECT2	TCGA-BR-8296-01A-11D-2340-08	TCGA-BR-8296-10A-01D-2340-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Frameshift	p.G645Vfs*58	0.3913	23.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.G645Vfs*58 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PO-01A-11D-A410-08	TCGA-VQ-A8PO-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.P327R	0.3662	71.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.P327R (Missense)		STAD_MUTECT2	TCGA-VQ-A91S-01A-11D-A410-08	TCGA-VQ-A91S-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.D1238N	0.25	36.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.D1238N (Missense)		STAD_MUTECT2	TCGA-VQ-A91S-01A-11D-A410-08	TCGA-VQ-A91S-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.N72H	0.198	101.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.N72H (Missense)		STAD_MUTECT2	TCGA-BR-4257-01A-01D-1126-08	TCGA-BR-4257-11A-01D-1126-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Nonsense	p.R810*	0.6667	129.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.R810* (Nonsense)		STAD_MUTECT2	TCGA-CG-5724-01A-11D-1600-08	TCGA-CG-5724-11A-01D-1600-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.E664D	0.2264	53.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.E664D (Missense)		STAD_MUTECT2	TCGA-CG-4306-01A-01D-1158-08	TCGA-CG-4306-10A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Frameshift	p.T938Hfs*8	0.4694	49.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.T938Hfs*8 (Frameshift)		STAD_MUTECT2	TCGA-CG-4306-01A-01D-1158-08	TCGA-CG-4306-10A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Nonsense	p.Q538*	0.1385	65.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.Q538* (Nonsense)		STAD_MUTECT2	TCGA-D7-A6ET-01A-32D-A32N-08	TCGA-D7-A6ET-10A-01D-A32N-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.R676W	0.2553	47.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.R676W (Missense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Frameshift	p.P59Rfs*13	0.3871	31.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.P59Rfs*13 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Frameshift	p.F1305Lfs*145	0.3455	55.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.F1305Lfs*145 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Frameshift	p.K839Sfs*17	0.68	25.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.K839Sfs*17 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.R1297H	0.061	82.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R1297H (Missense)		STAD_MUTECT2	TCGA-RD-A7BW-01A-11D-A32N-08	TCGA-RD-A7BW-10A-01D-A32N-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Splice Site	p.X1391_splice	0.5263	19.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.X1391_splice (Splice Site)		STAD_MUTECT2	TCGA-HU-8608-01A-11D-2394-08	TCGA-HU-8608-10A-01D-2394-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.A192V	0.3659	41.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.A192V (Missense)		STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.T698N	0.2759	58.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.T698N (Missense)		STAD_MUTECT2	TCGA-HU-A4GH-01A-11D-A24D-08	TCGA-HU-A4GH-10A-01D-A24F-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P831Q	0.094	117.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P831Q (Missense)		STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Frameshift	p.G400Afs*42	0.2973	37.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.G400Afs*42 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4GT-01A-21D-A25D-08	TCGA-HU-A4GT-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.Q518R	0.2222	18.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.Q518R (Missense)		STAD_MUTECT2	TCGA-BR-7851-01A-11D-2201-08	TCGA-BR-7851-10A-01D-2201-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Nonsense	p.K978*	0.3684	19.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.K978* (Nonsense)		STAD_MUTECT2	TCGA-F1-A448-01A-11D-A24D-08	TCGA-F1-A448-10A-01D-A24F-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Frameshift	p.G645Vfs*58	0.2195	41.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.G645Vfs*58 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4GX-01A-12D-A25D-08	TCGA-HU-A4GX-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Frameshift	p.P1621Qfs*53	0.3902	41.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.P1621Qfs*53 (Frameshift)		STAD_MUTECT2	TCGA-SW-A7EA-01A-12D-A34U-08	TCGA-SW-A7EA-10A-01D-A34X-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.R124Q	0.0556	108.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R124Q (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.Y994C	0.3029	175.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.Y994C (Missense)		STAD_MUTECT2	TCGA-HF-7134-01A-11D-2053-08	TCGA-HF-7134-10A-01D-2053-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.Y436C	0.2597	181.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.Y436C (Missense)		STAD_MUTECT2	TCGA-HU-A4G8-01A-11D-A25D-08	TCGA-HU-A4G8-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Frameshift	p.C872*	0.2267	75.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.C872* (Frameshift)		STAD_MUTECT2	TCGA-3M-AB47-01A-22D-A410-08	TCGA-3M-AB47-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Frameshift	p.Q1208Tfs*8	0.4333	90.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.Q1208Tfs*8 (Frameshift)		STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.E99G	0.1289	349.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.E99G (Missense)		STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Frameshift	p.K427Nfs*35	0.1019	157.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.K427Nfs*35 (Frameshift)		STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.V996M	0.2137	131.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.V996M (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R1588Q	0.2667	15.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R1588Q (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.K668T	0.0955	178.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.K668T (Missense)		STAD_MUTECT2	TCGA-BR-8297-01A-12D-2340-08	TCGA-BR-8297-10A-01D-2340-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.N218K	0.5806	62.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.N218K (Missense)		STAD_MUTECT2	TCGA-B7-A5TJ-01A-11D-A31L-08	TCGA-B7-A5TJ-10A-01D-A31J-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.R729W	0.1458	48.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.R729W (Missense)		STAD_MUTECT2	TCGA-HF-7132-01A-11D-2053-08	TCGA-HF-7132-10A-01D-2053-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R1189W	0.125	72.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R1189W (Missense)		STAD_MUTECT2	TCGA-HF-7132-01A-11D-2053-08	TCGA-HF-7132-10A-01D-2053-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Nonsense	p.R1514*	0.125	48.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.R1514* (Nonsense)		STAD_MUTECT2	TCGA-BR-8366-01A-11D-2340-08	TCGA-BR-8366-10A-01D-2341-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.K262N	0.1007	139.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.K262N (Missense)		STAD_MUTECT2	TCGA-VQ-A924-01A-11D-A410-08	TCGA-VQ-A924-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R727Q	0.2174	46.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R727Q (Missense)		STAD_MUTECT2	TCGA-VQ-A924-01A-11D-A410-08	TCGA-VQ-A924-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Frameshift	p.S158Vfs*3	0.6429	56.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.S158Vfs*3 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A924-01A-11D-A410-08	TCGA-VQ-A924-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.W1055L	0.1504	133.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.W1055L (Missense)		STAD_MUTECT2	TCGA-BR-4256-01A-01D-1126-08	TCGA-BR-4256-11A-01D-1126-08
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Nonsense	p.W252*	0.1609	87.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.W252* (Nonsense)		STAD_MUTECT2	TCGA-BR-4256-01A-01D-1126-08	TCGA-BR-4256-11A-01D-1126-08
Investigate Actionability			Guideline	Somatic Variant	ZRSR2	Nonsense	p.R126*	0.1351	37.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ZRSR2 p.R126* (Nonsense)		STAD_MUTECT2	TCGA-BR-4256-01A-01D-1126-08	TCGA-BR-4256-11A-01D-1126-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.L544P	0.2353	102.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.L544P (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Frameshift	p.Y1441Mfs*9	0.1951	205.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.Y1441Mfs*9 (Frameshift)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Nonsense	p.K1721*	0.6481	54.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.K1721* (Nonsense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.A694S	0.4203	69.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.A694S (Missense)		STAD_MUTECT2	TCGA-BR-7703-01A-11D-2053-08	TCGA-BR-7703-10A-01D-2053-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Nonsense	p.R1217*	0.5616	73.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.R1217* (Nonsense)		STAD_MUTECT2	TCGA-BR-6707-01A-11D-1882-08	TCGA-BR-6707-10A-01D-1882-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Frameshift	p.L7Cfs*9	0.2077	130.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.L7Cfs*9 (Frameshift)		STAD_MUTECT2	TCGA-HJ-7597-01A-21D-2201-08	TCGA-HJ-7597-10A-01D-2201-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Frameshift	p.P59Rfs*13	0.6207	29.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.P59Rfs*13 (Frameshift)		STAD_MUTECT2	TCGA-BR-8361-01A-11D-2340-08	TCGA-BR-8361-10A-01D-2340-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Frameshift	p.L1617*	0.625	32.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.L1617* (Frameshift)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Frameshift	p.S158Vfs*3	0.3478	23.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.S158Vfs*3 (Frameshift)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Frameshift	p.D1555*	0.1395	43.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.D1555* (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PF-01A-11D-A410-08	TCGA-VQ-A8PF-10B-01D-A413-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.R234H	0.1844	141.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.R234H (Missense)		STAD_MUTECT2	TCGA-BR-4368-01A-01D-1158-08	TCGA-BR-4368-11A-01D-1158-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.G421S	0.1091	55.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.G421S (Missense)		STAD_MUTECT2	TCGA-VQ-A8P8-01A-11D-A397-08	TCGA-VQ-A8P8-10A-01D-A39A-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.G402S	0.2212	113.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.G402S (Missense)		STAD_MUTECT2	TCGA-CG-5728-01A-11D-1600-08	TCGA-CG-5728-11A-01D-1600-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.T917A	0.6842	76.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.T917A (Missense)		STAD_MUTECT2	TCGA-CG-4442-01A-01D-1158-08	TCGA-CG-4442-10A-01D-1158-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.P483L	0.2381	63.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.P483L (Missense)		STAD_MUTECT2	TCGA-HU-8604-01A-11D-2394-08	TCGA-HU-8604-10A-01D-2394-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.D1581Y	0.4286	35.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.D1581Y (Missense)		STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.Y254H	0.3252	123.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.Y254H (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.R1113C	0.3425	73.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.R1113C (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.A535V	0.7647	34.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.A535V (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.G858S	0.11	100.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.G858S (Missense)		STAD_MUTECT2	TCGA-D7-6815-01A-11D-1882-08	TCGA-D7-6815-10A-01D-1882-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.S126N	0.0753	93.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.S126N (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.I540N	0.1053	38.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.I540N (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.W1218C	0.5769	52.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.W1218C (Missense)		STAD_MUTECT2	TCGA-VQ-A8E3-01A-11D-A397-08	TCGA-VQ-A8E3-10A-01D-A39A-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.R683T	0.6332	766.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.R683T (Missense)		STAD_MUTECT2	TCGA-HU-8608-01A-11D-2394-08	TCGA-HU-8608-10A-01D-2394-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.D533N	0.24	50.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.D533N (Missense)		STAD_MUTECT2	TCGA-VQ-A91N-01A-11D-A410-08	TCGA-VQ-A91N-10A-01D-A413-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.Y227H	0.3918	97.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.Y227H (Missense)		STAD_MUTECT2	TCGA-HU-A4GT-01A-21D-A25D-08	TCGA-HU-A4GT-10A-01D-A25E-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.R63G	0.375	32.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.R63G (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.P870S	0.2407	108.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.P870S (Missense)		STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.T1691A	0.1519	79.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.T1691A (Missense)		STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.A658T	0.3704	27.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.A658T (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.R1361T	0.2	35.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.R1361T (Missense)		STAD_MUTECT2	TCGA-D7-A6F0-01A-11D-A31L-08	TCGA-D7-A6F0-10A-01D-A31J-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.G632S	0.425	40.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.G632S (Missense)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Nonsense	p.R603*	0.2347	98.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.R603* (Nonsense)	1	STAD_MUTECT2	TCGA-BR-4201-01A-01D-1126-08	TCGA-BR-4201-11A-01D-1126-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Frameshift	p.P403Lfs*8	0.1368	95.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.P403Lfs*8 (Frameshift)	1	STAD_MUTECT2	TCGA-BR-4362-01A-01D-1158-08	TCGA-BR-4362-11A-01D-1158-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Frameshift	p.P403Lfs*8	0.16	75.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.P403Lfs*8 (Frameshift)	1	STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Frameshift	p.P403Lfs*8	0.3	30.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.P403Lfs*8 (Frameshift)	1	STAD_MUTECT2	TCGA-BR-8078-01A-11D-2340-08	TCGA-BR-8078-10A-01D-2340-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Frameshift	p.P403Lfs*8	0.275	40.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.P403Lfs*8 (Frameshift)	1	STAD_MUTECT2	TCGA-BR-8368-01A-11D-2340-08	TCGA-BR-8368-10A-01D-2341-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Frameshift	p.P403Lfs*8	0.1389	72.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.P403Lfs*8 (Frameshift)	1	STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Frameshift	p.P403Lfs*8	0.3235	34.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.P403Lfs*8 (Frameshift)	1	STAD_MUTECT2	TCGA-BR-7851-01A-11D-2201-08	TCGA-BR-7851-10A-01D-2201-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Nonsense	p.G393*	0.0672	119.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.G393* (Nonsense)	1	STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Frameshift	p.P266Hfs*14	0.2783	115.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P266Hfs*14 (Frameshift)	1	STAD_MUTECT2	TCGA-F1-6874-01A-11D-1882-08	TCGA-F1-6874-10A-01D-1882-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.E1250K	0.2812	128.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E1250K (Missense)	1	STAD_MUTECT2	TCGA-HU-A4H3-01A-21D-A25D-08	TCGA-HU-A4H3-10A-01D-A25E-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.V1283Kfs*2	0.1316	38.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.V1283Kfs*2 (Frameshift)	0	STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.V1862*	0.1311	61.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.V1862* (Frameshift)	0	STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.L759Ffs*3	0.2314	121.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.L759Ffs*3 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-4362-01A-01D-1158-08	TCGA-BR-4362-11A-01D-1158-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.V899L	0.0493	142.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.V899L (Missense)	1	STAD_MUTECT2	TCGA-BR-4362-01A-01D-1158-08	TCGA-BR-4362-11A-01D-1158-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	RET	Frameshift	p.N950Tfs*15	0.1076	158.0	0.0	0.0		Investigate Actionability	Selpercatinib	RET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.	Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf. Revised May 2020. Accessed October 22, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.N950Tfs*15 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4H4-01A-21D-A25D-08	TCGA-HU-A4H4-11A-11D-A25E-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.K2124Tfs*8	0.1379	29.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.K2124Tfs*8 (Frameshift)	0	STAD_MUTECT2	TCGA-CD-A489-01A-11D-A24D-08	TCGA-CD-A489-10A-01D-A24F-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.N1784Kfs*3	0.1887	53.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.N1784Kfs*3 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-4368-01A-01D-1158-08	TCGA-BR-4368-11A-01D-1158-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.A1393V	0.0984	61.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.A1393V (Missense)	0	STAD_MUTECT2	TCGA-HU-A4GN-01A-11D-A25D-08	TCGA-HU-A4GN-10A-01D-A25E-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S3375G	0.0753	93.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S3375G (Missense)	0	STAD_MUTECT2	TCGA-HU-A4GN-01A-11D-A25D-08	TCGA-HU-A4GN-10A-01D-A25E-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.A887T	0.1504	113.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.A887T (Missense)	1	STAD_MUTECT2	TCGA-HU-A4GN-01A-11D-A25D-08	TCGA-HU-A4GN-10A-01D-A25E-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.N1935D	0.0753	385.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.N1935D (Missense)	0	STAD_MUTECT2	TCGA-IN-A6RO-01A-12D-A33T-08	TCGA-IN-A6RO-10A-01D-A33W-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.Q2539H	0.3014	73.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Q2539H (Missense)	0	STAD_MUTECT2	TCGA-HU-A4GU-01A-11D-A25D-08	TCGA-HU-A4GU-10A-01D-A25E-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.S1499F	0.359	39.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.S1499F (Missense)	1	STAD_MUTECT2	TCGA-BR-8591-01A-11D-2394-08	TCGA-BR-8591-10A-01D-2394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.N1784Kfs*3	0.2059	68.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.N1784Kfs*3 (Frameshift)	0	STAD_MUTECT2	TCGA-D7-A4YT-01A-11D-A25D-08	TCGA-D7-A4YT-10A-01D-A25E-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.E368G	0.0667	585.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E368G (Missense)	1	STAD_MUTECT2	TCGA-CG-5728-01A-11D-1600-08	TCGA-CG-5728-11A-01D-1600-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.Q3262P	0.1972	142.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Q3262P (Missense)	0	STAD_MUTECT2	TCGA-BR-7723-01A-11D-2053-08	TCGA-BR-7723-10A-01D-2053-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.K3313Q	0.3273	55.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.K3313Q (Missense)	0	STAD_MUTECT2	TCGA-BR-7723-01A-11D-2053-08	TCGA-BR-7723-10A-01D-2053-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.P1088Lfs*16	0.1562	96.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P1088Lfs*16 (Frameshift)	0	STAD_MUTECT2	TCGA-CD-8529-01A-11D-2340-08	TCGA-CD-8529-10A-01D-2341-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P2734H	0.0534	131.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P2734H (Missense)	0	STAD_MUTECT2	TCGA-CD-A4MJ-01A-11D-A25D-08	TCGA-CD-A4MJ-10A-01D-A25E-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.R1397M	0.274	146.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.R1397M (Missense)	1	STAD_MUTECT2	TCGA-CG-4442-01A-01D-1158-08	TCGA-CG-4442-10A-01D-1158-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.K991Q	0.3785	288.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.K991Q (Missense)	1	STAD_MUTECT2	TCGA-CG-4442-01A-01D-1158-08	TCGA-CG-4442-10A-01D-1158-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.D2202G	0.3846	39.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.D2202G (Missense)	0	STAD_MUTECT2	TCGA-VQ-A8PT-01A-11D-A410-08	TCGA-VQ-A8PT-10A-01D-A413-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.R610M	0.3182	88.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.R610M (Missense)	1	STAD_MUTECT2	TCGA-BR-8360-01A-11D-2340-08	TCGA-BR-8360-10A-01D-2340-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.P529S	0.4694	49.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.P529S (Missense)	1	STAD_MUTECT2	TCGA-CG-4449-01A-01D-1158-08	TCGA-CG-4449-10A-01D-1158-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.R468I	0.35	120.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.R468I (Missense)	0	STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.N2452T	0.3929	56.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.N2452T (Missense)	0	STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.K893N	0.4032	124.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.K893N (Missense)	1	STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.N1344Mfs*30	0.4324	37.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.N1344Mfs*30 (Frameshift)	0	STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.K2131Nfs*5	0.125	24.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.K2131Nfs*5 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-8486-01A-31D-2394-08	TCGA-BR-8486-10A-01D-2394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Frameshift	p.K614Nfs*14	0.0732	41.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.K614Nfs*14 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-8486-01A-31D-2394-08	TCGA-BR-8486-10A-01D-2394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.I332F	0.0696	158.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.I332F (Missense)	0	STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.E2981Rfs*37	0.1935	62.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E2981Rfs*37 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-8078-01A-11D-2340-08	TCGA-BR-8078-10A-01D-2340-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.T3085Nfs*26	0.3913	46.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.T3085Nfs*26 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-8078-01A-11D-2340-08	TCGA-BR-8078-10A-01D-2340-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.I605Yfs*9	0.3469	49.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.I605Yfs*9 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-8368-01A-11D-2340-08	TCGA-BR-8368-10A-01D-2341-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Nonsense	p.R1751*	0.2347	213.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.R1751* (Nonsense)	0	STAD_MUTECT2	TCGA-HU-8243-01A-11D-2340-08	TCGA-HU-8243-10A-01D-2341-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.K1691Nfs*15	0.2576	66.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.K1691Nfs*15 (Frameshift)	0	STAD_MUTECT2	TCGA-VQ-A8PO-01A-11D-A410-08	TCGA-VQ-A8PO-10A-01D-A413-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.P2352S	0.1486	175.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.P2352S (Missense)	0	STAD_MUTECT2	TCGA-CG-4305-01A-01D-1158-08	TCGA-CG-4305-10A-01D-1158-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.R1028C	0.1955	312.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.R1028C (Missense)	1	STAD_MUTECT2	TCGA-CG-4306-01A-01D-1158-08	TCGA-CG-4306-10A-01D-1158-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.A1393V	0.2222	45.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.A1393V (Missense)	0	STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.E1258G	0.0703	185.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E1258G (Missense)	1	STAD_MUTECT2	TCGA-BR-8589-01A-11D-2394-08	TCGA-BR-8589-10A-01D-2394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E3342K	0.3026	76.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E3342K (Missense)	0	STAD_MUTECT2	TCGA-HU-A4GT-01A-21D-A25D-08	TCGA-HU-A4GT-10A-01D-A25E-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.D1692N	0.3725	102.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.D1692N (Missense)	1	STAD_MUTECT2	TCGA-CG-4443-01A-01D-1158-08	TCGA-CG-4443-10A-01D-1158-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.I3418S	0.2771	83.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.I3418S (Missense)	0	STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.N852K	0.2381	63.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.N852K (Missense)	0	STAD_MUTECT2	TCGA-D7-6520-01A-11D-1800-08	TCGA-D7-6520-10A-01D-1800-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.D946Rfs*13	0.2424	66.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.D946Rfs*13 (Frameshift)	0	STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.V494A	0.3474	95.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.V494A (Missense)	0	STAD_MUTECT2	TCGA-HU-A4G8-01A-11D-A25D-08	TCGA-HU-A4G8-10A-01D-A25E-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.T3033Lfs*29	0.65	20.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.T3033Lfs*29 (Frameshift)	0	STAD_MUTECT2	TCGA-B7-A5TI-01A-11D-A31L-08	TCGA-B7-A5TI-10A-01D-A31J-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.V348A	0.3118	465.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.V348A (Missense)	0	STAD_MUTECT2	TCGA-CG-5733-01A-11D-1600-08	TCGA-CG-5733-11A-01D-1600-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.K1691Nfs*15	0.3109	119.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.K1691Nfs*15 (Frameshift)	0	STAD_MUTECT2	TCGA-CG-5733-01A-11D-1600-08	TCGA-CG-5733-11A-01D-1600-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S1121T	0.0833	60.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S1121T (Missense)	0	STAD_MUTECT2	TCGA-BR-8384-01A-21D-2394-08	TCGA-BR-8384-10A-01D-2394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.C1159S	0.0609	115.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.C1159S (Missense)	0	STAD_MUTECT2	TCGA-BR-8384-01A-21D-2394-08	TCGA-BR-8384-10A-01D-2394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.Q3047H	0.122	41.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Q3047H (Missense)	0	STAD_MUTECT2	TCGA-D7-A6EZ-01A-11D-A31L-08	TCGA-D7-A6EZ-10A-01D-A31J-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.N1619D	0.3109	119.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.N1619D (Missense)	0	STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.A2351T	0.3223	121.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.A2351T (Missense)	0	STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.K3416Nfs*11	0.2558	86.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.K3416Nfs*11 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.D946Ifs*14	0.2051	78.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.D946Ifs*14 (Frameshift)	0	STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.G1338D	0.2162	37.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.G1338D (Missense)	0	STAD_MUTECT2	TCGA-HF-7132-01A-11D-2053-08	TCGA-HF-7132-10A-01D-2053-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S2022L	0.2316	177.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S2022L (Missense)	0	STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S1115F	0.2857	98.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S1115F (Missense)	0	STAD_MUTECT2	TCGA-IN-A6RP-01A-21D-A33T-08	TCGA-IN-A6RP-10A-01D-A33W-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.T2515Hfs*9	0.2886	149.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.T2515Hfs*9 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-8361-01A-11D-2340-08	TCGA-BR-8361-10A-01D-2340-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.V2545I	0.1948	77.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.V2545I (Missense)	0	STAD_MUTECT2	TCGA-BR-6852-01A-11D-1882-08	TCGA-BR-6852-10A-01D-1882-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.N986Ifs*5	0.1204	108.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.N986Ifs*5 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.A1439T	0.2414	116.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.A1439T (Missense)	0	STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.A2951V	0.313	115.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.A2951V (Missense)	0	STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Frameshift	p.Q252Hfs*6	0.0612	49.0	0.0	0.0		Investigate Actionability	Imatinib	KIT inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for imatinib for patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 	Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.Q252Hfs*6 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-8486-01A-31D-2394-08	TCGA-BR-8486-10A-01D-2394-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R314H	0.4211	114.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R314H (Missense)		STAD_MUTECT2	TCGA-BR-8368-01A-11D-2340-08	TCGA-BR-8368-10A-01D-2341-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH2	Nonsense	p.W375*	0.1357	140.0	0.0	0.0		Investigate Actionability	Enasidenib	IDH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.	Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf								Investigate Actionability	1	Mutation of IDH2 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH2 p.W375* (Nonsense)		STAD_MUTECT2	TCGA-BR-A4IY-01A-11D-A25D-08	TCGA-BR-A4IY-10A-01D-A25E-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH2	Frameshift	p.T146Dfs*126	0.411	73.0	0.0	0.0		Investigate Actionability	Enasidenib	IDH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.	Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf								Investigate Actionability	1	Mutation of IDH2 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH2 p.T146Dfs*126 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4G9-01A-11D-A24D-08	TCGA-HU-A4G9-10A-01D-A24F-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.P158L	0.0722	180.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.P158L (Missense)		STAD_MUTECT2	TCGA-R5-A7ZE-01B-11D-A34U-08	TCGA-R5-A7ZE-10A-01D-A34X-08
Investigate Actionability	FDA-Approved		Clinical trial	Somatic Variant	PIK3CA	Frameshift	p.L185Ifs*3	0.0625	48.0	0.0	0.0		Investigate Actionability	Alpelisib	PI3K/AKT/mTOR inhibition	Targeted therapy	Alpelisib is a kinase inhibitor indictated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endrocrine-based regime. 	Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf. Revised September 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.L185Ifs*3 (Frameshift)	1	STAD_MUTECT2	TCGA-FP-8099-01A-11D-2340-08	TCGA-FP-8099-10A-01D-2341-08
Investigate Actionability	FDA-Approved		Clinical trial	Somatic Variant	PIK3CA	Deletion	p.P104_V105del	0.0513	117.0	0.0	0.0		Investigate Actionability	Alpelisib	PI3K/AKT/mTOR inhibition	Targeted therapy	Alpelisib is a kinase inhibitor indictated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endrocrine-based regime. 	Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf. Revised September 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.P104_V105del (Deletion)	1	STAD_MUTECT2	TCGA-BR-A4IV-01A-31D-A25D-08	TCGA-BR-A4IV-10A-01D-A25E-08
Investigate Actionability	FDA-Approved		Clinical trial	Somatic Variant	PIK3CA	Frameshift	p.N1068Kfs*5	0.0909	66.0	0.0	0.0		Investigate Actionability	Alpelisib	PI3K/AKT/mTOR inhibition	Targeted therapy	Alpelisib is a kinase inhibitor indictated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endrocrine-based regime. 	Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf. Revised September 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.N1068Kfs*5 (Frameshift)	1	STAD_MUTECT2	TCGA-D7-6524-01A-11D-1800-08	TCGA-D7-6524-10A-01D-1800-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.P115H	0.1871	139.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.P115H (Missense)	1	STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.Q487R	0.0651	338.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.Q487R (Missense)	0	STAD_MUTECT2	TCGA-BR-4362-01A-01D-1158-08	TCGA-BR-4362-11A-01D-1158-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.P707S	0.3111	45.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.P707S (Missense)	0	STAD_MUTECT2	TCGA-HU-A4HD-01A-11D-A25D-08	TCGA-HU-A4HD-10A-01D-A25E-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Frameshift	p.K208Rfs*4	0.459	61.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.K208Rfs*4 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Frameshift	p.N280Tfs*8	0.4766	128.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.N280Tfs*8 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Splice Site	p.X233_splice	0.1301	123.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.X233_splice (Splice Site)	1	STAD_MUTECT2	TCGA-BR-6454-01A-11D-1800-08	TCGA-BR-6454-11A-01D-1800-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Frameshift	p.D172Mfs*40	0.1975	162.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.D172Mfs*40 (Frameshift)	0	STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.S46G	0.1528	72.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.S46G (Missense)	1	STAD_MUTECT2	TCGA-VQ-A91Z-01A-11D-A410-08	TCGA-VQ-A91Z-10A-01D-A413-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.R865W	0.2804	107.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.R865W (Missense)	1	STAD_MUTECT2	TCGA-D7-A4YV-01A-11D-A25D-08	TCGA-D7-A4YV-10A-01D-A25E-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Frameshift	p.N280Tfs*8	0.1261	119.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.N280Tfs*8 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-8081-01A-11D-2340-08	TCGA-BR-8081-10A-01D-2340-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Frameshift	p.E394Kfs*20	0.22	50.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.E394Kfs*20 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-8081-01A-11D-2340-08	TCGA-BR-8081-10A-01D-2340-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Splice Site	p.X411_splice	0.3934	61.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.X411_splice (Splice Site)	1	STAD_MUTECT2	TCGA-VQ-A8PX-01A-12D-A410-08	TCGA-VQ-A8PX-10A-01D-A413-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.R442W	0.25	60.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.R442W (Missense)	1	STAD_MUTECT2	TCGA-BR-8591-01A-11D-2394-08	TCGA-BR-8591-10A-01D-2394-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Frameshift	p.P1009Lfs*6	0.2903	62.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.P1009Lfs*6 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-8591-01A-11D-2394-08	TCGA-BR-8591-10A-01D-2394-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51D	Missense	p.M292I	0.1601	281.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51D p.M292I (Missense)	0	STAD_MUTECT2	TCGA-D7-A4YT-01A-11D-A25D-08	TCGA-D7-A4YT-10A-01D-A25E-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.N744D	0.1733	75.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.N744D (Missense)	0	STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Frameshift	p.M296*	0.2564	117.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.M296* (Frameshift)	0	STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.F93V	0.2316	95.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.F93V (Missense)	1	STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.D898N	0.3155	187.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.D898N (Missense)	1	STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.R379Q	0.2759	87.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.R379Q (Missense)	1	STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Nonsense	p.W1140*	0.0714	42.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.W1140* (Nonsense)	1	STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.N1061S	0.3933	150.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.N1061S (Missense)	1	STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.G290S	0.303	99.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.G290S (Missense)	1	STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.D111G	0.0625	144.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.D111G (Missense)	0	STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Frameshift	p.F202Lfs*3	0.36	25.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.F202Lfs*3 (Frameshift)	0	STAD_MUTECT2	TCGA-CG-5726-01A-11D-1600-08	TCGA-CG-5726-11A-01D-1600-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Frameshift	p.K321Nfs*21	0.1359	103.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.K321Nfs*21 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.E223G	0.1232	138.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.E223G (Missense)	1	STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.L358P	0.1207	232.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.L358P (Missense)	1	STAD_MUTECT2	TCGA-CD-A4MI-01A-21D-A25D-08	TCGA-CD-A4MI-10A-01D-A25E-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.D336N	0.0667	105.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.D336N (Missense)	1	STAD_MUTECT2	TCGA-FP-8099-01A-11D-2340-08	TCGA-FP-8099-10A-01D-2341-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.G881S	0.27	100.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.G881S (Missense)	0	STAD_MUTECT2	TCGA-VQ-A8PB-01A-11D-A397-08	TCGA-VQ-A8PB-10A-01D-A39A-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51D	Missense	p.R300Q	0.2917	144.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51D p.R300Q (Missense)	0	STAD_MUTECT2	TCGA-MX-A5UJ-01A-11D-A31L-08	TCGA-MX-A5UJ-10A-01D-A31J-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Frameshift	p.K208Rfs*4	0.2137	117.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.K208Rfs*4 (Frameshift)	0	STAD_MUTECT2	TCGA-CG-4305-01A-01D-1158-08	TCGA-CG-4305-10A-01D-1158-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Frameshift	p.K209Efs*5	0.1855	124.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.K209Efs*5 (Frameshift)	0	STAD_MUTECT2	TCGA-CG-4306-01A-01D-1158-08	TCGA-CG-4306-10A-01D-1158-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Splice Site	p.X366_splice	0.3333	39.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.X366_splice (Splice Site)	0	STAD_MUTECT2	TCGA-HU-8244-01A-11D-2340-08	TCGA-HU-8244-10A-01D-2341-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.R370H	0.3243	74.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.R370H (Missense)	0	STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Frameshift	p.D172Mfs*40	0.1757	74.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.D172Mfs*40 (Frameshift)	0	STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.S682P	0.0612	147.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.S682P (Missense)	0	STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Frameshift	p.K197Rfs*15	0.377	61.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.K197Rfs*15 (Frameshift)	0	STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Frameshift	p.D172Mfs*40	0.0923	130.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.D172Mfs*40 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-6566-01A-11D-1800-08	TCGA-BR-6566-10A-01D-1800-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Frameshift	p.M296*	0.2564	117.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.M296* (Frameshift)	0	STAD_MUTECT2	TCGA-BR-6566-01A-11D-1800-08	TCGA-BR-6566-10A-01D-1800-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51D	Splice Site	p.X49_splice	0.178	118.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51D p.X49_splice (Splice Site)	0	STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.N154S	0.1481	81.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.N154S (Missense)	0	STAD_MUTECT2	TCGA-BR-6563-01A-13D-2053-08	TCGA-BR-6563-10A-01D-2053-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.S1165L	0.2644	174.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.S1165L (Missense)	0	STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Frameshift	p.K596Nfs*9	0.1769	130.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.K596Nfs*9 (Frameshift)	0	STAD_MUTECT2	TCGA-R5-A7ZI-01A-11D-A34U-08	TCGA-R5-A7ZI-10A-01D-A34X-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.P360L	0.1667	114.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.P360L (Missense)	0	STAD_MUTECT2	TCGA-R5-A7ZI-01A-11D-A34U-08	TCGA-R5-A7ZI-10A-01D-A34X-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.G753D	0.1333	45.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.G753D (Missense)	0	STAD_MUTECT2	TCGA-BR-8059-01A-11D-2340-08	TCGA-BR-8059-10A-01D-2340-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.L480S	0.3673	98.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.L480S (Missense)	0	STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Nonsense	p.E860*	0.2727	66.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.E860* (Nonsense)	1	STAD_MUTECT2	TCGA-VQ-AA64-01A-11D-A410-08	TCGA-VQ-AA64-10A-01D-A413-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.T375A	0.4128	109.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.T375A (Missense)	0	STAD_MUTECT2	TCGA-BR-4280-01A-01D-1126-08	TCGA-BR-4280-11A-01D-1126-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.T733A	0.125	152.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.T733A (Missense)	0	STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Frameshift	p.I504Sfs*22	0.2255	337.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.I504Sfs*22 (Frameshift)	1	STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.R474H	0.274	146.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.R474H (Missense)	0	STAD_MUTECT2	TCGA-HJ-7597-01A-21D-2201-08	TCGA-HJ-7597-10A-01D-2201-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Frameshift	p.D172Mfs*40	0.2872	94.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.D172Mfs*40 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-8361-01A-11D-2340-08	TCGA-BR-8361-10A-01D-2340-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Frameshift	p.N280Tfs*8	0.1905	105.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.N280Tfs*8 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-6852-01A-11D-1882-08	TCGA-BR-6852-10A-01D-1882-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51D	Missense	p.R145C	0.4298	114.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51D p.R145C (Missense)	0	STAD_MUTECT2	TCGA-HF-A5NB-01A-11D-A31L-08	TCGA-HF-A5NB-10A-01D-A31J-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.R365Q	0.1667	78.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.R365Q (Missense)	0	STAD_MUTECT2	TCGA-BR-4201-01A-01D-1126-08	TCGA-BR-4201-11A-01D-1126-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R981H	0.1525	59.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R981H (Missense)	0	STAD_MUTECT2	TCGA-BR-4201-01A-01D-1126-08	TCGA-BR-4201-11A-01D-1126-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.Q906P	0.3116	199.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.Q906P (Missense)		STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.V225M	0.2157	51.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.V225M (Missense)		STAD_MUTECT2	TCGA-BR-6458-01A-11D-1800-08	TCGA-BR-6458-10A-01D-1800-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Nonsense	p.G1446*	0.051	98.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.G1446* (Nonsense)	0	STAD_MUTECT2	TCGA-HU-A4H4-01A-21D-A25D-08	TCGA-HU-A4H4-11A-11D-A25E-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.G382D	0.3048	210.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.G382D (Missense)		STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Deletion	p.P362del	0.3294	85.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.P362del (Deletion)		STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.M168I	0.3913	138.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.M168I (Missense)		STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.R1457Q	0.2432	37.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.R1457Q (Missense)		STAD_MUTECT2	TCGA-BR-6454-01A-11D-1800-08	TCGA-BR-6454-11A-01D-1800-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.L926I	0.0534	131.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.L926I (Missense)	0	STAD_MUTECT2	TCGA-IN-A6RL-01A-11D-A32N-08	TCGA-IN-A6RL-10A-01D-A32N-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.P535H	0.4556	90.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.P535H (Missense)		STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.R718C	0.1935	124.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.R718C (Missense)		STAD_MUTECT2	TCGA-HU-A4GN-01A-11D-A25D-08	TCGA-HU-A4GN-10A-01D-A25E-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.R22W	0.0988	81.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.R22W (Missense)		STAD_MUTECT2	TCGA-VQ-AA68-01A-11D-A410-08	TCGA-VQ-AA68-10A-01D-A413-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.C811R	0.2	45.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.C811R (Missense)		STAD_MUTECT2	TCGA-BR-8081-01A-11D-2340-08	TCGA-BR-8081-10A-01D-2340-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.E254K	0.2841	176.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.E254K (Missense)		STAD_MUTECT2	TCGA-RD-A7C1-01A-11D-A32N-08	TCGA-RD-A7C1-10A-01D-A32N-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.G923V	0.3026	76.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.G923V (Missense)	0	STAD_MUTECT2	TCGA-CG-4442-01A-01D-1158-08	TCGA-CG-4442-10A-01D-1158-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Frameshift	p.G1271Dfs*23	0.2864	213.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.G1271Dfs*23 (Frameshift)	0	STAD_MUTECT2	TCGA-VQ-A8PT-01A-11D-A410-08	TCGA-VQ-A8PT-10A-01D-A413-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Frameshift	p.P573Rfs*53	0.2661	109.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.P573Rfs*53 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.R585H	0.2472	89.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.R585H (Missense)		STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R779C	0.1765	34.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R779C (Missense)	0	STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	FDA-Approved			Somatic Variant	FANCL	Missense	p.E277V	0.4198	81.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	FANCL p.E277V (Missense)	0	STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.E491K	0.2113	142.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.E491K (Missense)	0	STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	FDA-Approved			Somatic Variant	FANCL	Missense	p.H375R	0.1795	78.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	FANCL p.H375R (Missense)	0	STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	FDA-Approved			Somatic Variant	FANCL	Missense	p.A192G	0.0805	87.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	FANCL p.A192G (Missense)	0	STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	FDA-Approved			Somatic Variant	MET	Frameshift	p.L815Pfs*18	0.0938	96.0	0.0	0.0		Investigate Actionability	Capmatinib	MET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Revised May 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf																	MET p.L815Pfs*18 (Frameshift)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.I247T	0.3226	93.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.I247T (Missense)		STAD_MUTECT2	TCGA-VQ-A8E3-01A-11D-A397-08	TCGA-VQ-A8E3-10A-01D-A39A-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.G545D	0.1905	63.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.G545D (Missense)	0	STAD_MUTECT2	TCGA-CD-A4MI-01A-21D-A25D-08	TCGA-CD-A4MI-10A-01D-A25E-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.M570V	0.1444	187.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.M570V (Missense)	0	STAD_MUTECT2	TCGA-CD-A4MI-01A-21D-A25D-08	TCGA-CD-A4MI-10A-01D-A25E-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.R319W	0.3621	58.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.R319W (Missense)	0	STAD_MUTECT2	TCGA-VQ-A8PB-01A-11D-A397-08	TCGA-VQ-A8PB-10A-01D-A39A-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Frameshift	p.G1271Dfs*23	0.2154	441.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.G1271Dfs*23 (Frameshift)	0	STAD_MUTECT2	TCGA-MX-A5UJ-01A-11D-A31L-08	TCGA-MX-A5UJ-10A-01D-A31J-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.V813A	0.1385	65.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.V813A (Missense)		STAD_MUTECT2	TCGA-VQ-A8PO-01A-11D-A410-08	TCGA-VQ-A8PO-10A-01D-A413-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R779H	0.1781	73.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R779H (Missense)	0	STAD_MUTECT2	TCGA-CG-5724-01A-11D-1600-08	TCGA-CG-5724-11A-01D-1600-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.A1759T	0.3736	91.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.A1759T (Missense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Frameshift	p.P683Qfs*70	0.2778	54.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P683Qfs*70 (Frameshift)	0	STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R882Q	0.2185	119.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R882Q (Missense)	0	STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P915S	0.4783	69.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P915S (Missense)	0	STAD_MUTECT2	TCGA-HU-A4GH-01A-11D-A24D-08	TCGA-HU-A4GH-10A-01D-A24F-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Nonsense	p.R1356*	0.028	1610.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R1356* (Nonsense)	0	STAD_MUTECT2	TCGA-VQ-A8P5-01A-11D-A397-08	TCGA-VQ-A8P5-10A-01D-A39A-08
Investigate Actionability	FDA-Approved			Somatic Variant	FANCL	Missense	p.L154S	0.169	71.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	FANCL p.L154S (Missense)	0	STAD_MUTECT2	TCGA-BR-7851-01A-11D-2201-08	TCGA-BR-7851-10A-01D-2201-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.S376G	0.3243	37.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.S376G (Missense)	0	STAD_MUTECT2	TCGA-BR-7851-01A-11D-2201-08	TCGA-BR-7851-10A-01D-2201-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.R1745H	0.1613	93.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.R1745H (Missense)		STAD_MUTECT2	TCGA-F1-A448-01A-11D-A24D-08	TCGA-F1-A448-10A-01D-A24F-08
Investigate Actionability	FDA-Approved			Somatic Variant	FANCL	Frameshift	p.L191Wfs*4	0.1538	39.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	FANCL p.L191Wfs*4 (Frameshift)	0	STAD_MUTECT2	TCGA-HU-A4GX-01A-12D-A25D-08	TCGA-HU-A4GX-10A-01D-A25E-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Frameshift	p.P604Lfs*6	0.2039	358.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P604Lfs*6 (Frameshift)	0	STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P1091L	0.2885	52.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P1091L (Missense)	0	STAD_MUTECT2	TCGA-VQ-A8PE-01A-11D-A410-08	TCGA-VQ-A8PE-10A-01D-A413-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.T190M	0.5	70.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.T190M (Missense)	0	STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.M1691T	0.2794	136.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.M1691T (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Frameshift	p.P277Sfs*21	0.1594	138.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P277Sfs*21 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-6706-01A-11D-1882-08	TCGA-BR-6706-10A-01D-1882-08
Investigate Actionability	FDA-Approved			Somatic Variant	MET	Frameshift	p.K1199Sfs*49	0.28	25.0	0.0	0.0		Investigate Actionability	Capmatinib	MET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Revised May 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf																	MET p.K1199Sfs*49 (Frameshift)		STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.L369R	0.2424	66.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.L369R (Missense)		STAD_MUTECT2	TCGA-HU-A4G8-01A-11D-A25D-08	TCGA-HU-A4G8-10A-01D-A25E-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.A1117E	0.0787	127.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.A1117E (Missense)	0	STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.R978H	0.313	115.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.R978H (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.D121H	0.4028	72.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.D121H (Missense)	0	STAD_MUTECT2	TCGA-D7-6822-01A-11D-1882-08	TCGA-D7-6822-10A-01D-1882-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD51B	Missense	p.Y244C	0.2034	118.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD51B p.Y244C (Missense)	0	STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R378C	0.1859	156.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R378C (Missense)	0	STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Frameshift	p.P683Qfs*70	0.3636	55.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P683Qfs*70 (Frameshift)	0	STAD_MUTECT2	TCGA-HJ-7597-01A-21D-2201-08	TCGA-HJ-7597-10A-01D-2201-08
Investigate Actionability	FDA-Approved			Somatic Variant	FANCL	Missense	p.A51T	0.2881	59.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	FANCL p.A51T (Missense)	0	STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.A173V	0.2288	153.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.A173V (Missense)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.A1117V	0.2676	71.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.A1117V (Missense)	0	STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.L748I	0.1979	96.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.L748I (Missense)		STAD_MUTECT2	TCGA-BR-4201-01A-01D-1126-08	TCGA-BR-4201-11A-01D-1126-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.Y437C	0.1429	70.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.Y437C (Missense)		STAD_MUTECT2	TCGA-BR-4368-01A-01D-1158-08	TCGA-BR-4368-11A-01D-1158-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Nonsense	p.Y98*	0.0526	228.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.Y98* (Nonsense)	0	STAD_MUTECT2	TCGA-VQ-A91Q-01A-12D-A410-08	TCGA-VQ-A91Q-10A-01D-A413-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.C25F	0.4737	38.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.C25F (Missense)		STAD_MUTECT2	TCGA-B7-A5TN-01A-21D-A31L-08	TCGA-B7-A5TN-10A-01D-A31J-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.Q626H	0.1304	23.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.Q626H (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.H511R	0.1111	81.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.H511R (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Frameshift	p.P895Lfs*5	0.4821	56.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.P895Lfs*5 (Frameshift)	0	STAD_MUTECT2	TCGA-VQ-A8E3-01A-11D-A397-08	TCGA-VQ-A8E3-10A-01D-A39A-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Nonsense	p.G935*	0.3636	33.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.G935* (Nonsense)		STAD_MUTECT2	TCGA-VQ-A8E3-01A-11D-A397-08	TCGA-VQ-A8E3-10A-01D-A39A-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Frameshift	p.S189Vfs*18	0.2212	104.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.S189Vfs*18 (Frameshift)		STAD_MUTECT2	TCGA-CG-4306-01A-01D-1158-08	TCGA-CG-4306-10A-01D-1158-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Frameshift	p.V1006Gfs*3	0.2432	37.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.V1006Gfs*3 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Frameshift	p.Y819Lfs*2	0.24	125.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.Y819Lfs*2 (Frameshift)		STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Splice Site	p.X1137_splice	0.1576	165.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.X1137_splice (Splice Site)		STAD_MUTECT2	TCGA-CD-5813-01A-11D-1600-08	TCGA-CD-5813-10A-01D-1600-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.T279P	0.1212	33.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.T279P (Missense)		STAD_MUTECT2	TCGA-BR-8059-01A-11D-2340-08	TCGA-BR-8059-10A-01D-2340-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Frameshift	p.L615Sfs*24	0.2727	33.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.L615Sfs*24 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A91K-01A-11D-A410-08	TCGA-VQ-A91K-10A-01D-A413-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.S384G	0.2124	193.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.S384G (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.H661R	0.2131	61.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.H661R (Missense)		STAD_MUTECT2	TCGA-BR-8382-01A-11D-2394-08	TCGA-BR-8382-10A-01D-2394-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Frameshift	p.L171Tfs*5	0.4269	171.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.L171Tfs*5 (Frameshift)	1	STAD_MUTECT2	TCGA-RD-A7C1-01A-11D-A32N-08	TCGA-RD-A7C1-10A-01D-A32N-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.R1000Q	0.2931	58.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R1000Q (Missense)		STAD_MUTECT2	TCGA-CG-4438-01A-01D-1158-08	TCGA-CG-4438-10A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Frameshift	p.N135Tfs*40	0.3985	133.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.N135Tfs*40 (Frameshift)	0	STAD_MUTECT2	TCGA-HU-A4H3-01A-21D-A25D-08	TCGA-HU-A4H3-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Frameshift	p.N897Ifs*9	0.2667	105.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.N897Ifs*9 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.P44T	0.1875	16.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.P44T (Missense)		STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.T131A	0.4764	191.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.T131A (Missense)	0	STAD_MUTECT2	TCGA-IN-A6RL-01A-11D-A32N-08	TCGA-IN-A6RL-10A-01D-A32N-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Frameshift	p.F1104Lfs*11	0.2477	109.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.F1104Lfs*11 (Frameshift)		STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.A339D	0.1818	275.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.A339D (Missense)		STAD_MUTECT2	TCGA-BR-4368-01A-01D-1158-08	TCGA-BR-4368-11A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.P1008L	0.1818	242.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.P1008L (Missense)		STAD_MUTECT2	TCGA-BR-4368-01A-01D-1158-08	TCGA-BR-4368-11A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.D815G	0.0608	148.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.D815G (Missense)		STAD_MUTECT2	TCGA-HU-A4GN-01A-11D-A25D-08	TCGA-HU-A4GN-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.M724T	0.2745	153.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.M724T (Missense)		STAD_MUTECT2	TCGA-IN-AB1X-01A-11D-A397-08	TCGA-IN-AB1X-10E-01D-A39A-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.V891M	0.125	40.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.V891M (Missense)		STAD_MUTECT2	TCGA-VQ-AA6J-01A-11D-A410-08	TCGA-VQ-AA6J-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.E286K	0.2721	272.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.E286K (Missense)		STAD_MUTECT2	TCGA-IN-7806-01A-11D-2053-08	TCGA-IN-7806-10A-01D-2053-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.Y397H	0.3333	96.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.Y397H (Missense)		STAD_MUTECT2	TCGA-BR-8591-01A-11D-2394-08	TCGA-BR-8591-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Frameshift	p.S237Afs*28	0.2857	91.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S237Afs*28 (Frameshift)		STAD_MUTECT2	TCGA-BR-8591-01A-11D-2394-08	TCGA-BR-8591-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Frameshift	p.E586Nfs*24	0.5238	63.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.E586Nfs*24 (Frameshift)		STAD_MUTECT2	TCGA-BR-8591-01A-11D-2394-08	TCGA-BR-8591-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.R128H	0.1724	203.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.R128H (Missense)		STAD_MUTECT2	TCGA-BR-4370-01A-01D-1158-08	TCGA-BR-4370-11A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.R595W	0.3023	43.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R595W (Missense)		STAD_MUTECT2	TCGA-VQ-A8PT-01A-11D-A410-08	TCGA-VQ-A8PT-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Frameshift	p.A230Lfs*16	0.2444	45.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.A230Lfs*16 (Frameshift)		STAD_MUTECT2	TCGA-BR-8360-01A-11D-2340-08	TCGA-BR-8360-10A-01D-2340-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Deletion	p.T215_P216del	0.7	30.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.T215_P216del (Deletion)	0	STAD_MUTECT2	TCGA-BR-8360-01A-11D-2340-08	TCGA-BR-8360-10A-01D-2340-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Frameshift	p.N674Ifs*6	0.354	113.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.N674Ifs*6 (Frameshift)		STAD_MUTECT2	TCGA-F1-6874-01A-11D-1882-08	TCGA-F1-6874-10A-01D-1882-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Nonsense	p.Y408*	0.2056	107.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.Y408* (Nonsense)		STAD_MUTECT2	TCGA-IN-7808-01A-11D-2201-08	TCGA-IN-7808-10A-01D-2201-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Frameshift	p.G241Afs*24	0.2241	58.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.G241Afs*24 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.R14H	0.2	40.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.R14H (Missense)		STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.R1379W	0.0714	98.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R1379W (Missense)		STAD_MUTECT2	TCGA-BR-4292-01A-01D-1126-08	TCGA-BR-4292-11A-01D-1126-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Frameshift	p.V378Cfs*26	0.2637	91.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.V378Cfs*26 (Frameshift)		STAD_MUTECT2	TCGA-BR-4292-01A-01D-1126-08	TCGA-BR-4292-11A-01D-1126-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.R929Q	0.4643	56.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.R929Q (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.D918Y	0.3592	206.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.D918Y (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.C176Y	0.4459	157.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.C176Y (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.A192V	0.4333	60.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.A192V (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Frameshift	p.V378Cfs*26	0.4375	32.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.V378Cfs*26 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Frameshift	p.F411Lfs*41	0.1933	150.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.F411Lfs*41 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.Y1290F	0.0806	62.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y1290F (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.Q719R	0.1141	149.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q719R (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Splice Site	p.X291_splice	0.0857	70.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.X291_splice (Splice Site)	0	STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Nonsense	p.Q481*	0.25	12.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.Q481* (Nonsense)	0	STAD_MUTECT2	TCGA-KB-A6F7-01A-12D-A32N-08	TCGA-KB-A6F7-10A-01D-A32N-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Frameshift	p.N674Ifs*6	0.25	92.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.N674Ifs*6 (Frameshift)		STAD_MUTECT2	TCGA-BR-8078-01A-11D-2340-08	TCGA-BR-8078-10A-01D-2340-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Frameshift	p.L207Yfs*85	0.3929	28.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.L207Yfs*85 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-8368-01A-11D-2340-08	TCGA-BR-8368-10A-01D-2341-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.R243W	0.5946	37.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.R243W (Missense)		STAD_MUTECT2	TCGA-FP-8099-01A-11D-2340-08	TCGA-FP-8099-10A-01D-2341-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Frameshift	p.R255Gfs*37	0.234	47.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.R255Gfs*37 (Frameshift)	0	STAD_MUTECT2	TCGA-MX-A5UJ-01A-11D-A31L-08	TCGA-MX-A5UJ-10A-01D-A31J-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Frameshift	p.A230Lfs*16	0.1975	81.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.A230Lfs*16 (Frameshift)		STAD_MUTECT2	TCGA-CG-4306-01A-01D-1158-08	TCGA-CG-4306-10A-01D-1158-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Nonsense	p.R305*	0.4925	67.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.R305* (Nonsense)		STAD_MUTECT2	TCGA-HU-8244-01A-11D-2340-08	TCGA-HU-8244-10A-01D-2341-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.A1214T	0.3971	68.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.A1214T (Missense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.V978I	0.0625	176.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.V978I (Missense)		STAD_MUTECT2	TCGA-VQ-AA6D-01A-11D-A410-08	TCGA-VQ-AA6D-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.F1051V	0.2564	78.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.F1051V (Missense)		STAD_MUTECT2	TCGA-BR-8589-01A-11D-2394-08	TCGA-BR-8589-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Frameshift	p.E586Nfs*24	0.5625	64.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.E586Nfs*24 (Frameshift)		STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Frameshift	p.A230Lfs*16	0.1442	104.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.A230Lfs*16 (Frameshift)		STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Frameshift	p.V378Cfs*26	0.1812	149.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.V378Cfs*26 (Frameshift)		STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Insertion	p.N1338dup	0.34	150.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.N1338dup (Insertion)		STAD_MUTECT2	TCGA-KB-A93J-01A-11D-A397-08	TCGA-KB-A93J-10A-01D-A39A-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.E1054V	0.1101	109.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E1054V (Missense)		STAD_MUTECT2	TCGA-CD-5801-01A-11D-1600-08	TCGA-CD-5801-10A-01D-1600-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.T1010A	0.1807	83.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.T1010A (Missense)		STAD_MUTECT2	TCGA-F1-A448-01A-11D-A24D-08	TCGA-F1-A448-10A-01D-A24F-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Frameshift	p.R255Gfs*37	0.3333	30.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.R255Gfs*37 (Frameshift)	0	STAD_MUTECT2	TCGA-SW-A7EA-01A-12D-A34U-08	TCGA-SW-A7EA-10A-01D-A34X-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.H106Y	0.3881	268.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.H106Y (Missense)	0	STAD_MUTECT2	TCGA-BR-8679-01A-11D-2394-08	TCGA-BR-8679-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.T1168I	0.2267	75.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.T1168I (Missense)		STAD_MUTECT2	TCGA-R5-A7ZI-01A-11D-A34U-08	TCGA-R5-A7ZI-10A-01D-A34X-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Frameshift	p.S237Afs*28	0.4237	59.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S237Afs*28 (Frameshift)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Frameshift	p.N434Ifs*20	0.4127	63.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.N434Ifs*20 (Frameshift)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Frameshift	p.D642Tfs*67	0.4804	102.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.D642Tfs*67 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.V964I	0.2347	196.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.V964I (Missense)		STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.R576H	0.3214	56.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R576H (Missense)		STAD_MUTECT2	TCGA-HU-A4G8-01A-11D-A25D-08	TCGA-HU-A4G8-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X1130_splice	0.15	200.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X1130_splice (Splice Site)		STAD_MUTECT2	TCGA-CD-5813-01A-11D-1600-08	TCGA-CD-5813-10A-01D-1600-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.T269S	0.1015	325.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.T269S (Missense)		STAD_MUTECT2	TCGA-BR-7959-01A-11D-2340-08	TCGA-BR-7959-10A-01D-2340-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.K61T	0.3	150.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K61T (Missense)		STAD_MUTECT2	TCGA-CG-5733-01A-11D-1600-08	TCGA-CG-5733-11A-01D-1600-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.R976H	0.3396	53.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.R976H (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.R381H	0.1026	39.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.R381H (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Frameshift	p.R255Gfs*37	0.6667	36.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.R255Gfs*37 (Frameshift)	0	STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.S883F	0.2841	176.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.S883F (Missense)		STAD_MUTECT2	TCGA-VQ-A924-01A-11D-A410-08	TCGA-VQ-A924-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.R381H	0.2778	54.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.R381H (Missense)		STAD_MUTECT2	TCGA-VQ-A924-01A-11D-A410-08	TCGA-VQ-A924-10A-01D-A413-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.F916L	0.321	81.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.F916L (Missense)		STAD_MUTECT2	TCGA-VQ-A8DU-01A-11D-A364-08	TCGA-VQ-A8DU-10A-01D-A362-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.Q41H	0.3056	36.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.Q41H (Missense)		STAD_MUTECT2	TCGA-BR-4280-01A-01D-1126-08	TCGA-BR-4280-11A-01D-1126-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.V460A	0.2151	93.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.V460A (Missense)	0	STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Frameshift	p.K392Rfs*20	0.2366	131.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.K392Rfs*20 (Frameshift)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.D667V	0.1923	338.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.D667V (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.M868T	0.2169	249.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.M868T (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.T857A	0.1667	60.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.T857A (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Frameshift	p.N674Ifs*6	0.2452	208.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.N674Ifs*6 (Frameshift)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.A142T	0.1992	246.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.A142T (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Frameshift	p.F19Lfs*45	0.3333	6.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.F19Lfs*45 (Frameshift)		STAD_MUTECT2	TCGA-BR-8284-01A-11D-2340-08	TCGA-BR-8284-10A-01D-2340-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.V20L	0.3333	6.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.V20L (Missense)		STAD_MUTECT2	TCGA-BR-8284-01A-11D-2340-08	TCGA-BR-8284-10A-01D-2340-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Frameshift	p.F1104Lfs*11	0.1975	81.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.F1104Lfs*11 (Frameshift)		STAD_MUTECT2	TCGA-BR-8382-01A-11D-2394-08	TCGA-BR-8382-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Frameshift	p.P135Rfs*60	0.1687	166.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.P135Rfs*60 (Frameshift)		STAD_MUTECT2	TCGA-BR-8382-01A-11D-2394-08	TCGA-BR-8382-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Frameshift	p.L509*	0.1011	89.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.L509* (Frameshift)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Frameshift	p.N674Ifs*6	0.439	82.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.N674Ifs*6 (Frameshift)		STAD_MUTECT2	TCGA-HF-A5NB-01A-11D-A31L-08	TCGA-HF-A5NB-10A-01D-A31J-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.T167S	0.1714	105.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.T167S (Missense)	1	STAD_MUTECT2	TCGA-IN-A6RN-01A-12D-A33T-08	TCGA-IN-A6RN-10A-01D-A33W-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.C124S	0.5185	81.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.C124S (Missense)	1	STAD_MUTECT2	TCGA-3M-AB46-01A-11D-A410-08	TCGA-3M-AB46-10A-01D-A413-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Deletion		0.0619	97.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN  (Deletion)	1	STAD_MUTECT2	TCGA-BR-7958-01A-21D-2340-08	TCGA-BR-7958-10A-01D-2340-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.R159S	0.4419	43.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R159S (Missense)	1	STAD_MUTECT2	TCGA-BR-7704-01A-11D-2053-08	TCGA-BR-7704-10A-01D-2053-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.I28S	0.1	50.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.I28S (Missense)	1	STAD_MUTECT2	TCGA-FP-7735-01A-11D-2053-08	TCGA-FP-7735-10A-01D-2053-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.D24E	0.0595	84.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.D24E (Missense)	1	STAD_MUTECT2	TCGA-BR-8381-01A-11D-2394-08	TCGA-BR-8381-10A-01D-2394-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.R130Q	0.3197	147.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R130Q (Missense)	1	STAD_MUTECT2	TCGA-B7-A5TI-01A-11D-A31L-08	TCGA-B7-A5TI-10A-01D-A31J-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.A126D	0.5092	163.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.A126D (Missense)	1	STAD_MUTECT2	TCGA-D7-5577-01A-01D-1600-08	TCGA-D7-5577-10A-01D-1600-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.R130Q	0.2735	117.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R130Q (Missense)	1	STAD_MUTECT2	TCGA-BR-6707-01A-11D-1882-08	TCGA-BR-6707-10A-01D-1882-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Frameshift	p.F691Lfs*13	0.3629	124.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.F691Lfs*13 (Frameshift)	0	STAD_MUTECT2	TCGA-CG-4442-01A-01D-1158-08	TCGA-CG-4442-10A-01D-1158-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Nonsense	p.G414*	0.1855	221.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.G414* (Nonsense)	0	STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Frameshift	p.L838Pfs*27	0.1311	61.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.L838Pfs*27 (Frameshift)		STAD_MUTECT2	TCGA-CD-A4MI-01A-21D-A25D-08	TCGA-CD-A4MI-10A-01D-A25E-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Splice Site	p.X472_splice	0.2564	78.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.X472_splice (Splice Site)		STAD_MUTECT2	TCGA-BR-8286-01A-12D-2340-08	TCGA-BR-8286-10A-01D-2340-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Nonsense	p.K665*	0.1143	70.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.K665* (Nonsense)		STAD_MUTECT2	TCGA-VQ-A8PF-01A-11D-A410-08	TCGA-VQ-A8PF-10B-01D-A413-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P1048S	0.1835	109.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1048S (Missense)		STAD_MUTECT2	TCGA-BR-4201-01A-01D-1126-08	TCGA-BR-4201-11A-01D-1126-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.K142Rfs*26	0.1579	57.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.K142Rfs*26 (Frameshift)		STAD_MUTECT2	TCGA-BR-4201-01A-01D-1126-08	TCGA-BR-4201-11A-01D-1126-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.T1743M	0.2586	263.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.T1743M (Missense)		STAD_MUTECT2	TCGA-BR-4362-01A-01D-1158-08	TCGA-BR-4362-11A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Splice Site	p.X1705_splice	0.2683	41.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.X1705_splice (Splice Site)		STAD_MUTECT2	TCGA-FP-7916-01A-11D-2201-08	TCGA-FP-7916-10A-01D-2201-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Splice Site	p.X601_splice	0.3982	113.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.X601_splice (Splice Site)		STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.R1103Sfs*5	0.2538	130.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.R1103Sfs*5 (Frameshift)		STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.K860Nfs*16	0.4731	167.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.K860Nfs*16 (Frameshift)		STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.N339Ifs*3	0.5303	66.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.N339Ifs*3 (Frameshift)		STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.G2012D	0.1609	87.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G2012D (Missense)		STAD_MUTECT2	TCGA-D7-A6EY-01A-21D-A31L-08	TCGA-D7-A6EY-10A-01D-A31J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Splice Site	p.X807_splice	0.3571	14.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.X807_splice (Splice Site)		STAD_MUTECT2	TCGA-VQ-AA6J-01A-11D-A410-08	TCGA-VQ-AA6J-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Splice Site	p.X1335_splice	0.401	207.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.X1335_splice (Splice Site)		STAD_MUTECT2	TCGA-D7-A4YT-01A-11D-A25D-08	TCGA-D7-A4YT-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.G673Vfs*30	0.1681	226.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.G673Vfs*30 (Frameshift)		STAD_MUTECT2	TCGA-CG-5728-01A-11D-1600-08	TCGA-CG-5728-11A-01D-1600-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.L2258R	0.4462	130.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.L2258R (Missense)		STAD_MUTECT2	TCGA-BR-6455-01A-11D-1800-08	TCGA-BR-6455-10A-01D-1800-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.G2087R	0.1949	195.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G2087R (Missense)		STAD_MUTECT2	TCGA-BR-4370-01A-01D-1158-08	TCGA-BR-4370-11A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.K142Rfs*26	0.2743	113.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.K142Rfs*26 (Frameshift)		STAD_MUTECT2	TCGA-BR-4370-01A-01D-1158-08	TCGA-BR-4370-11A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.L2195P	0.2593	108.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.L2195P (Missense)		STAD_MUTECT2	TCGA-CD-A4MJ-01A-11D-A25D-08	TCGA-CD-A4MJ-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.K860Nfs*16	0.3636	275.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.K860Nfs*16 (Frameshift)		STAD_MUTECT2	TCGA-CG-4442-01A-01D-1158-08	TCGA-CG-4442-10A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.K142Rfs*26	0.2283	92.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.K142Rfs*26 (Frameshift)		STAD_MUTECT2	TCGA-CG-4442-01A-01D-1158-08	TCGA-CG-4442-10A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.S571L	0.3231	229.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S571L (Missense)		STAD_MUTECT2	TCGA-VQ-A8PT-01A-11D-A410-08	TCGA-VQ-A8PT-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.R1446Q	0.25	108.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1446Q (Missense)		STAD_MUTECT2	TCGA-BR-8372-01A-11D-2340-08	TCGA-BR-8372-10A-01D-2341-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.K860Nfs*16	0.1949	118.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.K860Nfs*16 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Splice Site	p.X1367_splice	0.2264	159.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.X1367_splice (Splice Site)		STAD_MUTECT2	TCGA-D7-A4YU-01A-21D-A25D-08	TCGA-D7-A4YU-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.R2158Q	0.3118	93.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R2158Q (Missense)		STAD_MUTECT2	TCGA-BR-4292-01A-01D-1126-08	TCGA-BR-4292-11A-01D-1126-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.T1004A	0.3871	62.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.T1004A (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.S1126F	0.1509	53.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1126F (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.P430Rfs*2	0.43	100.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.P430Rfs*2 (Frameshift)		STAD_MUTECT2	TCGA-CD-8536-01A-11D-2340-08	TCGA-CD-8536-10A-01D-2341-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.G1520D	0.4412	68.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G1520D (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.K860Nfs*16	0.3628	113.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.K860Nfs*16 (Frameshift)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Splice Site	p.X1180_splice	0.6351	74.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.X1180_splice (Splice Site)		STAD_MUTECT2	TCGA-FP-8099-01A-11D-2340-08	TCGA-FP-8099-10A-01D-2341-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.K860Nfs*16	0.3182	110.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.K860Nfs*16 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PB-01A-11D-A397-08	TCGA-VQ-A8PB-10A-01D-A39A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.A770T	0.4146	164.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.A770T (Missense)		STAD_MUTECT2	TCGA-HU-A4H8-01A-11D-A25D-08	TCGA-HU-A4H8-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P2265Q	0.2149	121.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P2265Q (Missense)		STAD_MUTECT2	TCGA-MX-A5UJ-01A-11D-A31L-08	TCGA-MX-A5UJ-10A-01D-A31J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.K860Nfs*16	0.221	181.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.K860Nfs*16 (Frameshift)		STAD_MUTECT2	TCGA-CG-4305-01A-01D-1158-08	TCGA-CG-4305-10A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.I143Dfs*9	0.6875	48.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.I143Dfs*9 (Frameshift)		STAD_MUTECT2	TCGA-EQ-A4SO-01A-11D-A25D-08	TCGA-EQ-A4SO-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.L431Vfs*22	0.3051	59.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.L431Vfs*22 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.K2025T	0.0763	118.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.K2025T (Missense)		STAD_MUTECT2	TCGA-HU-A4GH-01A-11D-A24D-08	TCGA-HU-A4GH-10A-01D-A24F-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.K860Nfs*16	0.1824	170.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.K860Nfs*16 (Frameshift)		STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.K860Nfs*16	0.244	209.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.K860Nfs*16 (Frameshift)		STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.L2008R	0.7447	94.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.L2008R (Missense)		STAD_MUTECT2	TCGA-CG-4469-01A-01D-1158-08	TCGA-CG-4469-10A-01D-1158-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.D734G	0.0857	70.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D734G (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.K142Rfs*26	0.3623	69.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.K142Rfs*26 (Frameshift)		STAD_MUTECT2	TCGA-B7-A5TI-01A-11D-A31L-08	TCGA-B7-A5TI-10A-01D-A31J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.G1265S	0.1458	48.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G1265S (Missense)		STAD_MUTECT2	TCGA-BR-8059-01A-11D-2340-08	TCGA-BR-8059-10A-01D-2340-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.K860Nfs*16	0.1522	92.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.K860Nfs*16 (Frameshift)		STAD_MUTECT2	TCGA-BR-8059-01A-11D-2340-08	TCGA-BR-8059-10A-01D-2340-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.N339Ifs*3	0.2069	29.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.N339Ifs*3 (Frameshift)		STAD_MUTECT2	TCGA-BR-8059-01A-11D-2340-08	TCGA-BR-8059-10A-01D-2340-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P687H	0.0879	91.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P687H (Missense)		STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P773L	0.2796	93.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P773L (Missense)		STAD_MUTECT2	TCGA-VQ-A924-01A-11D-A410-08	TCGA-VQ-A924-10A-01D-A413-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Splice Site	p.X1709_splice	0.4986	345.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.X1709_splice (Splice Site)		STAD_MUTECT2	TCGA-BR-8284-01A-11D-2340-08	TCGA-BR-8284-10A-01D-2340-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.S2104P	0.3235	102.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S2104P (Missense)		STAD_MUTECT2	TCGA-BR-8361-01A-11D-2340-08	TCGA-BR-8361-10A-01D-2340-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.A1263V	0.2174	69.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.A1263V (Missense)		STAD_MUTECT2	TCGA-BR-8382-01A-11D-2394-08	TCGA-BR-8382-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.G1549V	0.1935	31.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G1549V (Missense)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.R1833C	0.2857	56.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1833C (Missense)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.K860Nfs*16	0.1875	96.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.K860Nfs*16 (Frameshift)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.Q1403L	0.3469	98.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1403L (Missense)		STAD_MUTECT2	TCGA-HF-A5NB-01A-11D-A31L-08	TCGA-HF-A5NB-10A-01D-A31J-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Splice Site	p.X195_splice	0.2667	15.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.X195_splice (Splice Site)		STAD_MUTECT2	TCGA-BR-4201-01A-01D-1126-08	TCGA-BR-4201-11A-01D-1126-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.G1194R	0.2063	63.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.G1194R (Missense)		STAD_MUTECT2	TCGA-BR-4201-01A-01D-1126-08	TCGA-BR-4201-11A-01D-1126-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.Q358*	0.5846	65.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.Q358* (Nonsense)		STAD_MUTECT2	TCGA-BR-8485-01A-11D-2394-08	TCGA-BR-8485-10A-01D-2394-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.E470K	0.2308	52.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.E470K (Missense)	0	STAD_MUTECT2	TCGA-CD-8525-01A-11D-2340-08	TCGA-CD-8525-10A-01D-2341-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.W284L	0.1731	52.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.W284L (Missense)		STAD_MUTECT2	TCGA-HU-A4H4-01A-21D-A25D-08	TCGA-HU-A4H4-11A-11D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.E1051K	0.1842	38.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.E1051K (Missense)	0	STAD_MUTECT2	TCGA-BR-8364-01A-11D-2340-08	TCGA-BR-8364-10A-01D-2341-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Nonsense	p.E113*	0.0588	119.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.E113* (Nonsense)	0	STAD_MUTECT2	TCGA-IN-A6RL-01A-11D-A32N-08	TCGA-IN-A6RL-10A-01D-A32N-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Frameshift	p.M240Cfs*14	0.1709	158.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.M240Cfs*14 (Frameshift)		STAD_MUTECT2	TCGA-BR-7707-01A-11D-2053-08	TCGA-BR-7707-10A-01D-2053-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Frameshift	p.R473Kfs*4	0.2784	194.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R473Kfs*4 (Frameshift)		STAD_MUTECT2	TCGA-D7-A4YV-01A-11D-A25D-08	TCGA-D7-A4YV-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Frameshift	p.T930Nfs*8	0.2429	70.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.T930Nfs*8 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-A4PD-01A-11D-A25D-08	TCGA-BR-A4PD-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Frameshift	p.F446Lfs*7	0.3415	41.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.F446Lfs*7 (Frameshift)	0	STAD_MUTECT2	TCGA-HU-A4GU-01A-11D-A25D-08	TCGA-HU-A4GU-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Frameshift	p.L682Afs*12	0.22	300.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.L682Afs*12 (Frameshift)		STAD_MUTECT2	TCGA-CG-5728-01A-11D-1600-08	TCGA-CG-5728-11A-01D-1600-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.G271R	0.1233	73.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.G271R (Missense)		STAD_MUTECT2	TCGA-CG-5728-01A-11D-1600-08	TCGA-CG-5728-11A-01D-1600-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Frameshift	p.S668Vfs*39	0.4118	153.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.S668Vfs*39 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PT-01A-11D-A410-08	TCGA-VQ-A8PT-10A-01D-A413-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R1411W	0.2523	107.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1411W (Missense)		STAD_MUTECT2	TCGA-F1-6874-01A-11D-1882-08	TCGA-F1-6874-10A-01D-1882-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.Y545*	0.4054	222.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.Y545* (Nonsense)		STAD_MUTECT2	TCGA-BR-4371-01A-01D-1158-08	TCGA-BR-4371-11A-01D-1158-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.R321Q	0.3679	106.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.R321Q (Missense)	0	STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Frameshift	p.R473Efs*25	0.2181	243.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R473Efs*25 (Frameshift)		STAD_MUTECT2	TCGA-CD-8536-01A-11D-2340-08	TCGA-CD-8536-10A-01D-2341-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.D999N	0.2405	79.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.D999N (Missense)		STAD_MUTECT2	TCGA-CD-8536-01A-11D-2340-08	TCGA-CD-8536-10A-01D-2341-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.A1272T	0.4737	38.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.A1272T (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.T859A	0.1429	63.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.T859A (Missense)	0	STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.I670L	0.0444	270.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.I670L (Missense)	0	STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.E158K	0.1099	91.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.E158K (Missense)	0	STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.G630D	0.101	99.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.G630D (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.V742A	0.0991	111.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.V742A (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.A1002V	0.2105	57.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.A1002V (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R1515C	0.1622	37.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1515C (Missense)		STAD_MUTECT2	TCGA-BR-8078-01A-11D-2340-08	TCGA-BR-8078-10A-01D-2340-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E920K	0.2308	26.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E920K (Missense)		STAD_MUTECT2	TCGA-BR-8368-01A-11D-2340-08	TCGA-BR-8368-10A-01D-2341-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.V1016M	0.3	40.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.V1016M (Missense)		STAD_MUTECT2	TCGA-BR-8368-01A-11D-2340-08	TCGA-BR-8368-10A-01D-2341-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R973Q	0.8667	30.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R973Q (Missense)		STAD_MUTECT2	TCGA-FP-8099-01A-11D-2340-08	TCGA-FP-8099-10A-01D-2341-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.A1117V	0.0786	229.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.A1117V (Missense)		STAD_MUTECT2	TCGA-HU-A4H8-01A-11D-A25D-08	TCGA-HU-A4H8-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R1192C	0.4732	112.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1192C (Missense)		STAD_MUTECT2	TCGA-HU-A4H8-01A-11D-A25D-08	TCGA-HU-A4H8-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.T417M	0.2105	38.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.T417M (Missense)	0	STAD_MUTECT2	TCGA-MX-A5UJ-01A-11D-A31L-08	TCGA-MX-A5UJ-10A-01D-A31J-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Frameshift	p.V341Sfs*22	0.2921	89.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.V341Sfs*22 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PO-01A-11D-A410-08	TCGA-VQ-A8PO-10A-01D-A413-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.G782S	0.1429	70.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.G782S (Missense)		STAD_MUTECT2	TCGA-CG-4474-01A-02D-1158-08	TCGA-CG-4474-10A-01D-1158-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.A1186V	0.2653	49.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.A1186V (Missense)		STAD_MUTECT2	TCGA-SW-A7EB-01A-11D-A34U-08	TCGA-SW-A7EB-10A-01D-A34X-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.W582R	0.1898	137.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.W582R (Missense)	0	STAD_MUTECT2	TCGA-BR-4257-01A-01D-1126-08	TCGA-BR-4257-11A-01D-1126-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Frameshift	p.A660Lfs*10	0.1304	69.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.A660Lfs*10 (Frameshift)	0	STAD_MUTECT2	TCGA-CG-4306-01A-01D-1158-08	TCGA-CG-4306-10A-01D-1158-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R1135Q	0.3478	23.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1135Q (Missense)		STAD_MUTECT2	TCGA-IN-A6RR-01A-12D-A32N-08	TCGA-IN-A6RR-10A-01D-A32N-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Frameshift	p.T482Ifs*16	0.2833	60.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.T482Ifs*16 (Frameshift)		STAD_MUTECT2	TCGA-VQ-AA6D-01A-11D-A410-08	TCGA-VQ-AA6D-10A-01D-A413-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Frameshift	p.L52*	0.2471	85.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.L52* (Frameshift)	0	STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.Q722H	0.1627	252.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.Q722H (Missense)		STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.M781I	0.1138	123.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.M781I (Missense)		STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.E470K	0.1746	63.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.E470K (Missense)	0	STAD_MUTECT2	TCGA-BR-8285-01A-11D-2340-08	TCGA-BR-8285-10A-01D-2340-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P262S	0.45	60.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P262S (Missense)		STAD_MUTECT2	TCGA-HU-A4GT-01A-21D-A25D-08	TCGA-HU-A4GT-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.R278*	0.2245	49.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R278* (Nonsense)		STAD_MUTECT2	TCGA-BR-7851-01A-11D-2201-08	TCGA-BR-7851-10A-01D-2201-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.I996S	0.1935	62.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.I996S (Missense)		STAD_MUTECT2	TCGA-HU-A4GX-01A-12D-A25D-08	TCGA-HU-A4GX-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.T910M	0.3182	22.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.T910M (Missense)		STAD_MUTECT2	TCGA-IN-A7NT-01A-21D-A34U-08	TCGA-IN-A7NT-10A-01D-A34X-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.M145L	0.3333	60.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.M145L (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R397Q	0.3382	136.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R397Q (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P1277L	0.38	50.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P1277L (Missense)		STAD_MUTECT2	TCGA-HU-A4G8-01A-11D-A25D-08	TCGA-HU-A4G8-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Nonsense	p.E522Afs*3	0.1987	317.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.E522Afs*3 (Nonsense)	0	STAD_MUTECT2	TCGA-CG-5733-01A-11D-1600-08	TCGA-CG-5733-11A-01D-1600-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.T910M	0.1489	47.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.T910M (Missense)		STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.Q618*	0.5094	53.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.Q618* (Nonsense)		STAD_MUTECT2	TCGA-VQ-A8DU-01A-11D-A364-08	TCGA-VQ-A8DU-10A-01D-A362-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.G1232S	0.3436	163.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.G1232S (Missense)		STAD_MUTECT2	TCGA-IN-A6RP-01A-21D-A33T-08	TCGA-IN-A6RP-10A-01D-A33W-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Frameshift	p.N377Mfs*35	0.2819	227.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.N377Mfs*35 (Frameshift)	0	STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Frameshift	p.R180Efs*72	0.2597	77.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.R180Efs*72 (Frameshift)		STAD_MUTECT2	TCGA-BR-7707-01A-11D-2053-08	TCGA-BR-7707-10A-01D-2053-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Splice Site	p.X2250_splice	0.375	80.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.X2250_splice (Splice Site)		STAD_MUTECT2	TCGA-CG-4442-01A-01D-1158-08	TCGA-CG-4442-10A-01D-1158-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Frameshift	p.P116Hfs*53	0.2424	66.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.P116Hfs*53 (Frameshift)		STAD_MUTECT2	TCGA-BR-4363-01A-01D-1158-08	TCGA-BR-4363-11A-01D-1158-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Frameshift	p.V551Ffs*12	0.3984	123.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.V551Ffs*12 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4GT-01A-21D-A25D-08	TCGA-HU-A4GT-10A-01D-A25E-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Frameshift	p.P116Hfs*53	0.0968	93.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.P116Hfs*53 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4GT-01A-21D-A25D-08	TCGA-HU-A4GT-10A-01D-A25E-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Frameshift	p.K1550Nfs*12	0.2333	120.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.K1550Nfs*12 (Frameshift)		STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Frameshift	p.F699Vfs*11	0.3444	90.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.F699Vfs*11 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A91K-01A-11D-A410-08	TCGA-VQ-A91K-10A-01D-A413-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Splice Site	p.X111_splice	0.1667	114.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.X111_splice (Splice Site)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Splice Site	p.X751_splice	0.2514	175.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.X751_splice (Splice Site)		STAD_MUTECT2	TCGA-HJ-7597-01A-21D-2201-08	TCGA-HJ-7597-10A-01D-2201-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Frameshift	p.W243Lfs*20	0.2034	59.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.W243Lfs*20 (Frameshift)		STAD_MUTECT2	TCGA-BR-8361-01A-11D-2340-08	TCGA-BR-8361-10A-01D-2340-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Deletion	p.S240_C242del	0.4054	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S240_C242del (Deletion)		STAD_MUTECT2	TCGA-BR-8295-01A-11D-2340-08	TCGA-BR-8295-10A-01D-2340-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Deletion	p.T253_D259del	0.0923	65.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.T253_D259del (Deletion)		STAD_MUTECT2	TCGA-HU-8610-01A-22D-2394-08	TCGA-HU-8610-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Deletion	p.H178_S183del	0.3684	38.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H178_S183del (Deletion)		STAD_MUTECT2	TCGA-CD-A486-01A-11D-A24D-08	TCGA-CD-A486-10A-01D-A24F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Deletion	p.Q136del	0.678	59.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q136del (Deletion)		STAD_MUTECT2	TCGA-B7-A5TJ-01A-11D-A31L-08	TCGA-B7-A5TJ-10A-01D-A31J-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Frameshift	p.V981Ffs*88	0.1387	137.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.V981Ffs*88 (Frameshift)		STAD_MUTECT2	TCGA-BR-7707-01A-11D-2053-08	TCGA-BR-7707-10A-01D-2053-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Splice Site	p.X304_splice	0.2	80.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.X304_splice (Splice Site)		STAD_MUTECT2	TCGA-HU-A4GT-01A-21D-A25D-08	TCGA-HU-A4GT-10A-01D-A25E-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Frameshift	p.R785Gfs*3	0.3404	47.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.R785Gfs*3 (Frameshift)		STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Nonsense	p.R577*	0.2727	110.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.R577* (Nonsense)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.T594M	0.28	50.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.T594M (Missense)		STAD_MUTECT2	TCGA-BR-7196-01A-11D-2053-08	TCGA-BR-7196-10A-01D-2053-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.R854H	0.2615	65.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.R854H (Missense)		STAD_MUTECT2	TCGA-HU-A4HD-01A-11D-A25D-08	TCGA-HU-A4HD-10A-01D-A25E-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Frameshift	p.P99Hfs*10	0.2353	17.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.P99Hfs*10 (Frameshift)		STAD_MUTECT2	TCGA-BR-8591-01A-11D-2394-08	TCGA-BR-8591-10A-01D-2394-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Frameshift	p.A149Pfs*30	0.1379	29.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.A149Pfs*30 (Frameshift)		STAD_MUTECT2	TCGA-CG-5728-01A-11D-1600-08	TCGA-CG-5728-11A-01D-1600-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.D491G	0.1765	85.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.D491G (Missense)		STAD_MUTECT2	TCGA-CG-5728-01A-11D-1600-08	TCGA-CG-5728-11A-01D-1600-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.L203M	0.2044	137.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.L203M (Missense)		STAD_MUTECT2	TCGA-BR-4370-01A-01D-1158-08	TCGA-BR-4370-11A-01D-1158-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Frameshift	p.D225Mfs*27	0.4194	62.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.D225Mfs*27 (Frameshift)		STAD_MUTECT2	TCGA-F1-6874-01A-11D-1882-08	TCGA-F1-6874-10A-01D-1882-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Frameshift	p.A32Gfs*16	0.2372	156.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.A32Gfs*16 (Frameshift)		STAD_MUTECT2	TCGA-CD-8536-01A-11D-2340-08	TCGA-CD-8536-10A-01D-2341-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.P907L	0.3773	273.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.P907L (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Nonsense	p.R477*	0.1418	134.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.R477* (Nonsense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.V376A	0.367	109.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.V376A (Missense)		STAD_MUTECT2	TCGA-BR-8368-01A-11D-2340-08	TCGA-BR-8368-10A-01D-2341-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.A13T	0.1111	36.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.A13T (Missense)		STAD_MUTECT2	TCGA-BR-4257-01A-01D-1126-08	TCGA-BR-4257-11A-01D-1126-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.D1106N	0.1111	63.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.D1106N (Missense)		STAD_MUTECT2	TCGA-CG-4305-01A-01D-1158-08	TCGA-CG-4305-10A-01D-1158-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.R567C	0.2754	69.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.R567C (Missense)		STAD_MUTECT2	TCGA-HU-A4GF-01A-11D-A24D-08	TCGA-HU-A4GF-10A-01D-A24F-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.A68T	0.375	16.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.A68T (Missense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.T311M	0.1875	64.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.T311M (Missense)		STAD_MUTECT2	TCGA-BR-4188-01A-01D-1126-08	TCGA-BR-4188-11A-01D-1126-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.K702T	0.1236	89.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.K702T (Missense)		STAD_MUTECT2	TCGA-BR-8589-01A-11D-2394-08	TCGA-BR-8589-10A-01D-2394-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Nonsense	p.W755*	0.0889	45.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.W755* (Nonsense)		STAD_MUTECT2	TCGA-BR-8589-01A-11D-2394-08	TCGA-BR-8589-10A-01D-2394-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.V533M	0.3117	77.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.V533M (Missense)		STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Frameshift	p.Y531Lfs*21	0.3061	49.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.Y531Lfs*21 (Frameshift)		STAD_MUTECT2	TCGA-CG-4477-01A-01D-1158-08	TCGA-CG-4477-10A-01D-1158-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Frameshift	p.D225Mfs*27	0.3196	97.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.D225Mfs*27 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4GT-01A-21D-A25D-08	TCGA-HU-A4GT-10A-01D-A25E-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.R1072C	0.1556	45.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.R1072C (Missense)		STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.L354M	0.1364	110.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.L354M (Missense)		STAD_MUTECT2	TCGA-D7-6817-01A-11D-1882-08	TCGA-D7-6817-10A-01D-1882-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.P464S	0.375	40.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.P464S (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.C240Y	0.3019	53.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.C240Y (Missense)		STAD_MUTECT2	TCGA-HU-A4G8-01A-11D-A25D-08	TCGA-HU-A4G8-10A-01D-A25E-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.G241S	0.0566	106.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.G241S (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Frameshift	p.P269Rfs*58	0.2778	18.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.P269Rfs*58 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A924-01A-11D-A410-08	TCGA-VQ-A924-10A-01D-A413-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.P152T	0.1786	28.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.P152T (Missense)		STAD_MUTECT2	TCGA-VQ-A91X-01A-12D-A410-08	TCGA-VQ-A91X-10A-01D-A413-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.P214Q	0.11	200.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.P214Q (Missense)		STAD_MUTECT2	TCGA-CG-5722-01A-21D-1600-08	TCGA-CG-5722-11A-02D-1600-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.Q198H	0.2	60.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.Q198H (Missense)		STAD_MUTECT2	TCGA-VQ-A924-01A-11D-A410-08	TCGA-VQ-A924-10A-01D-A413-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.A452T	0.2426	202.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.A452T (Missense)		STAD_MUTECT2	TCGA-VQ-AA64-01A-11D-A410-08	TCGA-VQ-AA64-10A-01D-A413-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Deletion	p.K445_S447delinsT	0.4348	161.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.K445_S447delinsT (Deletion)		STAD_MUTECT2	TCGA-VQ-A8PJ-01A-11D-A410-08	TCGA-VQ-A8PJ-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.D1004N	0.2564	117.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.D1004N (Missense)		STAD_MUTECT2	TCGA-BR-A4PE-01A-31D-A25D-08	TCGA-BR-A4PE-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Frameshift	p.D168Efs*2	0.125	136.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.D168Efs*2 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8DL-01A-11D-A364-08	TCGA-VQ-A8DL-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.T390A	0.1373	51.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.T390A (Missense)		STAD_MUTECT2	TCGA-RD-A8NB-01A-12D-A397-08	TCGA-RD-A8NB-10A-01D-A39A-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.L329I	0.2795	161.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.L329I (Missense)		STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Frameshift	p.P829Hfs*24	0.2707	133.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.P829Hfs*24 (Frameshift)		STAD_MUTECT2	TCGA-BR-4362-01A-01D-1158-08	TCGA-BR-4362-11A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Frameshift	p.R421Dfs*23	0.2973	37.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R421Dfs*23 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4H4-01A-21D-A25D-08	TCGA-HU-A4H4-11A-11D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.L129P	0.2388	67.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.L129P (Missense)		STAD_MUTECT2	TCGA-HU-A4HD-01A-11D-A25D-08	TCGA-HU-A4HD-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R293G	0.2935	92.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R293G (Missense)		STAD_MUTECT2	TCGA-FP-A9TM-01A-11D-A397-08	TCGA-FP-A9TM-10A-01D-A39A-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.V1015A	0.1733	75.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.V1015A (Missense)		STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.V807I	0.3566	129.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.V807I (Missense)		STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R1068Q	0.3575	221.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R1068Q (Missense)		STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.T411M	0.1386	101.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.T411M (Missense)		STAD_MUTECT2	TCGA-BR-4368-01A-01D-1158-08	TCGA-BR-4368-11A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R240H	0.1659	217.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R240H (Missense)		STAD_MUTECT2	TCGA-BR-4368-01A-01D-1158-08	TCGA-BR-4368-11A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Nonsense	p.R1588*	0.2857	21.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R1588* (Nonsense)		STAD_MUTECT2	TCGA-BR-4368-01A-01D-1158-08	TCGA-BR-4368-11A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.P900S	0.2549	153.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.P900S (Missense)		STAD_MUTECT2	TCGA-BR-4368-01A-01D-1158-08	TCGA-BR-4368-11A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R845W	0.1145	166.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R845W (Missense)		STAD_MUTECT2	TCGA-HU-A4GN-01A-11D-A25D-08	TCGA-HU-A4GN-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Frameshift	p.A1581Pfs*30	0.375	24.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.A1581Pfs*30 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4GN-01A-11D-A25D-08	TCGA-HU-A4GN-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.T1027N	0.1724	58.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.T1027N (Missense)		STAD_MUTECT2	TCGA-IN-A6RO-01A-12D-A33T-08	TCGA-IN-A6RO-10A-01D-A33W-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.S207G	0.25	76.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.S207G (Missense)		STAD_MUTECT2	TCGA-D7-A6EY-01A-21D-A31L-08	TCGA-D7-A6EY-10A-01D-A31J-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.L136H	0.25	160.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.L136H (Missense)		STAD_MUTECT2	TCGA-D7-6820-01A-11D-1882-08	TCGA-D7-6820-10A-01D-1882-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R92H	0.4098	61.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R92H (Missense)		STAD_MUTECT2	TCGA-VQ-A8PX-01A-12D-A410-08	TCGA-VQ-A8PX-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Frameshift	p.R1300Kfs*5	0.1064	141.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R1300Kfs*5 (Frameshift)		STAD_MUTECT2	TCGA-BR-4370-01A-01D-1158-08	TCGA-BR-4370-11A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R603H	0.3268	153.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R603H (Missense)		STAD_MUTECT2	TCGA-VQ-A8PT-01A-11D-A410-08	TCGA-VQ-A8PT-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Frameshift	p.R421Dfs*23	0.2857	42.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R421Dfs*23 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PT-01A-11D-A410-08	TCGA-VQ-A8PT-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R498C	0.3093	97.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R498C (Missense)		STAD_MUTECT2	TCGA-BR-8360-01A-11D-2340-08	TCGA-BR-8360-10A-01D-2340-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Frameshift	p.D138Tfs*69	0.1944	72.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.D138Tfs*69 (Frameshift)		STAD_MUTECT2	TCGA-BR-8360-01A-11D-2340-08	TCGA-BR-8360-10A-01D-2340-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Nonsense	p.G1119*	0.2716	81.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.G1119* (Nonsense)		STAD_MUTECT2	TCGA-BR-8360-01A-11D-2340-08	TCGA-BR-8360-10A-01D-2340-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.T586S	0.52	25.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.T586S (Missense)		STAD_MUTECT2	TCGA-BR-8360-01A-11D-2340-08	TCGA-BR-8360-10A-01D-2340-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.P63H	0.4107	56.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.P63H (Missense)		STAD_MUTECT2	TCGA-BR-8372-01A-11D-2340-08	TCGA-BR-8372-10A-01D-2341-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.R370Q	0.64	25.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.R370Q (Missense)		STAD_MUTECT2	TCGA-BR-8372-01A-11D-2340-08	TCGA-BR-8372-10A-01D-2341-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.Y391C	0.0833	84.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.Y391C (Missense)		STAD_MUTECT2	TCGA-VQ-A8PZ-01A-11D-A410-08	TCGA-VQ-A8PZ-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Frameshift	p.N147Ifs*60	0.4493	69.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.N147Ifs*60 (Frameshift)		STAD_MUTECT2	TCGA-F1-6177-01A-11D-1800-08	TCGA-F1-6177-10A-01D-1800-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R545H	0.4173	139.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R545H (Missense)		STAD_MUTECT2	TCGA-F1-6177-01A-11D-1800-08	TCGA-F1-6177-10A-01D-1800-08
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Missense	p.R319H	0.1739	23.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.R319H (Missense)		STAD_MUTECT2	TCGA-F1-6874-01A-11D-1882-08	TCGA-F1-6874-10A-01D-1882-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R686W	0.0645	155.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R686W (Missense)		STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.E541D	0.344	125.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.E541D (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.L1340R	0.114	114.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.L1340R (Missense)		STAD_MUTECT2	TCGA-CG-4437-01A-01D-1800-08	TCGA-CG-4437-10A-01D-1800-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Splice Site	p.X385_splice	0.4844	64.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.X385_splice (Splice Site)		STAD_MUTECT2	TCGA-3M-AB46-01A-11D-A410-08	TCGA-3M-AB46-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.G1127D	0.3853	109.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.G1127D (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.A407T	0.3495	186.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.A407T (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.D177N	0.1354	96.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.D177N (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R265C	0.0652	92.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R265C (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.R110Q	0.8158	76.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.R110Q (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.R433H	0.0872	218.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.R433H (Missense)		STAD_MUTECT2	TCGA-D7-A747-01A-22D-A33T-08	TCGA-D7-A747-10A-21D-A33W-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R82H	0.226	146.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R82H (Missense)		STAD_MUTECT2	TCGA-BR-A4J4-01A-12D-A25D-08	TCGA-BR-A4J4-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.R199Q	0.0847	177.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.R199Q (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.M1237I	0.0714	70.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.M1237I (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.L1467I	0.0781	64.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.L1467I (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Missense	p.V211A	0.0952	147.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.V211A (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.G503V	0.125	144.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.G503V (Missense)		STAD_MUTECT2	TCGA-R5-A804-01A-11D-A364-08	TCGA-R5-A804-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.D1055N	0.0902	122.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.D1055N (Missense)		STAD_MUTECT2	TCGA-BR-8296-01A-11D-2340-08	TCGA-BR-8296-10A-01D-2340-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.D1602G	0.2316	95.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.D1602G (Missense)		STAD_MUTECT2	TCGA-VQ-A8PO-01A-11D-A410-08	TCGA-VQ-A8PO-10A-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Frameshift	p.R421Kfs*5	0.234	94.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R421Kfs*5 (Frameshift)		STAD_MUTECT2	TCGA-BR-4257-01A-01D-1126-08	TCGA-BR-4257-11A-01D-1126-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.S109A	0.2812	96.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.S109A (Missense)		STAD_MUTECT2	TCGA-CG-4305-01A-01D-1158-08	TCGA-CG-4305-10A-01D-1158-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Nonsense	p.Q858*	0.41	100.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.Q858* (Nonsense)		STAD_MUTECT2	TCGA-FP-8631-01A-11D-2394-08	TCGA-FP-8631-10A-01D-2394-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.R211H	0.2607	257.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.R211H (Missense)		STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.P902S	0.1598	194.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.P902S (Missense)		STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Investigate Actionability			Guideline	Somatic Variant	ZRSR2	Missense	p.G465D	0.1667	72.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ZRSR2 p.G465D (Missense)		STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.R55C	0.3256	86.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.R55C (Missense)		STAD_MUTECT2	TCGA-HU-A4G9-01A-11D-A24D-08	TCGA-HU-A4G9-10A-01D-A24F-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.D831N	0.6	50.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.D831N (Missense)		STAD_MUTECT2	TCGA-BR-7851-01A-11D-2201-08	TCGA-BR-7851-10A-01D-2201-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.L1889F	0.0862	58.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.L1889F (Missense)		STAD_MUTECT2	TCGA-BR-6563-01A-13D-2053-08	TCGA-BR-6563-10A-01D-2053-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R302C	0.3617	47.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R302C (Missense)		STAD_MUTECT2	TCGA-VQ-A91V-01A-11D-A410-08	TCGA-VQ-A91V-10B-01D-A413-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.K1073E	0.1263	95.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.K1073E (Missense)		STAD_MUTECT2	TCGA-R5-A7ZI-01A-11D-A34U-08	TCGA-R5-A7ZI-10A-01D-A34X-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.T468M	0.507	71.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.T468M (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.K162E	0.1795	39.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.K162E (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Frameshift	p.D1670Tfs*23	0.2475	101.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.D1670Tfs*23 (Frameshift)		STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R549H	0.2113	142.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R549H (Missense)		STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Frameshift	p.N147Kfs*2	0.2056	107.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.N147Kfs*2 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4G8-01A-11D-A25D-08	TCGA-HU-A4G8-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.P987Q	0.1731	52.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.P987Q (Missense)		STAD_MUTECT2	TCGA-HU-A4G8-01A-11D-A25D-08	TCGA-HU-A4G8-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.G503V	0.252	250.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.G503V (Missense)		STAD_MUTECT2	TCGA-CG-5733-01A-11D-1600-08	TCGA-CG-5733-11A-01D-1600-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R620H	0.0769	39.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R620H (Missense)		STAD_MUTECT2	TCGA-BR-8059-01A-11D-2340-08	TCGA-BR-8059-10A-01D-2340-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.T468M	0.0824	182.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.T468M (Missense)		STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.A754T	0.2826	453.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.A754T (Missense)		STAD_MUTECT2	TCGA-HF-7132-01A-11D-2053-08	TCGA-HF-7132-10A-01D-2053-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.E484D	0.1641	323.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.E484D (Missense)		STAD_MUTECT2	TCGA-D7-6822-01A-11D-1882-08	TCGA-D7-6822-10A-01D-1882-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.T589M	0.1761	142.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.T589M (Missense)		STAD_MUTECT2	TCGA-BR-4256-01A-01D-1126-08	TCGA-BR-4256-11A-01D-1126-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.A627V	0.3889	18.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.A627V (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.Y1028N	0.2769	325.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.Y1028N (Missense)		STAD_MUTECT2	TCGA-D7-5577-01A-01D-1600-08	TCGA-D7-5577-10A-01D-1600-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.R181C	0.2359	301.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.R181C (Missense)		STAD_MUTECT2	TCGA-HJ-7597-01A-21D-2201-08	TCGA-HJ-7597-10A-01D-2201-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.Q573R	0.169	71.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Q573R (Missense)		STAD_MUTECT2	TCGA-BR-6852-01A-11D-1882-08	TCGA-BR-6852-10A-01D-1882-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.L56I	0.125	80.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.L56I (Missense)		STAD_MUTECT2	TCGA-BR-8382-01A-11D-2394-08	TCGA-BR-8382-10A-01D-2394-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.A1218T	0.4242	66.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.A1218T (Missense)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Splice Site	p.X364_splice	0.0943	53.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.X364_splice (Splice Site)		STAD_MUTECT2	TCGA-HF-A5NB-01A-11D-A31L-08	TCGA-HF-A5NB-10A-01D-A31J-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.V1168L	0.3673	147.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.V1168L (Missense)		STAD_MUTECT2	TCGA-HF-A5NB-01A-11D-A31L-08	TCGA-HF-A5NB-10A-01D-A31J-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.R879H	0.3571	14.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.R879H (Missense)		STAD_MUTECT2	TCGA-BR-4362-01A-01D-1158-08	TCGA-BR-4362-11A-01D-1158-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.R808H	0.5133	113.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.R808H (Missense)		STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.N493S	0.0687	233.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.N493S (Missense)		STAD_MUTECT2	TCGA-BR-6454-01A-11D-1800-08	TCGA-BR-6454-11A-01D-1800-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Frameshift	p.E458Kfs*14	0.3071	140.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.E458Kfs*14 (Frameshift)		STAD_MUTECT2	TCGA-BR-7707-01A-11D-2053-08	TCGA-BR-7707-10A-01D-2053-08
Investigate Actionability			Clinical evidence	Somatic Variant	MC1R	Missense	p.H260Y	0.0609	115.0	0.0	0.0																Investigate Actionability	0	The presence of MC1R polymorphisms in a cohort of 53 metastatic melanoma patients treated with BRAF inhibitors was associated with a poorer prognosis (ORR: 59% vs. 95%; PFS shorter than 6 months: 72% vs. 33%).	Guida M, Strippoli S, Ferretta A, et al. Detrimental effects of Melanocortin-1 receptor (MC1R) polymorphisms on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell Melanoma Res. 2016;	https://doi.org/10.1111/pcmr.12516					MC1R p.H260Y (Missense)		STAD_MUTECT2	TCGA-BR-7707-01A-11D-2053-08	TCGA-BR-7707-10A-01D-2053-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Frameshift	p.Y784*	0.1466	116.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.Y784* (Frameshift)		STAD_MUTECT2	TCGA-CD-A4MH-01A-11D-A25D-08	TCGA-CD-A4MH-10A-01D-A25E-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.R710C	0.0411	146.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.R710C (Missense)		STAD_MUTECT2	TCGA-BR-8081-01A-11D-2340-08	TCGA-BR-8081-10A-01D-2340-08
Investigate Actionability			Clinical evidence	Somatic Variant	MC1R	Missense	p.R213W	0.0882	34.0	0.0	0.0																Investigate Actionability	0	The presence of MC1R polymorphisms in a cohort of 53 metastatic melanoma patients treated with BRAF inhibitors was associated with a poorer prognosis (ORR: 59% vs. 95%; PFS shorter than 6 months: 72% vs. 33%).	Guida M, Strippoli S, Ferretta A, et al. Detrimental effects of Melanocortin-1 receptor (MC1R) polymorphisms on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell Melanoma Res. 2016;	https://doi.org/10.1111/pcmr.12516					MC1R p.R213W (Missense)		STAD_MUTECT2	TCGA-BR-A4QI-01A-12D-A25D-08	TCGA-BR-A4QI-10A-01D-A25E-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Nonsense	p.R959*	0.2955	132.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.R959* (Nonsense)		STAD_MUTECT2	TCGA-HU-A4GU-01A-11D-A25D-08	TCGA-HU-A4GU-10A-01D-A25E-08
Investigate Actionability			Clinical evidence	Somatic Variant	MC1R	Missense	p.M73V	0.2857	35.0	0.0	0.0																Investigate Actionability	0	The presence of MC1R polymorphisms in a cohort of 53 metastatic melanoma patients treated with BRAF inhibitors was associated with a poorer prognosis (ORR: 59% vs. 95%; PFS shorter than 6 months: 72% vs. 33%).	Guida M, Strippoli S, Ferretta A, et al. Detrimental effects of Melanocortin-1 receptor (MC1R) polymorphisms on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell Melanoma Res. 2016;	https://doi.org/10.1111/pcmr.12516					MC1R p.M73V (Missense)		STAD_MUTECT2	TCGA-VQ-A91E-01A-31D-A410-08	TCGA-VQ-A91E-10A-01D-A413-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Frameshift	p.R822Kfs*36	0.1356	118.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.R822Kfs*36 (Frameshift)		STAD_MUTECT2	TCGA-BR-4370-01A-01D-1158-08	TCGA-BR-4370-11A-01D-1158-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.P1340T	0.3784	74.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.P1340T (Missense)		STAD_MUTECT2	TCGA-F1-6177-01A-11D-1800-08	TCGA-F1-6177-10A-01D-1800-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Frameshift	p.Y323Tfs*12	0.625	16.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.Y323Tfs*12 (Frameshift)		STAD_MUTECT2	TCGA-D7-A4YU-01A-21D-A25D-08	TCGA-D7-A4YU-10A-01D-A25E-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33P	0.4737	57.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S33P (Missense)		STAD_MUTECT2	TCGA-HU-A4H5-01A-21D-A25D-08	TCGA-HU-A4H5-11A-11D-A25E-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.V166G	0.3137	51.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.V166G (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.R587Q	0.2844	225.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.R587Q (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.D568N	0.375	56.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.D568N (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.A652T	0.4375	16.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.A652T (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.A464V	0.3902	82.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.A464V (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.R535Q	0.375	56.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.R535Q (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.I327T	0.0471	170.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.I327T (Missense)		STAD_MUTECT2	TCGA-CG-5726-01A-11D-1600-08	TCGA-CG-5726-11A-01D-1600-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.A622P	0.0926	108.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.A622P (Missense)		STAD_MUTECT2	TCGA-D7-A747-01A-22D-A33T-08	TCGA-D7-A747-10A-21D-A33W-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Frameshift	p.R151Vfs*6	0.1967	61.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.R151Vfs*6 (Frameshift)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Frameshift	p.D194Efs*12	0.0426	47.0	0.0	0.0																Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK2 p.D194Efs*12 (Frameshift)		STAD_MUTECT2	TCGA-BR-8677-01A-11D-2394-08	TCGA-BR-8677-10A-01D-2394-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Frameshift	p.D757Tfs*4	0.2344	64.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.D757Tfs*4 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PB-01A-11D-A397-08	TCGA-VQ-A8PB-10A-01D-A39A-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Frameshift	p.N193Kfs*10	0.2115	52.0	0.0	0.0																Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK2 p.N193Kfs*10 (Frameshift)		STAD_MUTECT2	TCGA-BR-4257-01A-01D-1126-08	TCGA-BR-4257-11A-01D-1126-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Frameshift	p.L437*	0.35	20.0	0.0	0.0																Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK2 p.L437* (Frameshift)		STAD_MUTECT2	TCGA-BR-4257-01A-01D-1126-08	TCGA-BR-4257-11A-01D-1126-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Splice Site	p.X76_splice	0.1562	96.0	0.0	0.0																Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK2 p.X76_splice (Splice Site)		STAD_MUTECT2	TCGA-CG-4305-01A-01D-1158-08	TCGA-CG-4305-10A-01D-1158-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Frameshift	p.N515Mfs*16	0.2713	129.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.N515Mfs*16 (Frameshift)		STAD_MUTECT2	TCGA-CG-4306-01A-01D-1158-08	TCGA-CG-4306-10A-01D-1158-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.E1143K	0.215	200.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.E1143K (Missense)		STAD_MUTECT2	TCGA-CG-4306-01A-01D-1158-08	TCGA-CG-4306-10A-01D-1158-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Frameshift	p.A152Pfs*2	0.0698	43.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.A152Pfs*2 (Frameshift)		STAD_MUTECT2	TCGA-HU-8244-01A-11D-2340-08	TCGA-HU-8244-10A-01D-2341-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.G575R	0.1327	98.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.G575R (Missense)		STAD_MUTECT2	TCGA-BR-4188-01A-01D-1126-08	TCGA-BR-4188-11A-01D-1126-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32H	0.2791	43.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32H (Missense)		STAD_MUTECT2	TCGA-BR-8589-01A-11D-2394-08	TCGA-BR-8589-10A-01D-2394-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32Y	0.5667	30.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32Y (Missense)		STAD_MUTECT2	TCGA-VQ-AA69-01A-11D-A410-08	TCGA-VQ-AA69-10A-01D-A413-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.L1410R	0.0776	116.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.L1410R (Missense)		STAD_MUTECT2	TCGA-HU-A4GH-01A-11D-A24D-08	TCGA-HU-A4GH-10A-01D-A24F-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T3A	0.2093	129.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T3A (Missense)		STAD_MUTECT2	TCGA-BR-6566-01A-11D-1800-08	TCGA-BR-6566-10A-01D-1800-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.D684Y	0.2	145.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.D684Y (Missense)		STAD_MUTECT2	TCGA-CD-A48A-01A-12D-A24D-08	TCGA-CD-A48A-10A-01D-A24F-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Deletion	p.D120_E124del	0.4167	12.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.D120_E124del (Deletion)		STAD_MUTECT2	TCGA-BR-6565-01A-11D-1800-08	TCGA-BR-6565-10A-01D-1800-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.E118D	0.3725	51.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.E118D (Missense)		STAD_MUTECT2	TCGA-HU-A4GT-01A-21D-A25D-08	TCGA-HU-A4GT-10A-01D-A25E-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S37C	0.3387	62.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S37C (Missense)		STAD_MUTECT2	TCGA-CG-5727-01A-11D-1600-08	TCGA-CG-5727-11A-01D-1600-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Nonsense	p.R474*	0.0565	177.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.R474* (Nonsense)		STAD_MUTECT2	TCGA-BR-A4J5-01A-21D-A25D-08	TCGA-BR-A4J5-10A-01D-A25E-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.P675H	0.451	51.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.P675H (Missense)		STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.G84R	0.1508	126.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.G84R (Missense)		STAD_MUTECT2	TCGA-D7-6524-01A-11D-1800-08	TCGA-D7-6524-10A-01D-1800-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.Q123H	0.2326	86.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.Q123H (Missense)		STAD_MUTECT2	TCGA-D7-6524-01A-11D-1800-08	TCGA-D7-6524-10A-01D-1800-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Frameshift	p.R449Lfs*23	0.397	267.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.R449Lfs*23 (Frameshift)		STAD_MUTECT2	TCGA-CG-4469-01A-01D-1158-08	TCGA-CG-4469-10A-01D-1158-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.G34R	0.8	20.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.G34R (Missense)		STAD_MUTECT2	TCGA-HU-A4G6-01A-11D-A24D-08	TCGA-HU-A4G6-10A-01D-A24F-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Deletion	p.T41_S47del	0.3571	56.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T41_S47del (Deletion)		STAD_MUTECT2	TCGA-D7-8573-01A-11D-2340-08	TCGA-D7-8573-10A-01D-2341-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.D153Y	0.0484	124.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.D153Y (Missense)		STAD_MUTECT2	TCGA-KB-A93G-01A-11D-A397-08	TCGA-KB-A93G-10A-01D-A39A-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32H	0.3636	44.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32H (Missense)		STAD_MUTECT2	TCGA-D7-A6EX-01A-11D-A31L-08	TCGA-D7-A6EX-10A-01D-A31J-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.G34R	0.1136	44.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.G34R (Missense)		STAD_MUTECT2	TCGA-BR-A4J6-01A-11D-A25D-08	TCGA-BR-A4J6-10A-01D-A25E-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.R151C	0.1867	75.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.R151C (Missense)		STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Frameshift	p.D757Tfs*4	0.2842	95.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.D757Tfs*4 (Frameshift)		STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.K54N	0.2	30.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.K54N (Missense)		STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S37F	0.4722	36.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S37F (Missense)		STAD_MUTECT2	TCGA-HF-7134-01A-11D-2053-08	TCGA-HF-7134-10A-01D-2053-08
Investigate Actionability			Clinical evidence	Somatic Variant	MC1R	Missense	p.R229H	0.2373	59.0	0.0	0.0																Investigate Actionability	0	The presence of MC1R polymorphisms in a cohort of 53 metastatic melanoma patients treated with BRAF inhibitors was associated with a poorer prognosis (ORR: 59% vs. 95%; PFS shorter than 6 months: 72% vs. 33%).	Guida M, Strippoli S, Ferretta A, et al. Detrimental effects of Melanocortin-1 receptor (MC1R) polymorphisms on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell Melanoma Res. 2016;	https://doi.org/10.1111/pcmr.12516					MC1R p.R229H (Missense)		STAD_MUTECT2	TCGA-HU-A4G8-01A-11D-A25D-08	TCGA-HU-A4G8-10A-01D-A25E-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.R263W	0.5263	19.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.R263W (Missense)		STAD_MUTECT2	TCGA-HU-A4G8-01A-11D-A25D-08	TCGA-HU-A4G8-10A-01D-A25E-08
Investigate Actionability			Clinical evidence	Somatic Variant	MC1R	Missense	p.V205M	0.4091	44.0	0.0	0.0																Investigate Actionability	0	The presence of MC1R polymorphisms in a cohort of 53 metastatic melanoma patients treated with BRAF inhibitors was associated with a poorer prognosis (ORR: 59% vs. 95%; PFS shorter than 6 months: 72% vs. 33%).	Guida M, Strippoli S, Ferretta A, et al. Detrimental effects of Melanocortin-1 receptor (MC1R) polymorphisms on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell Melanoma Res. 2016;	https://doi.org/10.1111/pcmr.12516					MC1R p.V205M (Missense)		STAD_MUTECT2	TCGA-CG-5733-01A-11D-1600-08	TCGA-CG-5733-11A-01D-1600-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S37C	0.7222	54.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S37C (Missense)		STAD_MUTECT2	TCGA-D7-A6EZ-01A-11D-A31L-08	TCGA-D7-A6EZ-10A-01D-A31J-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Frameshift	p.K335Nfs*10	0.1127	142.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.K335Nfs*10 (Frameshift)		STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.I460T	0.1137	211.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.I460T (Missense)		STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.G1308R	0.0847	118.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.G1308R (Missense)		STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S37F	0.1647	85.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S37F (Missense)		STAD_MUTECT2	TCGA-D7-6822-01A-11D-1882-08	TCGA-D7-6822-10A-01D-1882-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T339N	0.1152	165.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T339N (Missense)		STAD_MUTECT2	TCGA-D7-6822-01A-11D-1882-08	TCGA-D7-6822-10A-01D-1882-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Frameshift	p.K991Nfs*12	0.2692	130.0	0.0	0.0																Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK2 p.K991Nfs*12 (Frameshift)		STAD_MUTECT2	TCGA-BR-4191-01A-02D-1126-08	TCGA-BR-4191-11A-01D-1126-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Frameshift	p.K335Nfs*10	0.3258	89.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.K335Nfs*10 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A91K-01A-11D-A410-08	TCGA-VQ-A91K-10A-01D-A413-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T653K	0.3143	105.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T653K (Missense)		STAD_MUTECT2	TCGA-VQ-A91K-01A-11D-A410-08	TCGA-VQ-A91K-10A-01D-A413-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.E1313D	0.3167	60.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.E1313D (Missense)		STAD_MUTECT2	TCGA-VQ-A91K-01A-11D-A410-08	TCGA-VQ-A91K-10A-01D-A413-08
Investigate Actionability			Clinical evidence	Somatic Variant	MC1R	Missense	p.F280L	0.2368	76.0	0.0	0.0																Investigate Actionability	0	The presence of MC1R polymorphisms in a cohort of 53 metastatic melanoma patients treated with BRAF inhibitors was associated with a poorer prognosis (ORR: 59% vs. 95%; PFS shorter than 6 months: 72% vs. 33%).	Guida M, Strippoli S, Ferretta A, et al. Detrimental effects of Melanocortin-1 receptor (MC1R) polymorphisms on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell Melanoma Res. 2016;	https://doi.org/10.1111/pcmr.12516					MC1R p.F280L (Missense)		STAD_MUTECT2	TCGA-BR-4256-01A-01D-1126-08	TCGA-BR-4256-11A-01D-1126-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.D292G	0.0787	89.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.D292G (Missense)		STAD_MUTECT2	TCGA-BR-4280-01A-01D-1126-08	TCGA-BR-4280-11A-01D-1126-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Frameshift	p.N515Mfs*16	0.4	80.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.N515Mfs*16 (Frameshift)		STAD_MUTECT2	TCGA-BR-4280-01A-01D-1126-08	TCGA-BR-4280-11A-01D-1126-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.G34E	0.2105	38.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.G34E (Missense)		STAD_MUTECT2	TCGA-VQ-A91W-01A-11D-A410-08	TCGA-VQ-A91W-10A-01D-A413-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Nonsense	p.R95*	0.2008	264.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.R95* (Nonsense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.R108Q	0.2727	22.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.R108Q (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Investigate Actionability			Clinical evidence	Somatic Variant	MC1R	Missense	p.A204V	0.1429	49.0	0.0	0.0																Investigate Actionability	0	The presence of MC1R polymorphisms in a cohort of 53 metastatic melanoma patients treated with BRAF inhibitors was associated with a poorer prognosis (ORR: 59% vs. 95%; PFS shorter than 6 months: 72% vs. 33%).	Guida M, Strippoli S, Ferretta A, et al. Detrimental effects of Melanocortin-1 receptor (MC1R) polymorphisms on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell Melanoma Res. 2016;	https://doi.org/10.1111/pcmr.12516					MC1R p.A204V (Missense)		STAD_MUTECT2	TCGA-BR-8284-01A-11D-2340-08	TCGA-BR-8284-10A-01D-2340-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.D190H	0.0732	82.0	0.0	0.0																									MYC p.D190H (Missense)		STAD_MUTECT2	TCGA-CD-A48C-01A-11D-A24D-08	TCGA-CD-A48C-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.S788N	0.3526	156.0	0.0	0.0																									RB1 p.S788N (Missense)		STAD_MUTECT2	TCGA-CD-A48C-01A-11D-A24D-08	TCGA-CD-A48C-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.R161P	0.1846	130.0	0.0	0.0																									NTRK1 p.R161P (Missense)		STAD_MUTECT2	TCGA-CG-4438-01A-01D-1158-08	TCGA-CG-4438-10A-01D-1158-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.G642D	0.1667	18.0	0.0	0.0																									NTRK2 p.G642D (Missense)		STAD_MUTECT2	TCGA-CG-4436-01A-01D-1158-08	TCGA-CG-4436-10A-01D-1158-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.S556F	0.2247	89.0	0.0	0.0																									ESRP1 p.S556F (Missense)		STAD_MUTECT2	TCGA-HU-A4H3-01A-21D-A25D-08	TCGA-HU-A4H3-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.I280T	0.32	25.0	0.0	0.0																									NF1 p.I280T (Missense)		STAD_MUTECT2	TCGA-HU-A4H3-01A-21D-A25D-08	TCGA-HU-A4H3-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.6667	15.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		STAD_MUTECT2	TCGA-VQ-AA6I-01A-11D-A410-08	TCGA-VQ-AA6I-10A-01D-A413-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.R444W	0.1696	112.0	0.0	0.0																									NTRK1 p.R444W (Missense)		STAD_MUTECT2	TCGA-BR-4201-01A-01D-1126-08	TCGA-BR-4201-11A-01D-1126-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.R725H	0.1867	75.0	0.0	0.0																									MLH1 p.R725H (Missense)		STAD_MUTECT2	TCGA-BR-4201-01A-01D-1126-08	TCGA-BR-4201-11A-01D-1126-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.R1047W	0.2778	18.0	0.0	0.0																									BRD4 p.R1047W (Missense)		STAD_MUTECT2	TCGA-BR-8373-01A-11D-2340-08	TCGA-BR-8373-10A-01D-2341-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.A25V	0.1837	49.0	0.0	0.0																									FLI1 p.A25V (Missense)		STAD_MUTECT2	TCGA-EQ-8122-01A-11D-2340-08	TCGA-EQ-8122-10A-01D-2341-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.D155E	0.2717	92.0	0.0	0.0																									POT1 p.D155E (Missense)		STAD_MUTECT2	TCGA-VQ-A8P3-01A-11D-A364-08	TCGA-VQ-A8P3-10A-01D-A362-08
Biologically Relevant				Somatic Variant	PMS2	Frameshift	p.R151Afs*50	0.1159	138.0	0.0	0.0																									PMS2 p.R151Afs*50 (Frameshift)		STAD_MUTECT2	TCGA-RD-A8NB-01A-12D-A397-08	TCGA-RD-A8NB-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	POT1	Nonsense	p.Q331*	0.1176	34.0	0.0	0.0																									POT1 p.Q331* (Nonsense)		STAD_MUTECT2	TCGA-RD-A8NB-01A-12D-A397-08	TCGA-RD-A8NB-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.G627S	0.1566	83.0	0.0	0.0																									BRD4 p.G627S (Missense)		STAD_MUTECT2	TCGA-RD-A8NB-01A-12D-A397-08	TCGA-RD-A8NB-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.L384V	0.0338	237.0	0.0	0.0																									MYC p.L384V (Missense)		STAD_MUTECT2	TCGA-BR-7196-01A-11D-2053-08	TCGA-BR-7196-10A-01D-2053-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.T1176M	0.2647	68.0	0.0	0.0																									MTOR p.T1176M (Missense)		STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.R69S	0.3939	33.0	0.0	0.0																									MLH1 p.R69S (Missense)		STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Biologically Relevant				Somatic Variant	MLH1	Frameshift	p.R497Gfs*11	0.2678	239.0	0.0	0.0																									MLH1 p.R497Gfs*11 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2241G	0.3023	43.0	0.0	0.0																									ROS1 p.E2241G (Missense)		STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Biologically Relevant				Somatic Variant	FGFR2	Frameshift	p.N194Tfs*39	0.2737	95.0	0.0	0.0																									FGFR2 p.N194Tfs*39 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Biologically Relevant				Somatic Variant	MDM2	Frameshift	p.S348Qfs*17	0.1649	97.0	0.0	0.0																									MDM2 p.S348Qfs*17 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.G533W	0.3226	31.0	0.0	0.0																									LIMK2 p.G533W (Missense)		STAD_MUTECT2	TCGA-VQ-A8PP-01A-21D-A410-08	TCGA-VQ-A8PP-10A-01D-A413-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.H521N	0.3529	51.0	0.0	0.0																									NTRK3 p.H521N (Missense)		STAD_MUTECT2	TCGA-D7-6519-01A-11D-1800-08	TCGA-D7-6519-10A-01D-1800-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.G298D	0.1132	53.0	0.0	0.0																									FGFR2 p.G298D (Missense)		STAD_MUTECT2	TCGA-VQ-A922-01A-11D-A410-08	TCGA-VQ-A922-10A-01D-A413-08
Biologically Relevant				Somatic Variant	CCND3	Missense	p.R241Q	0.1149	87.0	0.0	0.0																									CCND3 p.R241Q (Missense)		STAD_MUTECT2	TCGA-BR-4362-01A-01D-1158-08	TCGA-BR-4362-11A-01D-1158-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.R475W	0.179	257.0	0.0	0.0																									FGFR1 p.R475W (Missense)		STAD_MUTECT2	TCGA-BR-4362-01A-01D-1158-08	TCGA-BR-4362-11A-01D-1158-08
Biologically Relevant				Somatic Variant	CD274	Missense	p.T290M	0.2909	110.0	0.0	0.0																									CD274 p.T290M (Missense)		STAD_MUTECT2	TCGA-BR-4362-01A-01D-1158-08	TCGA-BR-4362-11A-01D-1158-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.R131C	0.1321	53.0	0.0	0.0																									CDKN2A p.R131C (Missense)		STAD_MUTECT2	TCGA-BR-4362-01A-01D-1158-08	TCGA-BR-4362-11A-01D-1158-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.L79Yfs*6	0.25	104.0	0.0	0.0																									NF1 p.L79Yfs*6 (Frameshift)		STAD_MUTECT2	TCGA-BR-4362-01A-01D-1158-08	TCGA-BR-4362-11A-01D-1158-08
Biologically Relevant				Somatic Variant	NTRK3	Splice Site	p.X208_splice	0.2973	37.0	0.0	0.0																									NTRK3 p.X208_splice (Splice Site)		STAD_MUTECT2	TCGA-HU-A4H4-01A-21D-A25D-08	TCGA-HU-A4H4-11A-11D-A25E-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.E120*	0.4133	75.0	0.0	0.0																									CDKN2A p.E120* (Nonsense)		STAD_MUTECT2	TCGA-IN-8663-01A-11D-2394-08	TCGA-IN-8663-10A-01D-2394-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R394W	0.0945	127.0	0.0	0.0																									RUNX1T1 p.R394W (Missense)		STAD_MUTECT2	TCGA-FP-A9TM-01A-11D-A397-08	TCGA-FP-A9TM-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.V162I	0.1316	114.0	0.0	0.0																									ERG p.V162I (Missense)		STAD_MUTECT2	TCGA-VQ-A91Y-01A-11D-A410-08	TCGA-VQ-A91Y-10A-01D-A413-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.Y44*	0.514	428.0	0.0	0.0																									CDKN2A p.Y44* (Nonsense)		STAD_MUTECT2	TCGA-CD-A489-01A-11D-A24D-08	TCGA-CD-A489-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.T416A	0.4414	111.0	0.0	0.0																									MTOR p.T416A (Missense)		STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1894D	0.3725	204.0	0.0	0.0																									ROS1 p.E1894D (Missense)		STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R1569Q	0.3247	77.0	0.0	0.0																									ROS1 p.R1569Q (Missense)		STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.G90D	0.25	48.0	0.0	0.0																									MYC p.G90D (Missense)		STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.D358Y	0.3804	92.0	0.0	0.0																									NTRK2 p.D358Y (Missense)		STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.A847T	0.5536	112.0	0.0	0.0																									COL1A1 p.A847T (Missense)		STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.G814D	0.2381	21.0	0.0	0.0																									BRD4 p.G814D (Missense)		STAD_MUTECT2	TCGA-BR-A4QL-01A-31D-A25D-08	TCGA-BR-A4QL-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.Q50*	0.3709	302.0	0.0	0.0																									CDKN2A p.Q50* (Nonsense)		STAD_MUTECT2	TCGA-MX-A663-01A-11D-A31L-08	TCGA-MX-A663-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.R273W	0.2302	139.0	0.0	0.0																									SLC45A3 p.R273W (Missense)		STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.R273W	0.3	70.0	0.0	0.0																									POT1 p.R273W (Missense)		STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.R661Q	0.3229	96.0	0.0	0.0																									FGFR1 p.R661Q (Missense)		STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Biologically Relevant				Somatic Variant	MDM2	Missense	p.T224M	0.3239	213.0	0.0	0.0																									MDM2 p.T224M (Missense)		STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R251*	0.4513	113.0	0.0	0.0																									RB1 p.R251* (Nonsense)		STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R918H	0.3526	173.0	0.0	0.0																									COL1A1 p.R918H (Missense)		STAD_MUTECT2	TCGA-CG-4460-01A-01D-1158-08	TCGA-CG-4460-10A-01D-1158-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.L150P	0.0826	121.0	0.0	0.0																									NTRK1 p.L150P (Missense)		STAD_MUTECT2	TCGA-BR-7707-01A-11D-2053-08	TCGA-BR-7707-10A-01D-2053-08
Biologically Relevant				Somatic Variant	NTRK2	Frameshift	p.I98Nfs*12	0.0905	210.0	0.0	0.0																									NTRK2 p.I98Nfs*12 (Frameshift)		STAD_MUTECT2	TCGA-BR-7707-01A-11D-2053-08	TCGA-BR-7707-10A-01D-2053-08
Biologically Relevant				Somatic Variant	MYC	Frameshift	p.A399Pfs*29	0.0958	240.0	0.0	0.0																									MYC p.A399Pfs*29 (Frameshift)		STAD_MUTECT2	TCGA-BR-4368-01A-01D-1158-08	TCGA-BR-4368-11A-01D-1158-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.G617Vfs*6	0.2308	65.0	0.0	0.0																									RB1 p.G617Vfs*6 (Frameshift)		STAD_MUTECT2	TCGA-BR-4368-01A-01D-1158-08	TCGA-BR-4368-11A-01D-1158-08
Biologically Relevant				Somatic Variant	TACC3	Frameshift	p.M396Cfs*65	0.213	108.0	0.0	0.0																									TACC3 p.M396Cfs*65 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4GN-01A-11D-A25D-08	TCGA-HU-A4GN-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	POLE2	Missense	p.R133Q	0.2265	340.0	0.0	0.0																									POLE2 p.R133Q (Missense)		STAD_MUTECT2	TCGA-HU-A4GN-01A-11D-A25D-08	TCGA-HU-A4GN-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.S191G	0.1156	199.0	0.0	0.0																									LIMK2 p.S191G (Missense)		STAD_MUTECT2	TCGA-HU-A4GN-01A-11D-A25D-08	TCGA-HU-A4GN-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	RUNX1T1	Splice Site	p.X247_splice	0.3019	106.0	0.0	0.0																									RUNX1T1 p.X247_splice (Splice Site)		STAD_MUTECT2	TCGA-BR-4357-01A-01D-1158-08	TCGA-BR-4357-11A-01D-1158-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.F175V	0.2558	172.0	0.0	0.0																									RUNX1T1 p.F175V (Missense)		STAD_MUTECT2	TCGA-BR-4357-01A-01D-1158-08	TCGA-BR-4357-11A-01D-1158-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L1892V	0.4462	195.0	0.0	0.0																									NF1 p.L1892V (Missense)		STAD_MUTECT2	TCGA-BR-4357-01A-01D-1158-08	TCGA-BR-4357-11A-01D-1158-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.E365Q	0.7609	138.0	0.0	0.0																									RB1 p.E365Q (Missense)		STAD_MUTECT2	TCGA-IN-A6RO-01A-12D-A33T-08	TCGA-IN-A6RO-10A-01D-A33W-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.Q204H	0.1081	37.0	0.0	0.0																									TPX2 p.Q204H (Missense)		STAD_MUTECT2	TCGA-BR-7716-01A-21D-2053-08	TCGA-BR-7716-10A-01D-2053-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.Q1624R	0.1034	58.0	0.0	0.0																									MTOR p.Q1624R (Missense)		STAD_MUTECT2	TCGA-D7-A6EY-01A-21D-A31L-08	TCGA-D7-A6EY-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.R508Q	0.1856	167.0	0.0	0.0																									NTRK1 p.R508Q (Missense)		STAD_MUTECT2	TCGA-D7-A6EY-01A-21D-A31L-08	TCGA-D7-A6EY-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.E321D	0.25	68.0	0.0	0.0																									TACC3 p.E321D (Missense)		STAD_MUTECT2	TCGA-D7-A6EY-01A-21D-A31L-08	TCGA-D7-A6EY-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	ROS1	Frameshift	p.Y363Lfs*25	0.25	52.0	0.0	0.0																									ROS1 p.Y363Lfs*25 (Frameshift)		STAD_MUTECT2	TCGA-D7-A6EY-01A-21D-A31L-08	TCGA-D7-A6EY-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	CD274	Missense	p.E60K	0.068	103.0	0.0	0.0																									CD274 p.E60K (Missense)		STAD_MUTECT2	TCGA-D7-A6EY-01A-21D-A31L-08	TCGA-D7-A6EY-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	NF1	Deletion	p.V2732del	0.2788	165.0	0.0	0.0																									NF1 p.V2732del (Deletion)		STAD_MUTECT2	TCGA-D7-A6EY-01A-21D-A31L-08	TCGA-D7-A6EY-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.R475Q	0.1937	222.0	0.0	0.0																									FGFR1 p.R475Q (Missense)		STAD_MUTECT2	TCGA-D7-A4YV-01A-11D-A25D-08	TCGA-D7-A4YV-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1667L	0.0612	98.0	0.0	0.0																									ROS1 p.P1667L (Missense)		STAD_MUTECT2	TCGA-BR-8484-01A-11D-2394-08	TCGA-BR-8484-10A-01D-2394-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.V915F	0.2456	57.0	0.0	0.0																									MTOR p.V915F (Missense)		STAD_MUTECT2	TCGA-RD-A8MV-01A-11D-A364-08	TCGA-RD-A8MV-10A-01D-A362-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.E206K	0.0575	87.0	0.0	0.0																									CDK4 p.E206K (Missense)		STAD_MUTECT2	TCGA-BR-8371-01A-11D-2340-08	TCGA-BR-8371-10A-01D-2341-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.N1105I	0.0702	57.0	0.0	0.0																									ROS1 p.N1105I (Missense)		STAD_MUTECT2	TCGA-FP-A8CX-01A-11D-A364-08	TCGA-FP-A8CX-10A-01D-A362-08
Biologically Relevant				Somatic Variant	TPX2	Deletion	p.E552del	0.3396	53.0	0.0	0.0																									TPX2 p.E552del (Deletion)		STAD_MUTECT2	TCGA-FP-A8CX-01A-11D-A364-08	TCGA-FP-A8CX-10A-01D-A362-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.S257L	0.1818	66.0	0.0	0.0																									RAF1 p.S257L (Missense)		STAD_MUTECT2	TCGA-BR-8081-01A-11D-2340-08	TCGA-BR-8081-10A-01D-2340-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.V501M	0.2048	83.0	0.0	0.0																									PMS2 p.V501M (Missense)		STAD_MUTECT2	TCGA-BR-8081-01A-11D-2340-08	TCGA-BR-8081-10A-01D-2340-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.V159A	0.1399	143.0	0.0	0.0																									PMS2 p.V159A (Missense)		STAD_MUTECT2	TCGA-BR-8081-01A-11D-2340-08	TCGA-BR-8081-10A-01D-2340-08
Biologically Relevant				Somatic Variant	BRD4	Nonsense	p.Q64*	0.2192	73.0	0.0	0.0																									BRD4 p.Q64* (Nonsense)		STAD_MUTECT2	TCGA-BR-8081-01A-11D-2340-08	TCGA-BR-8081-10A-01D-2340-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.L197F	0.5882	85.0	0.0	0.0																									NTRK3 p.L197F (Missense)		STAD_MUTECT2	TCGA-D7-8575-01A-11D-2340-08	TCGA-D7-8575-10A-01D-2341-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.Q350P	0.2	25.0	0.0	0.0																									NTRK1 p.Q350P (Missense)		STAD_MUTECT2	TCGA-VQ-A8PX-01A-12D-A410-08	TCGA-VQ-A8PX-10A-01D-A413-08
Biologically Relevant				Somatic Variant	MLH1	Splice Site	p.X226_splice	0.3704	27.0	0.0	0.0																									MLH1 p.X226_splice (Splice Site)		STAD_MUTECT2	TCGA-VQ-A8PX-01A-12D-A410-08	TCGA-VQ-A8PX-10A-01D-A413-08
Biologically Relevant				Somatic Variant	MTOR	Splice Site	p.X2339_splice	0.25	128.0	0.0	0.0																									MTOR p.X2339_splice (Splice Site)		STAD_MUTECT2	TCGA-HU-A4GU-01A-11D-A25D-08	TCGA-HU-A4GU-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.E390K	0.2537	67.0	0.0	0.0																									PDGFRB p.E390K (Missense)		STAD_MUTECT2	TCGA-HU-A4GU-01A-11D-A25D-08	TCGA-HU-A4GU-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.P65H	0.2581	31.0	0.0	0.0																									NTRK2 p.P65H (Missense)		STAD_MUTECT2	TCGA-HU-A4GU-01A-11D-A25D-08	TCGA-HU-A4GU-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	MDM2	Missense	p.T224M	0.2183	197.0	0.0	0.0																									MDM2 p.T224M (Missense)		STAD_MUTECT2	TCGA-HU-A4GU-01A-11D-A25D-08	TCGA-HU-A4GU-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.Y751C	0.0638	94.0	0.0	0.0																									PDGFRB p.Y751C (Missense)		STAD_MUTECT2	TCGA-CG-4465-01A-01D-1158-08	TCGA-CG-4465-10A-01D-1158-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.N706I	0.5091	55.0	0.0	0.0																									ROS1 p.N706I (Missense)		STAD_MUTECT2	TCGA-VQ-A91E-01A-31D-A410-08	TCGA-VQ-A91E-10A-01D-A413-08
Biologically Relevant				Somatic Variant	PAK1	Missense	p.M453V	0.1447	76.0	0.0	0.0																									PAK1 p.M453V (Missense)		STAD_MUTECT2	TCGA-VQ-A91E-01A-31D-A410-08	TCGA-VQ-A91E-10A-01D-A413-08
Biologically Relevant				Somatic Variant	MTOR	Frameshift	p.E1066*	0.2138	145.0	0.0	0.0																									MTOR p.E1066* (Frameshift)		STAD_MUTECT2	TCGA-CG-5728-01A-11D-1600-08	TCGA-CG-5728-11A-01D-1600-08
Biologically Relevant				Somatic Variant	ESRP1	Frameshift	p.N512Tfs*2	0.2407	108.0	0.0	0.0																									ESRP1 p.N512Tfs*2 (Frameshift)		STAD_MUTECT2	TCGA-CG-5728-01A-11D-1600-08	TCGA-CG-5728-11A-01D-1600-08
Biologically Relevant				Somatic Variant	NF1	Deletion	p.T1843_K1844del	0.1316	114.0	0.0	0.0																									NF1 p.T1843_K1844del (Deletion)		STAD_MUTECT2	TCGA-CG-5728-01A-11D-1600-08	TCGA-CG-5728-11A-01D-1600-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.M336I	0.1918	219.0	0.0	0.0																									CCNE1 p.M336I (Missense)		STAD_MUTECT2	TCGA-CG-5728-01A-11D-1600-08	TCGA-CG-5728-11A-01D-1600-08
Biologically Relevant				Somatic Variant	NTRK3	Nonsense	p.L17*	0.1136	44.0	0.0	0.0																									NTRK3 p.L17* (Nonsense)		STAD_MUTECT2	TCGA-ZQ-A9CR-01A-11D-A397-08	TCGA-ZQ-A9CR-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R2193C	0.15	120.0	0.0	0.0																									MTOR p.R2193C (Missense)		STAD_MUTECT2	TCGA-BR-4370-01A-01D-1158-08	TCGA-BR-4370-11A-01D-1158-08
Biologically Relevant				Somatic Variant	MTOR	Nonsense	p.Q1624*	0.1827	104.0	0.0	0.0																									MTOR p.Q1624* (Nonsense)		STAD_MUTECT2	TCGA-BR-4370-01A-01D-1158-08	TCGA-BR-4370-11A-01D-1158-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.P309S	0.2727	11.0	0.0	0.0																									NTRK1 p.P309S (Missense)		STAD_MUTECT2	TCGA-BR-4370-01A-01D-1158-08	TCGA-BR-4370-11A-01D-1158-08
Biologically Relevant				Somatic Variant	MLH1	Nonsense	p.R659*	0.2871	101.0	0.0	0.0																									MLH1 p.R659* (Nonsense)		STAD_MUTECT2	TCGA-BR-4370-01A-01D-1158-08	TCGA-BR-4370-11A-01D-1158-08
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.D90N	0.2315	108.0	0.0	0.0																									FIP1L1 p.D90N (Missense)		STAD_MUTECT2	TCGA-BR-4370-01A-01D-1158-08	TCGA-BR-4370-11A-01D-1158-08
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.A593T	0.1946	257.0	0.0	0.0																									FIP1L1 p.A593T (Missense)		STAD_MUTECT2	TCGA-BR-4370-01A-01D-1158-08	TCGA-BR-4370-11A-01D-1158-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.K2456Nfs*33	0.1618	241.0	0.0	0.0																									NF1 p.K2456Nfs*33 (Frameshift)		STAD_MUTECT2	TCGA-BR-4370-01A-01D-1158-08	TCGA-BR-4370-11A-01D-1158-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.R1282C	0.2105	19.0	0.0	0.0																									BRD4 p.R1282C (Missense)		STAD_MUTECT2	TCGA-BR-4370-01A-01D-1158-08	TCGA-BR-4370-11A-01D-1158-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.G406V	0.1335	352.0	0.0	0.0																									IL12RB1 p.G406V (Missense)		STAD_MUTECT2	TCGA-BR-4370-01A-01D-1158-08	TCGA-BR-4370-11A-01D-1158-08
Biologically Relevant				Somatic Variant	NF1	Deletion	p.R816_S818delinsP	0.0882	102.0	0.0	0.0																									NF1 p.R816_S818delinsP (Deletion)		STAD_MUTECT2	TCGA-CG-5722-01A-21D-1600-08	TCGA-CG-5722-11A-02D-1600-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G257A	0.05	80.0	0.0	0.0																									COL1A1 p.G257A (Missense)		STAD_MUTECT2	TCGA-CD-8529-01A-11D-2340-08	TCGA-CD-8529-10A-01D-2341-08
Biologically Relevant				Somatic Variant	MTOR	Nonsense	p.R460*	0.3241	108.0	0.0	0.0																									MTOR p.R460* (Nonsense)		STAD_MUTECT2	TCGA-CD-A4MJ-01A-11D-A25D-08	TCGA-CD-A4MJ-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.A471V	0.2604	96.0	0.0	0.0																									RUNX1T1 p.A471V (Missense)		STAD_MUTECT2	TCGA-CD-A4MJ-01A-11D-A25D-08	TCGA-CD-A4MJ-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	ESRP1	Frameshift	p.N512Tfs*2	0.4651	129.0	0.0	0.0																									ESRP1 p.N512Tfs*2 (Frameshift)		STAD_MUTECT2	TCGA-CD-A4MJ-01A-11D-A25D-08	TCGA-CD-A4MJ-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.K384R	0.3353	173.0	0.0	0.0																									MTOR p.K384R (Missense)		STAD_MUTECT2	TCGA-CG-4442-01A-01D-1158-08	TCGA-CG-4442-10A-01D-1158-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.R329H	0.2385	130.0	0.0	0.0																									ESRP1 p.R329H (Missense)		STAD_MUTECT2	TCGA-CG-4442-01A-01D-1158-08	TCGA-CG-4442-10A-01D-1158-08
Biologically Relevant				Somatic Variant	ESRP1	Frameshift	p.N512Tfs*2	0.5942	138.0	0.0	0.0																									ESRP1 p.N512Tfs*2 (Frameshift)		STAD_MUTECT2	TCGA-CG-4442-01A-01D-1158-08	TCGA-CG-4442-10A-01D-1158-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.I679Dfs*21	0.6923	91.0	0.0	0.0																									NF1 p.I679Dfs*21 (Frameshift)		STAD_MUTECT2	TCGA-CG-4442-01A-01D-1158-08	TCGA-CG-4442-10A-01D-1158-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.R273Q	0.2523	107.0	0.0	0.0																									NTRK1 p.R273Q (Missense)		STAD_MUTECT2	TCGA-D7-A4YX-01A-11D-A25D-08	TCGA-D7-A4YX-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.T1221I	0.381	147.0	0.0	0.0																									MTOR p.T1221I (Missense)		STAD_MUTECT2	TCGA-VQ-A8PT-01A-11D-A410-08	TCGA-VQ-A8PT-10A-01D-A413-08
Biologically Relevant				Somatic Variant	RUNX1T1	Frameshift	p.N24Tfs*22	0.2581	93.0	0.0	0.0																									RUNX1T1 p.N24Tfs*22 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PT-01A-11D-A410-08	TCGA-VQ-A8PT-10A-01D-A413-08
Biologically Relevant				Somatic Variant	ERG	Frameshift	p.F453Lfs*59	0.28	25.0	0.0	0.0																									ERG p.F453Lfs*59 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8PT-01A-11D-A410-08	TCGA-VQ-A8PT-10A-01D-A413-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.R286C	0.1875	48.0	0.0	0.0																									LIMK2 p.R286C (Missense)		STAD_MUTECT2	TCGA-VQ-A8PT-01A-11D-A410-08	TCGA-VQ-A8PT-10A-01D-A413-08
Biologically Relevant				Somatic Variant	CD274	Missense	p.R86W	0.3333	54.0	0.0	0.0																									CD274 p.R86W (Missense)		STAD_MUTECT2	TCGA-BR-8360-01A-11D-2340-08	TCGA-BR-8360-10A-01D-2340-08
Biologically Relevant				Somatic Variant	PMS2	Frameshift	p.D414Tfs*34	0.3433	67.0	0.0	0.0																									PMS2 p.D414Tfs*34 (Frameshift)		STAD_MUTECT2	TCGA-BR-8372-01A-11D-2340-08	TCGA-BR-8372-10A-01D-2341-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.S281N	0.2331	163.0	0.0	0.0																									FGFR1 p.S281N (Missense)		STAD_MUTECT2	TCGA-BR-8372-01A-11D-2340-08	TCGA-BR-8372-10A-01D-2341-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R1405H	0.2727	44.0	0.0	0.0																									COL1A1 p.R1405H (Missense)		STAD_MUTECT2	TCGA-BR-8372-01A-11D-2340-08	TCGA-BR-8372-10A-01D-2341-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.Y537H	0.2727	22.0	0.0	0.0																									KEAP1 p.Y537H (Missense)		STAD_MUTECT2	TCGA-BR-8372-01A-11D-2340-08	TCGA-BR-8372-10A-01D-2341-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.T598M	0.0469	128.0	0.0	0.0																									BRD4 p.T598M (Missense)		STAD_MUTECT2	TCGA-BR-8372-01A-11D-2340-08	TCGA-BR-8372-10A-01D-2341-08
Biologically Relevant				Somatic Variant	TPX2	Splice Site	p.X399_splice	0.3908	87.0	0.0	0.0																									TPX2 p.X399_splice (Splice Site)		STAD_MUTECT2	TCGA-BR-8372-01A-11D-2340-08	TCGA-BR-8372-10A-01D-2341-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.G24A	0.2105	95.0	0.0	0.0																									ESRP1 p.G24A (Missense)		STAD_MUTECT2	TCGA-VQ-AA6B-01A-11D-A410-08	TCGA-VQ-AA6B-10A-01D-A413-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.Q477H	0.3578	109.0	0.0	0.0																									MTOR p.Q477H (Missense)		STAD_MUTECT2	TCGA-F1-6177-01A-11D-1800-08	TCGA-F1-6177-10A-01D-1800-08
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.R481H	0.3269	52.0	0.0	0.0																									FIP1L1 p.R481H (Missense)		STAD_MUTECT2	TCGA-F1-6177-01A-11D-1800-08	TCGA-F1-6177-10A-01D-1800-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.R250W	0.7021	47.0	0.0	0.0																									FGFR1 p.R250W (Missense)		STAD_MUTECT2	TCGA-F1-6177-01A-11D-1800-08	TCGA-F1-6177-10A-01D-1800-08
Biologically Relevant				Somatic Variant	ERG	Frameshift	p.G233Vfs*65	0.4286	70.0	0.0	0.0																									ERG p.G233Vfs*65 (Frameshift)		STAD_MUTECT2	TCGA-F1-6177-01A-11D-1800-08	TCGA-F1-6177-10A-01D-1800-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.A23T	0.5405	111.0	0.0	0.0																									EWSR1 p.A23T (Missense)		STAD_MUTECT2	TCGA-F1-6177-01A-11D-1800-08	TCGA-F1-6177-10A-01D-1800-08
Biologically Relevant				Somatic Variant	MLH1	Frameshift	p.L155Efs*10	0.3607	61.0	0.0	0.0																									MLH1 p.L155Efs*10 (Frameshift)		STAD_MUTECT2	TCGA-F1-6874-01A-11D-1882-08	TCGA-F1-6874-10A-01D-1882-08
Biologically Relevant				Somatic Variant	AURKB	Missense	p.G235D	0.2986	144.0	0.0	0.0																									AURKB p.G235D (Missense)		STAD_MUTECT2	TCGA-F1-6874-01A-11D-1882-08	TCGA-F1-6874-10A-01D-1882-08
Biologically Relevant				Somatic Variant	COL1A1	Frameshift	p.P376Lfs*165	0.3485	132.0	0.0	0.0																									COL1A1 p.P376Lfs*165 (Frameshift)		STAD_MUTECT2	TCGA-F1-6874-01A-11D-1882-08	TCGA-F1-6874-10A-01D-1882-08
Biologically Relevant				Somatic Variant	ERG	Frameshift	p.A454Cfs*19	0.2679	56.0	0.0	0.0																									ERG p.A454Cfs*19 (Frameshift)		STAD_MUTECT2	TCGA-F1-6874-01A-11D-1882-08	TCGA-F1-6874-10A-01D-1882-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R461*	0.4639	194.0	0.0	0.0																									NF1 p.R461* (Nonsense)		STAD_MUTECT2	TCGA-BR-4371-01A-01D-1158-08	TCGA-BR-4371-11A-01D-1158-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q2673*	0.3636	88.0	0.0	0.0																									NF1 p.Q2673* (Nonsense)		STAD_MUTECT2	TCGA-BR-4371-01A-01D-1158-08	TCGA-BR-4371-11A-01D-1158-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R910Q	0.2053	151.0	0.0	0.0																									MTOR p.R910Q (Missense)		STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.P311L	0.2432	37.0	0.0	0.0																									NTRK1 p.P311L (Missense)		STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	AURKB	Missense	p.R139C	0.2889	45.0	0.0	0.0																									AURKB p.R139C (Missense)		STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.M2782V	0.2941	204.0	0.0	0.0																									NF1 p.M2782V (Missense)		STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.A102T	0.2192	73.0	0.0	0.0																									TMPRSS2 p.A102T (Missense)		STAD_MUTECT2	TCGA-HU-A4GQ-01A-11D-A25D-08	TCGA-HU-A4GQ-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.L115P	0.1	160.0	0.0	0.0																									NTRK3 p.L115P (Missense)		STAD_MUTECT2	TCGA-RD-A7BT-01A-11D-A33T-08	TCGA-RD-A7BT-10A-01D-A33W-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.A2532V	0.2778	126.0	0.0	0.0																									MTOR p.A2532V (Missense)		STAD_MUTECT2	TCGA-BR-4292-01A-01D-1126-08	TCGA-BR-4292-11A-01D-1126-08
Biologically Relevant				Somatic Variant	EML4	Frameshift	p.E130Rfs*43	0.3375	80.0	0.0	0.0																									EML4 p.E130Rfs*43 (Frameshift)		STAD_MUTECT2	TCGA-BR-4292-01A-01D-1126-08	TCGA-BR-4292-11A-01D-1126-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.E737V	0.3894	113.0	0.0	0.0																									TACC3 p.E737V (Missense)		STAD_MUTECT2	TCGA-BR-4292-01A-01D-1126-08	TCGA-BR-4292-11A-01D-1126-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.K1422N	0.0783	115.0	0.0	0.0																									ROS1 p.K1422N (Missense)		STAD_MUTECT2	TCGA-BR-4292-01A-01D-1126-08	TCGA-BR-4292-11A-01D-1126-08
Biologically Relevant				Somatic Variant	ESRP1	Frameshift	p.E467Gfs*44	0.3111	90.0	0.0	0.0																									ESRP1 p.E467Gfs*44 (Frameshift)		STAD_MUTECT2	TCGA-BR-4292-01A-01D-1126-08	TCGA-BR-4292-11A-01D-1126-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.A97V	0.2526	95.0	0.0	0.0																									FGFR2 p.A97V (Missense)		STAD_MUTECT2	TCGA-BR-4292-01A-01D-1126-08	TCGA-BR-4292-11A-01D-1126-08
Biologically Relevant				Somatic Variant	FLI1	Frameshift	p.I430Nfs*12	0.3077	91.0	0.0	0.0																									FLI1 p.I430Nfs*12 (Frameshift)		STAD_MUTECT2	TCGA-BR-4292-01A-01D-1126-08	TCGA-BR-4292-11A-01D-1126-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.R997M	0.2406	133.0	0.0	0.0																									NF1 p.R997M (Missense)		STAD_MUTECT2	TCGA-BR-4292-01A-01D-1126-08	TCGA-BR-4292-11A-01D-1126-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.K2628Nfs*16	0.375	40.0	0.0	0.0																									NF1 p.K2628Nfs*16 (Frameshift)		STAD_MUTECT2	TCGA-BR-4292-01A-01D-1126-08	TCGA-BR-4292-11A-01D-1126-08
Biologically Relevant				Somatic Variant	PDGFB	Frameshift	p.K220Rfs*16	0.3421	38.0	0.0	0.0																									PDGFB p.K220Rfs*16 (Frameshift)		STAD_MUTECT2	TCGA-BR-4292-01A-01D-1126-08	TCGA-BR-4292-11A-01D-1126-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.I2500M	0.3129	147.0	0.0	0.0																									MTOR p.I2500M (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R604C	0.3448	29.0	0.0	0.0																									MTOR p.R604C (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1974K	0.2075	159.0	0.0	0.0																									ROS1 p.E1974K (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.N1800T	0.3864	44.0	0.0	0.0																									ROS1 p.N1800T (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Biologically Relevant				Somatic Variant	ROS1	Nonsense	p.E1737*	0.3291	79.0	0.0	0.0																									ROS1 p.E1737* (Nonsense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.V138A	0.3475	141.0	0.0	0.0																									POT1 p.V138A (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.S2Y	0.2615	65.0	0.0	0.0																									POT1 p.S2Y (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.A268V	0.3092	262.0	0.0	0.0																									NTRK2 p.A268V (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.R399Q	0.3023	129.0	0.0	0.0																									FGFR2 p.R399Q (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Biologically Relevant				Somatic Variant	PAK1	Missense	p.L107F	0.2626	99.0	0.0	0.0																									PAK1 p.L107F (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.R791W	0.4182	55.0	0.0	0.0																									NTRK3 p.R791W (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.K469Q	0.4375	48.0	0.0	0.0																									NF1 p.K469Q (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.F2708V	0.3061	49.0	0.0	0.0																									NF1 p.F2708V (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.R50H	0.3927	191.0	0.0	0.0																									KEAP1 p.R50H (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.K313N	0.3453	139.0	0.0	0.0																									TPX2 p.K313N (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.V162I	0.2947	95.0	0.0	0.0																									ERG p.V162I (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Biologically Relevant				Somatic Variant	CRKL	Missense	p.D138Y	0.4156	154.0	0.0	0.0																									CRKL p.D138Y (Missense)		STAD_MUTECT2	TCGA-BR-8680-01A-11D-2394-08	TCGA-BR-8680-10A-01D-2394-08
Biologically Relevant				Somatic Variant	RB1	Deletion	p.F684_L688del	0.8365	104.0	0.0	0.0																									RB1 p.F684_L688del (Deletion)		STAD_MUTECT2	TCGA-3M-AB46-01A-11D-A410-08	TCGA-3M-AB46-10A-01D-A413-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.T862I	0.1633	98.0	0.0	0.0																									NF1 p.T862I (Missense)		STAD_MUTECT2	TCGA-3M-AB46-01A-11D-A410-08	TCGA-3M-AB46-10A-01D-A413-08
Biologically Relevant				Somatic Variant	RAF1	Nonsense	p.R554*	0.2909	165.0	0.0	0.0																									RAF1 p.R554* (Nonsense)		STAD_MUTECT2	TCGA-CD-8536-01A-11D-2340-08	TCGA-CD-8536-10A-01D-2341-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.D406N	0.0649	185.0	0.0	0.0																									TACC3 p.D406N (Missense)		STAD_MUTECT2	TCGA-CD-8536-01A-11D-2340-08	TCGA-CD-8536-10A-01D-2341-08
Biologically Relevant				Somatic Variant	FIP1L1	Nonsense	p.R504*	0.2375	80.0	0.0	0.0																									FIP1L1 p.R504* (Nonsense)		STAD_MUTECT2	TCGA-CD-8536-01A-11D-2340-08	TCGA-CD-8536-10A-01D-2341-08
Biologically Relevant				Somatic Variant	ROS1	Frameshift	p.N2224Kfs*2	0.1933	150.0	0.0	0.0																									ROS1 p.N2224Kfs*2 (Frameshift)		STAD_MUTECT2	TCGA-CD-8536-01A-11D-2340-08	TCGA-CD-8536-10A-01D-2341-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.C249Y	0.3158	95.0	0.0	0.0																									KEAP1 p.C249Y (Missense)		STAD_MUTECT2	TCGA-CD-8536-01A-11D-2340-08	TCGA-CD-8536-10A-01D-2341-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R260Q	0.1275	102.0	0.0	0.0																									MTOR p.R260Q (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.T311A	0.4444	36.0	0.0	0.0																									SLC45A3 p.T311A (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.V342I	0.1875	32.0	0.0	0.0																									TACC3 p.V342I (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.A168V	0.338	71.0	0.0	0.0																									PDGFRB p.A168V (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Biologically Relevant				Somatic Variant	ROS1	Nonsense	p.G697*	0.3544	79.0	0.0	0.0																									ROS1 p.G697* (Nonsense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R260K	0.3067	75.0	0.0	0.0																									ROS1 p.R260K (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Biologically Relevant				Somatic Variant	CD274	Missense	p.A5D	0.3896	77.0	0.0	0.0																									CD274 p.A5D (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.N799S	0.1538	26.0	0.0	0.0																									NTRK2 p.N799S (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Biologically Relevant				Somatic Variant	CCND1	Missense	p.A81T	0.2424	33.0	0.0	0.0																									CCND1 p.A81T (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.P194L	0.0737	95.0	0.0	0.0																									CDK4 p.P194L (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.R201H	0.4865	37.0	0.0	0.0																									NTRK3 p.R201H (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Biologically Relevant				Somatic Variant	AURKB	Missense	p.E59K	0.1818	33.0	0.0	0.0																									AURKB p.E59K (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X1477_splice	0.1379	58.0	0.0	0.0																									NF1 p.X1477_splice (Splice Site)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.R2179H	0.0641	78.0	0.0	0.0																									NF1 p.R2179H (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Biologically Relevant				Somatic Variant	COL1A1	Frameshift	p.G809Afs*299	0.3333	45.0	0.0	0.0																									COL1A1 p.G809Afs*299 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.V111I	0.3333	69.0	0.0	0.0																									IL12RB1 p.V111I (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Biologically Relevant				Somatic Variant	CRKL	Missense	p.R164Q	0.1316	76.0	0.0	0.0																									CRKL p.R164Q (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.K62T	0.0889	45.0	0.0	0.0																									LIMK2 p.K62T (Missense)		STAD_MUTECT2	TCGA-VQ-A8P2-01A-11D-A364-08	TCGA-VQ-A8P2-10A-01D-A362-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.V109M	0.1365	652.0	0.0	0.0																									TACC3 p.V109M (Missense)		STAD_MUTECT2	TCGA-CG-5726-01A-11D-1600-08	TCGA-CG-5726-11A-01D-1600-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.R695H	0.1567	134.0	0.0	0.0																									PDGFRB p.R695H (Missense)		STAD_MUTECT2	TCGA-CG-5726-01A-11D-1600-08	TCGA-CG-5726-11A-01D-1600-08
Biologically Relevant				Somatic Variant	RUNX1T1	Frameshift	p.S92Hfs*35	0.1839	87.0	0.0	0.0																									RUNX1T1 p.S92Hfs*35 (Frameshift)		STAD_MUTECT2	TCGA-CG-5726-01A-11D-1600-08	TCGA-CG-5726-11A-01D-1600-08
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.G53R	0.3864	44.0	0.0	0.0																									PDGFB p.G53R (Missense)		STAD_MUTECT2	TCGA-CG-5726-01A-11D-1600-08	TCGA-CG-5726-11A-01D-1600-08
Biologically Relevant				Somatic Variant	EPCAM	Missense	p.S289Y	0.0582	275.0	0.0	0.0																									EPCAM p.S289Y (Missense)		STAD_MUTECT2	TCGA-D7-A747-01A-22D-A33T-08	TCGA-D7-A747-10A-21D-A33W-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.T490M	0.3548	31.0	0.0	0.0																									NTRK3 p.T490M (Missense)		STAD_MUTECT2	TCGA-R5-A805-01A-11D-A364-08	TCGA-R5-A805-10A-01D-A362-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.I267V	0.0877	171.0	0.0	0.0																									MTOR p.I267V (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.P489S	0.082	61.0	0.0	0.0																									EML4 p.P489S (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.M350T	0.1057	123.0	0.0	0.0																									RAF1 p.M350T (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.V358I	0.1418	141.0	0.0	0.0																									FGFR1 p.V358I (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Biologically Relevant				Somatic Variant	ESRP1	Frameshift	p.N512Tfs*2	0.4963	135.0	0.0	0.0																									ESRP1 p.N512Tfs*2 (Frameshift)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.G160D	0.1129	62.0	0.0	0.0																									MYC p.G160D (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.G740R	0.092	174.0	0.0	0.0																									NTRK2 p.G740R (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.D655G	0.0971	175.0	0.0	0.0																									FGFR2 p.D655G (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Biologically Relevant				Somatic Variant	MDM2	Missense	p.C8R	0.0828	447.0	0.0	0.0																									MDM2 p.C8R (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Biologically Relevant				Somatic Variant	MDM2	Frameshift	p.T371Lfs*2	0.1067	75.0	0.0	0.0																									MDM2 p.T371Lfs*2 (Frameshift)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.W335R	0.1087	92.0	0.0	0.0																									NTRK3 p.W335R (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.S117T	0.0564	195.0	0.0	0.0																									NTRK3 p.S117T (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G1342C	0.1579	57.0	0.0	0.0																									COL1A1 p.G1342C (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Biologically Relevant				Somatic Variant	COL1A1	Frameshift	p.P624Lfs*142	0.2083	48.0	0.0	0.0																									COL1A1 p.P624Lfs*142 (Frameshift)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.S45F	0.0956	136.0	0.0	0.0																									KEAP1 p.S45F (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.S662F	0.0909	66.0	0.0	0.0																									BRD4 p.S662F (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.P142S	0.0846	201.0	0.0	0.0																									CCNE1 p.P142S (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Biologically Relevant				Somatic Variant	AURKA	Missense	p.V206A	0.0633	79.0	0.0	0.0																									AURKA p.V206A (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.S248G	0.1556	45.0	0.0	0.0																									EWSR1 p.S248G (Missense)		STAD_MUTECT2	TCGA-BR-6452-01A-12D-1800-08	TCGA-BR-6452-10A-01D-1800-08
Biologically Relevant				Somatic Variant	RUNX1T1	Splice Site	p.X331_splice	0.2103	195.0	0.0	0.0																									RUNX1T1 p.X331_splice (Splice Site)		STAD_MUTECT2	TCGA-BR-8078-01A-11D-2340-08	TCGA-BR-8078-10A-01D-2340-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.A195V	0.3099	71.0	0.0	0.0																									COL1A1 p.A195V (Missense)		STAD_MUTECT2	TCGA-BR-8078-01A-11D-2340-08	TCGA-BR-8078-10A-01D-2340-08
Biologically Relevant				Somatic Variant	NTRK1	Frameshift	p.L585Cfs*73	0.3333	39.0	0.0	0.0																									NTRK1 p.L585Cfs*73 (Frameshift)		STAD_MUTECT2	TCGA-BR-4363-01A-01D-1158-08	TCGA-BR-4363-11A-01D-1158-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.S257L	0.2103	195.0	0.0	0.0																									RAF1 p.S257L (Missense)		STAD_MUTECT2	TCGA-BR-4363-01A-01D-1158-08	TCGA-BR-4363-11A-01D-1158-08
Biologically Relevant				Somatic Variant	ESRP1	Frameshift	p.N512Tfs*2	0.6667	117.0	0.0	0.0																									ESRP1 p.N512Tfs*2 (Frameshift)		STAD_MUTECT2	TCGA-BR-4363-01A-01D-1158-08	TCGA-BR-4363-11A-01D-1158-08
Biologically Relevant				Somatic Variant	CCND1	Missense	p.A271T	0.2885	52.0	0.0	0.0																									CCND1 p.A271T (Missense)		STAD_MUTECT2	TCGA-BR-4363-01A-01D-1158-08	TCGA-BR-4363-11A-01D-1158-08
Biologically Relevant				Somatic Variant	POT1	Splice Site	p.X532_splice	0.1233	73.0	0.0	0.0																									POT1 p.X532_splice (Splice Site)		STAD_MUTECT2	TCGA-VQ-A8E3-01A-11D-A397-08	TCGA-VQ-A8E3-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.A189T	0.2222	207.0	0.0	0.0																									BRD4 p.A189T (Missense)		STAD_MUTECT2	TCGA-VQ-A8E3-01A-11D-A397-08	TCGA-VQ-A8E3-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	MTOR	Nonsense	p.R1203*	0.2857	63.0	0.0	0.0																									MTOR p.R1203* (Nonsense)		STAD_MUTECT2	TCGA-VQ-AA6G-01A-11D-A410-08	TCGA-VQ-AA6G-10A-01D-A413-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R564H	0.2	45.0	0.0	0.0																									COL1A1 p.R564H (Missense)		STAD_MUTECT2	TCGA-VQ-AA6G-01A-11D-A410-08	TCGA-VQ-AA6G-10A-01D-A413-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.R158H	0.2857	35.0	0.0	0.0																									SLC45A3 p.R158H (Missense)		STAD_MUTECT2	TCGA-BR-8368-01A-11D-2340-08	TCGA-BR-8368-10A-01D-2341-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R564H	0.2347	98.0	0.0	0.0																									COL1A1 p.R564H (Missense)		STAD_MUTECT2	TCGA-CG-4444-01A-01D-1158-08	TCGA-CG-4444-10A-01D-1158-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.R192C	0.3077	52.0	0.0	0.0																									EML4 p.R192C (Missense)		STAD_MUTECT2	TCGA-CD-A4MI-01A-21D-A25D-08	TCGA-CD-A4MI-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E90A	0.0983	173.0	0.0	0.0																									FGFR2 p.E90A (Missense)		STAD_MUTECT2	TCGA-CD-A4MI-01A-21D-A25D-08	TCGA-CD-A4MI-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.Y44Tfs*9	0.408	125.0	0.0	0.0																									CDKN2A p.Y44Tfs*9 (Frameshift)		STAD_MUTECT2	TCGA-FP-8099-01A-11D-2340-08	TCGA-FP-8099-10A-01D-2341-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.R787H	0.2667	90.0	0.0	0.0																									NTRK3 p.R787H (Missense)		STAD_MUTECT2	TCGA-FP-8099-01A-11D-2340-08	TCGA-FP-8099-10A-01D-2341-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.K447N	0.1919	172.0	0.0	0.0																									TPX2 p.K447N (Missense)		STAD_MUTECT2	TCGA-FP-8099-01A-11D-2340-08	TCGA-FP-8099-10A-01D-2341-08
Biologically Relevant				Somatic Variant	ROS1	Frameshift	p.I414Lfs*14	0.3525	366.0	0.0	0.0																									ROS1 p.I414Lfs*14 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4H8-01A-11D-A25D-08	TCGA-HU-A4H8-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	ESRP1	Frameshift	p.N512Tfs*2	0.6444	90.0	0.0	0.0																									ESRP1 p.N512Tfs*2 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4H8-01A-11D-A25D-08	TCGA-HU-A4H8-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.A76T	0.4375	48.0	0.0	0.0																									CDKN2A p.A76T (Missense)		STAD_MUTECT2	TCGA-HU-A4H8-01A-11D-A25D-08	TCGA-HU-A4H8-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R1257H	0.3664	131.0	0.0	0.0																									COL1A1 p.R1257H (Missense)		STAD_MUTECT2	TCGA-HU-A4H8-01A-11D-A25D-08	TCGA-HU-A4H8-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R394Q	0.1429	196.0	0.0	0.0																									RUNX1T1 p.R394Q (Missense)		STAD_MUTECT2	TCGA-MX-A5UJ-01A-11D-A31L-08	TCGA-MX-A5UJ-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P1022L	0.4545	11.0	0.0	0.0																									BRD4 p.P1022L (Missense)		STAD_MUTECT2	TCGA-MX-A5UJ-01A-11D-A31L-08	TCGA-MX-A5UJ-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.P498S	0.1905	168.0	0.0	0.0																									NTRK2 p.P498S (Missense)		STAD_MUTECT2	TCGA-D7-5579-01A-01D-1600-08	TCGA-D7-5579-10A-01D-1600-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.T271Efs*14	0.4156	77.0	0.0	0.0																									RB1 p.T271Efs*14 (Frameshift)		STAD_MUTECT2	TCGA-BR-A452-01A-91D-A25D-08	TCGA-BR-A452-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	EPCAM	Missense	p.L312P	0.1481	54.0	0.0	0.0																									EPCAM p.L312P (Missense)		STAD_MUTECT2	TCGA-VQ-A8PO-01A-11D-A410-08	TCGA-VQ-A8PO-10A-01D-A413-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.D2256G	0.2708	48.0	0.0	0.0																									ROS1 p.D2256G (Missense)		STAD_MUTECT2	TCGA-VQ-A8PO-01A-11D-A410-08	TCGA-VQ-A8PO-10A-01D-A413-08
Biologically Relevant				Somatic Variant	CCND1	Missense	p.D192Y	0.1282	39.0	0.0	0.0																									CCND1 p.D192Y (Missense)		STAD_MUTECT2	TCGA-VQ-A8PO-01A-11D-A410-08	TCGA-VQ-A8PO-10A-01D-A413-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L2045F	0.3333	90.0	0.0	0.0																									NF1 p.L2045F (Missense)		STAD_MUTECT2	TCGA-VQ-A8PO-01A-11D-A410-08	TCGA-VQ-A8PO-10A-01D-A413-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.T370K	0.2014	144.0	0.0	0.0																									FGFR2 p.T370K (Missense)		STAD_MUTECT2	TCGA-CG-4474-01A-02D-1158-08	TCGA-CG-4474-10A-01D-1158-08
Biologically Relevant				Somatic Variant	RUNX1T1	Nonsense	p.R373*	0.0549	164.0	0.0	0.0																									RUNX1T1 p.R373* (Nonsense)		STAD_MUTECT2	TCGA-BR-8687-01A-11D-2394-08	TCGA-BR-8687-10A-01D-2394-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.K181R	0.2619	42.0	0.0	0.0																									NTRK3 p.K181R (Missense)		STAD_MUTECT2	TCGA-BR-8289-01A-11D-2340-08	TCGA-BR-8289-10A-01D-2340-08
Biologically Relevant				Somatic Variant	ROS1	Nonsense	p.G1778*	0.1325	83.0	0.0	0.0																									ROS1 p.G1778* (Nonsense)		STAD_MUTECT2	TCGA-BR-4257-01A-01D-1126-08	TCGA-BR-4257-11A-01D-1126-08
Biologically Relevant				Somatic Variant	MYC	Frameshift	p.A399Pfs*29	0.1976	248.0	0.0	0.0																									MYC p.A399Pfs*29 (Frameshift)		STAD_MUTECT2	TCGA-BR-4257-01A-01D-1126-08	TCGA-BR-4257-11A-01D-1126-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.P621A	0.5556	9.0	0.0	0.0																									EWSR1 p.P621A (Missense)		STAD_MUTECT2	TCGA-BR-4257-01A-01D-1126-08	TCGA-BR-4257-11A-01D-1126-08
Biologically Relevant				Somatic Variant	EPCAM	Missense	p.I269V	0.2532	79.0	0.0	0.0																									EPCAM p.I269V (Missense)		STAD_MUTECT2	TCGA-CG-4305-01A-01D-1158-08	TCGA-CG-4305-10A-01D-1158-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.R470C	0.1613	248.0	0.0	0.0																									FGFR1 p.R470C (Missense)		STAD_MUTECT2	TCGA-CG-4305-01A-01D-1158-08	TCGA-CG-4305-10A-01D-1158-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.H352R	0.1695	118.0	0.0	0.0																									FGFR1 p.H352R (Missense)		STAD_MUTECT2	TCGA-CG-4305-01A-01D-1158-08	TCGA-CG-4305-10A-01D-1158-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.H311R	0.1951	82.0	0.0	0.0																									KEAP1 p.H311R (Missense)		STAD_MUTECT2	TCGA-CG-4305-01A-01D-1158-08	TCGA-CG-4305-10A-01D-1158-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.Q2141H	0.0597	134.0	0.0	0.0																									ROS1 p.Q2141H (Missense)		STAD_MUTECT2	TCGA-BR-8590-01A-11D-2394-08	TCGA-BR-8590-10A-01D-2394-08
Biologically Relevant				Somatic Variant	ESRP1	Frameshift	p.N512Tfs*2	0.2727	110.0	0.0	0.0																									ESRP1 p.N512Tfs*2 (Frameshift)		STAD_MUTECT2	TCGA-CG-4306-01A-01D-1158-08	TCGA-CG-4306-10A-01D-1158-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.L558P	0.2701	137.0	0.0	0.0																									TPX2 p.L558P (Missense)		STAD_MUTECT2	TCGA-CG-4306-01A-01D-1158-08	TCGA-CG-4306-10A-01D-1158-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.L422V	0.3734	233.0	0.0	0.0																									PDGFRB p.L422V (Missense)		STAD_MUTECT2	TCGA-EQ-A4SO-01A-11D-A25D-08	TCGA-EQ-A4SO-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.Q533K	0.3176	148.0	0.0	0.0																									BRD4 p.Q533K (Missense)		STAD_MUTECT2	TCGA-EQ-A4SO-01A-11D-A25D-08	TCGA-EQ-A4SO-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.F747V	0.3058	121.0	0.0	0.0																									NTRK2 p.F747V (Missense)		STAD_MUTECT2	TCGA-HU-A4GF-01A-11D-A24D-08	TCGA-HU-A4GF-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.P112S	0.3226	31.0	0.0	0.0																									FLI1 p.P112S (Missense)		STAD_MUTECT2	TCGA-HU-A4GF-01A-11D-A24D-08	TCGA-HU-A4GF-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.D189E	0.1346	52.0	0.0	0.0																									EML4 p.D189E (Missense)		STAD_MUTECT2	TCGA-CG-4301-01A-01D-1158-08	TCGA-CG-4301-10A-01D-1158-08
Biologically Relevant				Somatic Variant	PAK1	Splice Site	p.X258_splice	0.1152	269.0	0.0	0.0																									PAK1 p.X258_splice (Splice Site)		STAD_MUTECT2	TCGA-CG-4476-01A-01D-1158-08	TCGA-CG-4476-10A-01D-1158-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.T571M	0.3559	59.0	0.0	0.0																									MTOR p.T571M (Missense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Biologically Relevant				Somatic Variant	MLH1	Nonsense	p.K255*	0.7215	79.0	0.0	0.0																									MLH1 p.K255* (Nonsense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.P8S	0.4054	37.0	0.0	0.0																									PDGFRB p.P8S (Missense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Biologically Relevant				Somatic Variant	ROS1	Frameshift	p.N1499Tfs*5	0.36	50.0	0.0	0.0																									ROS1 p.N1499Tfs*5 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.V975A	0.377	61.0	0.0	0.0																									ROS1 p.V975A (Missense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Biologically Relevant				Somatic Variant	ESRP1	Frameshift	p.N512Tfs*2	0.4062	64.0	0.0	0.0																									ESRP1 p.N512Tfs*2 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.D47N	0.3846	65.0	0.0	0.0																									NTRK2 p.D47N (Missense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Biologically Relevant				Somatic Variant	FGFR2	Nonsense	p.R399*	0.2805	82.0	0.0	0.0																									FGFR2 p.R399* (Nonsense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.R326H	0.2857	49.0	0.0	0.0																									NTRK3 p.R326H (Missense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.R2269H	0.3434	99.0	0.0	0.0																									NF1 p.R2269H (Missense)		STAD_MUTECT2	TCGA-VQ-A91D-01A-11D-A410-08	TCGA-VQ-A91D-10A-01D-A413-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R448G	0.3846	52.0	0.0	0.0																									ROS1 p.R448G (Missense)		STAD_MUTECT2	TCGA-CD-8535-01A-11D-2340-08	TCGA-CD-8535-10A-01D-2341-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.P730S	0.25	68.0	0.0	0.0																									MLH1 p.P730S (Missense)		STAD_MUTECT2	TCGA-VQ-AA6D-01A-11D-A410-08	TCGA-VQ-AA6D-10A-01D-A413-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P57S	0.2727	55.0	0.0	0.0																									RUNX1T1 p.P57S (Missense)		STAD_MUTECT2	TCGA-VQ-AA6D-01A-11D-A410-08	TCGA-VQ-AA6D-10A-01D-A413-08
Biologically Relevant				Somatic Variant	COL1A1	Frameshift	p.G1088Dfs*20	0.3204	181.0	0.0	0.0																									COL1A1 p.G1088Dfs*20 (Frameshift)		STAD_MUTECT2	TCGA-VQ-AA6D-01A-11D-A410-08	TCGA-VQ-AA6D-10A-01D-A413-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.F610V	0.1143	35.0	0.0	0.0																									MTOR p.F610V (Missense)		STAD_MUTECT2	TCGA-BR-8589-01A-11D-2394-08	TCGA-BR-8589-10A-01D-2394-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.K471T	0.28	75.0	0.0	0.0																									MTOR p.K471T (Missense)		STAD_MUTECT2	TCGA-BR-8589-01A-11D-2394-08	TCGA-BR-8589-10A-01D-2394-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.R273Q	0.3538	65.0	0.0	0.0																									POT1 p.R273Q (Missense)		STAD_MUTECT2	TCGA-VQ-A8E7-01B-11D-A410-08	TCGA-VQ-A8E7-10B-01D-A413-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.R627Q	0.2407	108.0	0.0	0.0																									RAF1 p.R627Q (Missense)		STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Biologically Relevant				Somatic Variant	MLH1	Nonsense	p.R659*	0.2404	104.0	0.0	0.0																									MLH1 p.R659* (Nonsense)		STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.R61H	0.2222	126.0	0.0	0.0																									FGFR2 p.R61H (Missense)		STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.A1083T	0.3571	14.0	0.0	0.0																									COL1A1 p.A1083T (Missense)		STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.A353T	0.3064	359.0	0.0	0.0																									CCNE1 p.A353T (Missense)		STAD_MUTECT2	TCGA-FP-A4BE-01A-12D-A24D-08	TCGA-FP-A4BE-11A-11D-A24F-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.K647T	0.2241	116.0	0.0	0.0																									PMS2 p.K647T (Missense)		STAD_MUTECT2	TCGA-HU-A4GH-01A-11D-A24D-08	TCGA-HU-A4GH-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.K668T	0.1818	22.0	0.0	0.0																									FGFR2 p.K668T (Missense)		STAD_MUTECT2	TCGA-HU-A4GH-01A-11D-A24D-08	TCGA-HU-A4GH-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.I157S	0.093	43.0	0.0	0.0																									TMPRSS2 p.I157S (Missense)		STAD_MUTECT2	TCGA-HU-A4GH-01A-11D-A24D-08	TCGA-HU-A4GH-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.G570R	0.1394	165.0	0.0	0.0																									FGFR2 p.G570R (Missense)		STAD_MUTECT2	TCGA-BR-6566-01A-11D-1800-08	TCGA-BR-6566-10A-01D-1800-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.A23T	0.2561	82.0	0.0	0.0																									EWSR1 p.A23T (Missense)		STAD_MUTECT2	TCGA-BR-6566-01A-11D-1800-08	TCGA-BR-6566-10A-01D-1800-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R395W	0.0408	147.0	0.0	0.0																									RUNX1T1 p.R395W (Missense)		STAD_MUTECT2	TCGA-BR-8381-01A-11D-2394-08	TCGA-BR-8381-10A-01D-2394-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.T2294A	0.1262	103.0	0.0	0.0																									MTOR p.T2294A (Missense)		STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.L122I	0.0926	162.0	0.0	0.0																									NTRK1 p.L122I (Missense)		STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.A620T	0.1338	157.0	0.0	0.0																									RAF1 p.A620T (Missense)		STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.Y164H	0.1312	160.0	0.0	0.0																									ESRP1 p.Y164H (Missense)		STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R552*	0.1383	94.0	0.0	0.0																									RB1 p.R552* (Nonsense)		STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.R914W	0.1594	251.0	0.0	0.0																									NF1 p.R914W (Missense)		STAD_MUTECT2	TCGA-BR-8363-01A-11D-2340-08	TCGA-BR-8363-10A-01D-2341-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.V134M	0.1094	64.0	0.0	0.0																									ERG p.V134M (Missense)		STAD_MUTECT2	TCGA-CD-5801-01A-11D-1600-08	TCGA-CD-5801-10A-01D-1600-08
Biologically Relevant				Somatic Variant	ESRP1	Splice Site	p.X657_splice	0.2759	29.0	0.0	0.0																									ESRP1 p.X657_splice (Splice Site)		STAD_MUTECT2	TCGA-CG-4477-01A-01D-1158-08	TCGA-CG-4477-10A-01D-1158-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G2048D	0.1613	62.0	0.0	0.0																									ROS1 p.G2048D (Missense)		STAD_MUTECT2	TCGA-D7-6526-01A-11D-1800-08	TCGA-D7-6526-10A-01D-1800-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.R273H	0.3333	156.0	0.0	0.0																									PDGFRB p.R273H (Missense)		STAD_MUTECT2	TCGA-HU-A4G9-01A-11D-A24D-08	TCGA-HU-A4G9-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.S494L	0.449	98.0	0.0	0.0																									PMS2 p.S494L (Missense)		STAD_MUTECT2	TCGA-HU-A4G9-01A-11D-A24D-08	TCGA-HU-A4G9-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	ESRP1	Frameshift	p.N512Tfs*2	0.2826	92.0	0.0	0.0																									ESRP1 p.N512Tfs*2 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4G9-01A-11D-A24D-08	TCGA-HU-A4G9-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.D577N	0.25	116.0	0.0	0.0																									POT1 p.D577N (Missense)		STAD_MUTECT2	TCGA-VQ-A8P5-01A-11D-A397-08	TCGA-VQ-A8P5-10A-01D-A39A-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.T306I	0.3279	61.0	0.0	0.0																									NTRK2 p.T306I (Missense)		STAD_MUTECT2	TCGA-HU-A4GT-01A-21D-A25D-08	TCGA-HU-A4GT-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.R192*	0.3846	26.0	0.0	0.0																									NF1 p.R192* (Nonsense)		STAD_MUTECT2	TCGA-HU-A4GT-01A-21D-A25D-08	TCGA-HU-A4GT-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.N2470Mfs*19	0.3125	64.0	0.0	0.0																									NF1 p.N2470Mfs*19 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4GT-01A-21D-A25D-08	TCGA-HU-A4GT-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.R486H	0.3901	141.0	0.0	0.0																									EWSR1 p.R486H (Missense)		STAD_MUTECT2	TCGA-HU-A4GT-01A-21D-A25D-08	TCGA-HU-A4GT-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.R481H	0.2059	68.0	0.0	0.0																									FIP1L1 p.R481H (Missense)		STAD_MUTECT2	TCGA-BR-7851-01A-11D-2201-08	TCGA-BR-7851-10A-01D-2201-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.R991C	0.4706	34.0	0.0	0.0																									PDGFRB p.R991C (Missense)		STAD_MUTECT2	TCGA-BR-7851-01A-11D-2201-08	TCGA-BR-7851-10A-01D-2201-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1152T	0.3333	15.0	0.0	0.0																									ROS1 p.P1152T (Missense)		STAD_MUTECT2	TCGA-BR-7851-01A-11D-2201-08	TCGA-BR-7851-10A-01D-2201-08
Biologically Relevant				Somatic Variant	AURKB	Missense	p.S313L	0.5588	34.0	0.0	0.0																									AURKB p.S313L (Missense)		STAD_MUTECT2	TCGA-BR-7851-01A-11D-2201-08	TCGA-BR-7851-10A-01D-2201-08
Biologically Relevant				Somatic Variant	KEAP1	Nonsense	p.Q20*	0.075	40.0	0.0	0.0																									KEAP1 p.Q20* (Nonsense)		STAD_MUTECT2	TCGA-BR-7851-01A-11D-2201-08	TCGA-BR-7851-10A-01D-2201-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.A439V	0.2821	39.0	0.0	0.0																									ERG p.A439V (Missense)		STAD_MUTECT2	TCGA-BR-7851-01A-11D-2201-08	TCGA-BR-7851-10A-01D-2201-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.A399T	0.0625	64.0	0.0	0.0																									TMPRSS2 p.A399T (Missense)		STAD_MUTECT2	TCGA-B7-A5TK-01A-12D-A31L-08	TCGA-B7-A5TK-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	MLH1	Frameshift	p.K196Nfs*6	0.1364	418.0	0.0	0.0																									MLH1 p.K196Nfs*6 (Frameshift)		STAD_MUTECT2	TCGA-BR-6802-01A-11D-1882-08	TCGA-BR-6802-10A-01D-1882-08
Biologically Relevant				Somatic Variant	ERG	Frameshift	p.P411Rfs*25	0.0842	95.0	0.0	0.0																									ERG p.P411Rfs*25 (Frameshift)		STAD_MUTECT2	TCGA-F1-A448-01A-11D-A24D-08	TCGA-F1-A448-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R1616H	0.2179	78.0	0.0	0.0																									MTOR p.R1616H (Missense)		STAD_MUTECT2	TCGA-HU-A4GX-01A-12D-A25D-08	TCGA-HU-A4GX-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.E270K	0.2143	154.0	0.0	0.0																									MTOR p.E270K (Missense)		STAD_MUTECT2	TCGA-HU-A4GX-01A-12D-A25D-08	TCGA-HU-A4GX-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.V82M	0.2154	65.0	0.0	0.0																									CDKN2A p.V82M (Missense)		STAD_MUTECT2	TCGA-HU-A4GX-01A-12D-A25D-08	TCGA-HU-A4GX-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.G23R	0.4615	26.0	0.0	0.0																									CDKN2A p.G23R (Missense)		STAD_MUTECT2	TCGA-IN-A7NT-01A-21D-A34U-08	TCGA-IN-A7NT-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.K84N	0.0857	70.0	0.0	0.0																									KEAP1 p.K84N (Missense)		STAD_MUTECT2	TCGA-MX-A666-01A-11D-A31L-08	TCGA-MX-A666-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.R79C	0.3333	45.0	0.0	0.0																									SLC45A3 p.R79C (Missense)		STAD_MUTECT2	TCGA-SW-A7EA-01A-12D-A34U-08	TCGA-SW-A7EA-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.A887S	0.5745	47.0	0.0	0.0																									ROS1 p.A887S (Missense)		STAD_MUTECT2	TCGA-SW-A7EA-01A-12D-A34U-08	TCGA-SW-A7EA-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	PAK1	Missense	p.V87A	0.1902	163.0	0.0	0.0																									PAK1 p.V87A (Missense)		STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.L134V	0.2143	154.0	0.0	0.0																									RB1 p.L134V (Missense)		STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.V452I	0.1961	204.0	0.0	0.0																									IL12RB1 p.V452I (Missense)		STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Biologically Relevant				Somatic Variant	IL12RB1	Nonsense	p.R283*	0.2	45.0	0.0	0.0																									IL12RB1 p.R283* (Nonsense)		STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.A380T	0.2217	221.0	0.0	0.0																									TPX2 p.A380T (Missense)		STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.A53T	0.2564	78.0	0.0	0.0																									TMPRSS2 p.A53T (Missense)		STAD_MUTECT2	TCGA-CG-5723-01A-11D-1600-08	TCGA-CG-5723-11A-02D-1600-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.N915S	0.0974	154.0	0.0	0.0																									PDGFRB p.N915S (Missense)		STAD_MUTECT2	TCGA-D7-6524-01A-11D-1800-08	TCGA-D7-6524-10A-01D-1800-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.Y2225C	0.25	20.0	0.0	0.0																									MTOR p.Y2225C (Missense)		STAD_MUTECT2	TCGA-VQ-A8PE-01A-11D-A410-08	TCGA-VQ-A8PE-10A-01D-A413-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.E570A	0.1389	72.0	0.0	0.0																									PDGFRB p.E570A (Missense)		STAD_MUTECT2	TCGA-D7-8573-01A-11D-2340-08	TCGA-D7-8573-10A-01D-2341-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.L78R	0.1509	106.0	0.0	0.0																									TACC3 p.L78R (Missense)		STAD_MUTECT2	TCGA-VQ-A8PY-01A-11D-A410-08	TCGA-VQ-A8PY-10A-01D-A413-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.L16R	0.375	8.0	0.0	0.0																									CDKN2A p.L16R (Missense)		STAD_MUTECT2	TCGA-VQ-A91V-01A-11D-A410-08	TCGA-VQ-A91V-10B-01D-A413-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.G462R	0.5	36.0	0.0	0.0																									SLC45A3 p.G462R (Missense)		STAD_MUTECT2	TCGA-VQ-A92D-01A-11D-A410-08	TCGA-VQ-A92D-10A-01D-A413-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.G252D	0.119	42.0	0.0	0.0																									RUNX1T1 p.G252D (Missense)		STAD_MUTECT2	TCGA-D7-6521-01A-11D-1800-08	TCGA-D7-6521-10A-01D-1800-08
Biologically Relevant				Somatic Variant	MLH1	Splice Site	p.X103_splice	0.193	57.0	0.0	0.0																									MLH1 p.X103_splice (Splice Site)		STAD_MUTECT2	TCGA-R5-A7ZI-01A-11D-A34U-08	TCGA-R5-A7ZI-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.T320M	0.1316	76.0	0.0	0.0																									FGFR2 p.T320M (Missense)		STAD_MUTECT2	TCGA-R5-A7ZI-01A-11D-A34U-08	TCGA-R5-A7ZI-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.M1590I	0.0612	49.0	0.0	0.0																									MTOR p.M1590I (Missense)		STAD_MUTECT2	TCGA-BR-4267-01A-01D-1126-08	TCGA-BR-4267-11A-01D-1126-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R881C	0.3343	329.0	0.0	0.0																									MTOR p.R881C (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.N722D	0.3958	96.0	0.0	0.0																									MTOR p.N722D (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.T212M	0.4109	129.0	0.0	0.0																									FIP1L1 p.T212M (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.G407D	0.4583	144.0	0.0	0.0																									RUNX1T1 p.G407D (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.G334D	0.5	78.0	0.0	0.0																									RUNX1T1 p.G334D (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.V126D	0.4074	54.0	0.0	0.0																									CDKN2A p.V126D (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.R1237C	0.3846	26.0	0.0	0.0																									BRD4 p.R1237C (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Biologically Relevant				Somatic Variant	AURKA	Missense	p.R56C	0.4	110.0	0.0	0.0																									AURKA p.R56C (Missense)		STAD_MUTECT2	TCGA-BR-8487-01A-11D-2394-08	TCGA-BR-8487-10A-01D-2394-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.R136H	0.0583	206.0	0.0	0.0																									NTRK2 p.R136H (Missense)		STAD_MUTECT2	TCGA-BR-8369-01A-11D-2340-08	TCGA-BR-8369-10A-01D-2341-08
Biologically Relevant				Somatic Variant	NTRK1	Splice Site	p.X452_splice	0.2614	88.0	0.0	0.0																									NTRK1 p.X452_splice (Splice Site)		STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.T105M	0.225	80.0	0.0	0.0																									FIP1L1 p.T105M (Missense)		STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R2096Q	0.2222	153.0	0.0	0.0																									ROS1 p.R2096Q (Missense)		STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.E670G	0.119	84.0	0.0	0.0																									FGFR1 p.E670G (Missense)		STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.V377I	0.2088	182.0	0.0	0.0																									RUNX1T1 p.V377I (Missense)		STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.C382R	0.12	125.0	0.0	0.0																									FGFR2 p.C382R (Missense)		STAD_MUTECT2	TCGA-HU-8602-01A-11D-2394-08	TCGA-HU-8602-10A-01D-2394-08
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.L91Pfs*29	0.2338	77.0	0.0	0.0																									CDKN2A p.L91Pfs*29 (Frameshift)		STAD_MUTECT2	TCGA-HU-A4G8-01A-11D-A25D-08	TCGA-HU-A4G8-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.Q50*	0.2586	290.0	0.0	0.0																									CDKN2A p.Q50* (Nonsense)		STAD_MUTECT2	TCGA-HU-A4G8-01A-11D-A25D-08	TCGA-HU-A4G8-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.R471H	0.2048	83.0	0.0	0.0																									EWSR1 p.R471H (Missense)		STAD_MUTECT2	TCGA-HU-A4G8-01A-11D-A25D-08	TCGA-HU-A4G8-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.C365R	0.4545	11.0	0.0	0.0																									LIMK2 p.C365R (Missense)		STAD_MUTECT2	TCGA-HU-A4G8-01A-11D-A25D-08	TCGA-HU-A4G8-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.D1217E	0.1346	52.0	0.0	0.0																									NF1 p.D1217E (Missense)		STAD_MUTECT2	TCGA-RD-A8N1-01A-12D-A364-08	TCGA-RD-A8N1-10A-01D-A362-08
Biologically Relevant				Somatic Variant	MLH1	Nonsense	p.Q149*	0.5116	43.0	0.0	0.0																									MLH1 p.Q149* (Nonsense)		STAD_MUTECT2	TCGA-B7-A5TI-01A-11D-A31L-08	TCGA-B7-A5TI-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.R80H	0.3235	34.0	0.0	0.0																									FGFR1 p.R80H (Missense)		STAD_MUTECT2	TCGA-B7-A5TI-01A-11D-A31L-08	TCGA-B7-A5TI-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.T370A	0.2583	120.0	0.0	0.0																									FGFR2 p.T370A (Missense)		STAD_MUTECT2	TCGA-B7-A5TI-01A-11D-A31L-08	TCGA-B7-A5TI-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G320C	0.1923	52.0	0.0	0.0																									COL1A1 p.G320C (Missense)		STAD_MUTECT2	TCGA-B7-A5TI-01A-11D-A31L-08	TCGA-B7-A5TI-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	POLE2	Missense	p.R9W	0.6429	14.0	0.0	0.0																									POLE2 p.R9W (Missense)		STAD_MUTECT2	TCGA-FP-7829-01A-11D-2053-08	TCGA-FP-7829-10A-01D-2053-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.E425K	0.1111	108.0	0.0	0.0																									MYC p.E425K (Missense)		STAD_MUTECT2	TCGA-R5-A7O7-01A-11D-A33T-08	TCGA-R5-A7O7-10A-01D-A33W-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.D74Y	0.3889	18.0	0.0	0.0																									CDKN2A p.D74Y (Missense)		STAD_MUTECT2	TCGA-R5-A7O7-01A-11D-A33T-08	TCGA-R5-A7O7-10A-01D-A33W-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.A974V	0.3333	96.0	0.0	0.0																									ROS1 p.A974V (Missense)		STAD_MUTECT2	TCGA-VQ-A91U-01A-11D-A410-08	TCGA-VQ-A91U-10A-01D-A413-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Y1254*	0.5627	263.0	0.0	0.0																									NF1 p.Y1254* (Nonsense)		STAD_MUTECT2	TCGA-VQ-A91U-01A-11D-A410-08	TCGA-VQ-A91U-10A-01D-A413-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.T2206R	0.5	72.0	0.0	0.0																									NF1 p.T2206R (Missense)		STAD_MUTECT2	TCGA-D7-A6EV-01A-11D-A31L-08	TCGA-D7-A6EV-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.K362N	0.7658	363.0	0.0	0.0																									TPX2 p.K362N (Missense)		STAD_MUTECT2	TCGA-VQ-A8PH-01A-12D-A410-08	TCGA-VQ-A8PH-10A-01D-A413-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.A178T	0.2385	130.0	0.0	0.0																									CCNE1 p.A178T (Missense)		STAD_MUTECT2	TCGA-CG-5733-01A-11D-1600-08	TCGA-CG-5733-11A-01D-1600-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.A319T	0.1319	91.0	0.0	0.0																									RAF1 p.A319T (Missense)		STAD_MUTECT2	TCGA-BR-8059-01A-11D-2340-08	TCGA-BR-8059-10A-01D-2340-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.R440P	0.1705	88.0	0.0	0.0																									NF1 p.R440P (Missense)		STAD_MUTECT2	TCGA-3M-AB47-01A-22D-A410-08	TCGA-3M-AB47-10A-01D-A413-08
Biologically Relevant				Somatic Variant	EML4	Frameshift	p.E130Rfs*43	0.2917	48.0	0.0	0.0																									EML4 p.E130Rfs*43 (Frameshift)		STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.R223M	0.125	64.0	0.0	0.0																									RAF1 p.R223M (Missense)		STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.V415M	0.3226	93.0	0.0	0.0																									PMS2 p.V415M (Missense)		STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.A356T	0.2241	58.0	0.0	0.0																									POT1 p.A356T (Missense)		STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.F452L	0.0667	105.0	0.0	0.0																									NTRK2 p.F452L (Missense)		STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.M379L	0.237	135.0	0.0	0.0																									RB1 p.M379L (Missense)		STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Biologically Relevant				Somatic Variant	AURKB	Missense	p.A300V	0.2647	68.0	0.0	0.0																									AURKB p.A300V (Missense)		STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.D1481E	0.3315	181.0	0.0	0.0																									NF1 p.D1481E (Missense)		STAD_MUTECT2	TCGA-BR-4361-01A-01D-1158-08	TCGA-BR-4361-11A-01D-1158-08
Biologically Relevant				Somatic Variant	MTOR	Frameshift	p.R766Dfs*11	0.1077	195.0	0.0	0.0																									MTOR p.R766Dfs*11 (Frameshift)		STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.N246S	0.1	80.0	0.0	0.0																									EML4 p.N246S (Missense)		STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.V44L	0.0806	62.0	0.0	0.0																									TACC3 p.V44L (Missense)		STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.F71S	0.0611	180.0	0.0	0.0																									RUNX1T1 p.F71S (Missense)		STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.I782M	0.1228	391.0	0.0	0.0																									RB1 p.I782M (Missense)		STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.A1189V	0.1129	124.0	0.0	0.0																									BRD4 p.A1189V (Missense)		STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Biologically Relevant				Somatic Variant	AURKA	Missense	p.V84E	0.1235	243.0	0.0	0.0																									AURKA p.V84E (Missense)		STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.R455W	0.1056	180.0	0.0	0.0																									EWSR1 p.R455W (Missense)		STAD_MUTECT2	TCGA-B7-5816-01A-21D-1600-08	TCGA-B7-5816-10A-01D-1600-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.A386V	0.2405	79.0	0.0	0.0																									ESRP1 p.A386V (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.D676V	0.2679	56.0	0.0	0.0																									NTRK2 p.D676V (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.H483R	0.2083	24.0	0.0	0.0																									RB1 p.H483R (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.H486N	0.2308	26.0	0.0	0.0																									NTRK3 p.H486N (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	AURKB	Missense	p.R284H	0.2121	33.0	0.0	0.0																									AURKB p.R284H (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.Y1607Lfs*15	0.2979	47.0	0.0	0.0																									NF1 p.Y1607Lfs*15 (Frameshift)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.R1870Q	0.1633	49.0	0.0	0.0																									NF1 p.R1870Q (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R370C	0.2717	92.0	0.0	0.0																									COL1A1 p.R370C (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.V214M	0.1	60.0	0.0	0.0																									KEAP1 p.V214M (Missense)		STAD_MUTECT2	TCGA-CD-A4MG-01A-11D-A25D-08	TCGA-CD-A4MG-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.I605F	0.1295	139.0	0.0	0.0																									NF1 p.I605F (Missense)		STAD_MUTECT2	TCGA-CG-4440-01A-01D-1158-08	TCGA-CG-4440-10A-01D-1158-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.V325M	0.1014	69.0	0.0	0.0																									FGFR1 p.V325M (Missense)		STAD_MUTECT2	TCGA-BR-6453-01A-11D-1800-08	TCGA-BR-6453-11A-01D-1800-08
Biologically Relevant				Somatic Variant	EML4	Frameshift	p.E127Kfs*46	0.2727	22.0	0.0	0.0																									EML4 p.E127Kfs*46 (Frameshift)		STAD_MUTECT2	TCGA-HF-7132-01A-11D-2053-08	TCGA-HF-7132-10A-01D-2053-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.R398L	0.2368	76.0	0.0	0.0																									RAF1 p.R398L (Missense)		STAD_MUTECT2	TCGA-HF-7132-01A-11D-2053-08	TCGA-HF-7132-10A-01D-2053-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.D520G	0.144	125.0	0.0	0.0																									POT1 p.D520G (Missense)		STAD_MUTECT2	TCGA-HF-7132-01A-11D-2053-08	TCGA-HF-7132-10A-01D-2053-08
Biologically Relevant				Somatic Variant	POLE2	Missense	p.C74Y	0.099	101.0	0.0	0.0																									POLE2 p.C74Y (Missense)		STAD_MUTECT2	TCGA-HF-7132-01A-11D-2053-08	TCGA-HF-7132-10A-01D-2053-08
Biologically Relevant				Somatic Variant	FLI1	Frameshift	p.P113Lfs*5	0.2222	36.0	0.0	0.0																									FLI1 p.P113Lfs*5 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A924-01A-11D-A410-08	TCGA-VQ-A924-10A-01D-A413-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.Q542H	0.283	53.0	0.0	0.0																									IL12RB1 p.Q542H (Missense)		STAD_MUTECT2	TCGA-VQ-A924-01A-11D-A410-08	TCGA-VQ-A924-10A-01D-A413-08
Biologically Relevant				Somatic Variant	PDGFB	Frameshift	p.K220Rfs*16	0.4783	23.0	0.0	0.0																									PDGFB p.K220Rfs*16 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A924-01A-11D-A410-08	TCGA-VQ-A924-10A-01D-A413-08
Biologically Relevant				Somatic Variant	MDM2	Missense	p.T285P	0.172	186.0	0.0	0.0																									MDM2 p.T285P (Missense)		STAD_MUTECT2	TCGA-BR-8365-01A-21D-2340-08	TCGA-BR-8365-10A-01D-2341-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.V82E	0.3333	12.0	0.0	0.0																									CDKN2A p.V82E (Missense)		STAD_MUTECT2	TCGA-VQ-AA64-01A-11D-A410-08	TCGA-VQ-AA64-10A-01D-A413-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R454C	0.2955	44.0	0.0	0.0																									MTOR p.R454C (Missense)		STAD_MUTECT2	TCGA-VQ-A91K-01A-11D-A410-08	TCGA-VQ-A91K-10A-01D-A413-08
Biologically Relevant				Somatic Variant	TACC3	Frameshift	p.M396Hfs*17	0.3731	67.0	0.0	0.0																									TACC3 p.M396Hfs*17 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A91K-01A-11D-A410-08	TCGA-VQ-A91K-10A-01D-A413-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.T485A	0.35	80.0	0.0	0.0																									PMS2 p.T485A (Missense)		STAD_MUTECT2	TCGA-VQ-A91K-01A-11D-A410-08	TCGA-VQ-A91K-10A-01D-A413-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.P285S	0.3974	78.0	0.0	0.0																									FGFR1 p.P285S (Missense)		STAD_MUTECT2	TCGA-VQ-A91K-01A-11D-A410-08	TCGA-VQ-A91K-10A-01D-A413-08
Biologically Relevant				Somatic Variant	ESRP1	Frameshift	p.N512Tfs*2	0.3818	55.0	0.0	0.0																									ESRP1 p.N512Tfs*2 (Frameshift)		STAD_MUTECT2	TCGA-VQ-A91K-01A-11D-A410-08	TCGA-VQ-A91K-10A-01D-A413-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.R416Q	0.375	112.0	0.0	0.0																									NF1 p.R416Q (Missense)		STAD_MUTECT2	TCGA-VQ-A91K-01A-11D-A410-08	TCGA-VQ-A91K-10A-01D-A413-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.C2067G	0.0855	117.0	0.0	0.0																									ROS1 p.C2067G (Missense)		STAD_MUTECT2	TCGA-D7-6528-01A-11D-1800-08	TCGA-D7-6528-10A-01D-1800-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.V349I	0.265	117.0	0.0	0.0																									IL12RB1 p.V349I (Missense)		STAD_MUTECT2	TCGA-D7-6528-01A-11D-1800-08	TCGA-D7-6528-10A-01D-1800-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.G635V	0.1667	18.0	0.0	0.0																									EWSR1 p.G635V (Missense)		STAD_MUTECT2	TCGA-D7-6528-01A-11D-1800-08	TCGA-D7-6528-10A-01D-1800-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.Q657L	0.1538	26.0	0.0	0.0																									ESRP1 p.Q657L (Missense)		STAD_MUTECT2	TCGA-IN-A7NR-01A-11D-A34U-08	TCGA-IN-A7NR-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R395W	0.15	100.0	0.0	0.0																									RUNX1T1 p.R395W (Missense)		STAD_MUTECT2	TCGA-BR-4256-01A-01D-1126-08	TCGA-BR-4256-11A-01D-1126-08
Biologically Relevant				Somatic Variant	MYC	Deletion	p.S283del	0.1176	51.0	0.0	0.0																									MYC p.S283del (Deletion)		STAD_MUTECT2	TCGA-BR-4256-01A-01D-1126-08	TCGA-BR-4256-11A-01D-1126-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E335D	0.086	93.0	0.0	0.0																									FGFR2 p.E335D (Missense)		STAD_MUTECT2	TCGA-BR-4256-01A-01D-1126-08	TCGA-BR-4256-11A-01D-1126-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.D277G	0.1121	107.0	0.0	0.0																									NTRK3 p.D277G (Missense)		STAD_MUTECT2	TCGA-BR-4256-01A-01D-1126-08	TCGA-BR-4256-11A-01D-1126-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.H2480R	0.1566	83.0	0.0	0.0																									NF1 p.H2480R (Missense)		STAD_MUTECT2	TCGA-BR-4256-01A-01D-1126-08	TCGA-BR-4256-11A-01D-1126-08
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.R112Vfs*34	0.4	45.0	0.0	0.0																									CDKN2A p.R112Vfs*34 (Frameshift)		STAD_MUTECT2	TCGA-HF-7136-01A-11D-2053-08	TCGA-HF-7136-10A-01D-2053-08
Biologically Relevant				Somatic Variant	CDKN2A	Deletion	p.L32_L37del	0.5263	76.0	0.0	0.0																									CDKN2A p.L32_L37del (Deletion)		STAD_MUTECT2	TCGA-HF-7136-01A-11D-2053-08	TCGA-HF-7136-10A-01D-2053-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.Q444L	0.163	92.0	0.0	0.0																									RB1 p.Q444L (Missense)		STAD_MUTECT2	TCGA-BR-A4J2-01A-21D-A25D-08	TCGA-BR-A4J2-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P904S	0.4286	7.0	0.0	0.0																									BRD4 p.P904S (Missense)		STAD_MUTECT2	TCGA-HU-A4H0-01A-11D-A25D-08	TCGA-HU-A4H0-11A-11D-A25E-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.D1192V	0.194	201.0	0.0	0.0																									ROS1 p.D1192V (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.Y591C	0.1839	87.0	0.0	0.0																									ESRP1 p.Y591C (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.V157A	0.1857	237.0	0.0	0.0																									RB1 p.V157A (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.S592G	0.2308	169.0	0.0	0.0																									NF1 p.S592G (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q2824*	0.2308	78.0	0.0	0.0																									NF1 p.Q2824* (Nonsense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.T541I	0.1389	72.0	0.0	0.0																									KEAP1 p.T541I (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.C288R	0.2027	74.0	0.0	0.0																									KEAP1 p.C288R (Missense)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Biologically Relevant				Somatic Variant	EWSR1	Nonstop	p.*657Yext*16	0.06	150.0	0.0	0.0																									EWSR1 p.*657Yext*16 (Nonstop)		STAD_MUTECT2	TCGA-CG-5721-01A-11D-1600-08	TCGA-CG-5721-11A-01D-1600-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R320*	0.9341	91.0	0.0	0.0																									RB1 p.R320* (Nonsense)		STAD_MUTECT2	TCGA-BR-A4CR-01A-11D-A24D-08	TCGA-BR-A4CR-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.H83Y	0.7273	11.0	0.0	0.0																									CDKN2A p.H83Y (Missense)		STAD_MUTECT2	TCGA-CD-5799-01A-11D-1600-08	TCGA-CD-5799-10A-01D-1600-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.V740M	0.2182	55.0	0.0	0.0																									FGFR1 p.V740M (Missense)		STAD_MUTECT2	TCGA-HU-A4H2-01A-11D-A25D-08	TCGA-HU-A4H2-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.T134I	0.1488	121.0	0.0	0.0																									FLI1 p.T134I (Missense)		STAD_MUTECT2	TCGA-VQ-A91X-01A-12D-A410-08	TCGA-VQ-A91X-10A-01D-A413-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.R145Q	0.0518	676.0	0.0	0.0																									CCNE1 p.R145Q (Missense)		STAD_MUTECT2	TCGA-CD-A487-01A-21D-A24D-08	TCGA-CD-A487-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.N214*	0.5278	36.0	0.0	0.0																									NF1 p.N214* (Frameshift)		STAD_MUTECT2	TCGA-BR-A44U-01A-11D-A24D-08	TCGA-BR-A44U-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.R80Q	0.5429	35.0	0.0	0.0																									CDKN2A p.R80Q (Missense)		STAD_MUTECT2	TCGA-BR-4366-01A-01D-1158-08	TCGA-BR-4366-11A-01D-1158-08
Biologically Relevant				Somatic Variant	LIMK2	Frameshift	p.I104Hfs*71	0.125	32.0	0.0	0.0																									LIMK2 p.I104Hfs*71 (Frameshift)		STAD_MUTECT2	TCGA-CD-8527-01A-11D-2340-08	TCGA-CD-8527-10A-01D-2341-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.A268V	0.2679	209.0	0.0	0.0																									NTRK2 p.A268V (Missense)		STAD_MUTECT2	TCGA-BR-8284-01A-11D-2340-08	TCGA-BR-8284-10A-01D-2340-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.K566T	0.1194	67.0	0.0	0.0																									NTRK2 p.K566T (Missense)		STAD_MUTECT2	TCGA-BR-8284-01A-11D-2340-08	TCGA-BR-8284-10A-01D-2340-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.R659Q	0.0595	185.0	0.0	0.0																									NF1 p.R659Q (Missense)		STAD_MUTECT2	TCGA-BR-8284-01A-11D-2340-08	TCGA-BR-8284-10A-01D-2340-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R240H	0.2925	106.0	0.0	0.0																									COL1A1 p.R240H (Missense)		STAD_MUTECT2	TCGA-VQ-A8E0-01A-11D-A410-08	TCGA-VQ-A8E0-10B-01D-A413-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.V321M	0.2353	17.0	0.0	0.0																									NTRK1 p.V321M (Missense)		STAD_MUTECT2	TCGA-BR-7703-01A-11D-2053-08	TCGA-BR-7703-10A-01D-2053-08
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.P219H	0.52	25.0	0.0	0.0																									PDGFB p.P219H (Missense)		STAD_MUTECT2	TCGA-BR-7703-01A-11D-2053-08	TCGA-BR-7703-10A-01D-2053-08
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.R39H	0.2407	54.0	0.0	0.0																									PDGFB p.R39H (Missense)		STAD_MUTECT2	TCGA-BR-7703-01A-11D-2053-08	TCGA-BR-7703-10A-01D-2053-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R1482C	0.3053	226.0	0.0	0.0																									MTOR p.R1482C (Missense)		STAD_MUTECT2	TCGA-HJ-7597-01A-21D-2201-08	TCGA-HJ-7597-10A-01D-2201-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.R106H	0.2979	141.0	0.0	0.0																									PDGFRB p.R106H (Missense)		STAD_MUTECT2	TCGA-HJ-7597-01A-21D-2201-08	TCGA-HJ-7597-10A-01D-2201-08
Biologically Relevant				Somatic Variant	ESRP1	Frameshift	p.N512Tfs*2	0.2745	51.0	0.0	0.0																									ESRP1 p.N512Tfs*2 (Frameshift)		STAD_MUTECT2	TCGA-HJ-7597-01A-21D-2201-08	TCGA-HJ-7597-10A-01D-2201-08
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.A36Gfs*8	0.6522	115.0	0.0	0.0																									CDKN2A p.A36Gfs*8 (Frameshift)		STAD_MUTECT2	TCGA-HJ-7597-01A-21D-2201-08	TCGA-HJ-7597-10A-01D-2201-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.T942M	0.2286	35.0	0.0	0.0																									BRD4 p.T942M (Missense)		STAD_MUTECT2	TCGA-HJ-7597-01A-21D-2201-08	TCGA-HJ-7597-10A-01D-2201-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R957Q	0.35	80.0	0.0	0.0																									MTOR p.R957Q (Missense)		STAD_MUTECT2	TCGA-BR-8361-01A-11D-2340-08	TCGA-BR-8361-10A-01D-2340-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.A437V	0.3333	147.0	0.0	0.0																									RUNX1T1 p.A437V (Missense)		STAD_MUTECT2	TCGA-BR-8361-01A-11D-2340-08	TCGA-BR-8361-10A-01D-2340-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R311C	0.1918	146.0	0.0	0.0																									MTOR p.R311C (Missense)		STAD_MUTECT2	TCGA-BR-8382-01A-11D-2394-08	TCGA-BR-8382-10A-01D-2394-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.A570T	0.1167	60.0	0.0	0.0																									ESRP1 p.A570T (Missense)		STAD_MUTECT2	TCGA-BR-8382-01A-11D-2394-08	TCGA-BR-8382-10A-01D-2394-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.Y628Tfs*3	0.24	100.0	0.0	0.0																									NF1 p.Y628Tfs*3 (Frameshift)		STAD_MUTECT2	TCGA-BR-8382-01A-11D-2394-08	TCGA-BR-8382-10A-01D-2394-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R281C	0.1845	103.0	0.0	0.0																									MTOR p.R281C (Missense)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.Y778C	0.1339	112.0	0.0	0.0																									PDGFRB p.Y778C (Missense)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.E344K	0.1316	38.0	0.0	0.0																									POT1 p.E344K (Missense)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.R734W	0.2812	32.0	0.0	0.0																									FGFR1 p.R734W (Missense)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R380W	0.0662	151.0	0.0	0.0																									RUNX1T1 p.R380W (Missense)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.A187T	0.2424	33.0	0.0	0.0																									RUNX1T1 p.A187T (Missense)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.A373T	0.0952	105.0	0.0	0.0																									ESRP1 p.A373T (Missense)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.A34T	0.2273	66.0	0.0	0.0																									KEAP1 p.A34T (Missense)		STAD_MUTECT2	TCGA-BR-4184-01A-01D-1126-08	TCGA-BR-4184-11A-01D-1126-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.V1007I	0.4206	107.0	0.0	0.0																									PDGFRB p.V1007I (Missense)		STAD_MUTECT2	TCGA-HF-A5NB-01A-11D-A31L-08	TCGA-HF-A5NB-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L427P	0.5652	92.0	0.0	0.0																									ROS1 p.L427P (Missense)		STAD_MUTECT2	TCGA-HF-A5NB-01A-11D-A31L-08	TCGA-HF-A5NB-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.V1049A	0.1538	26.0	0.0	0.0																									NF1 p.V1049A (Missense)		STAD_MUTECT2	TCGA-HF-A5NB-01A-11D-A31L-08	TCGA-HF-A5NB-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.I1350V	0.4497	149.0	0.0	0.0																									NF1 p.I1350V (Missense)		STAD_MUTECT2	TCGA-HF-A5NB-01A-11D-A31L-08	TCGA-HF-A5NB-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.A1676T	0.5285	123.0	0.0	0.0																									NF1 p.A1676T (Missense)		STAD_MUTECT2	TCGA-HF-A5NB-01A-11D-A31L-08	TCGA-HF-A5NB-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P831L	0.4583	24.0	0.0	0.0																									BRD4 p.P831L (Missense)		STAD_MUTECT2	TCGA-HF-A5NB-01A-11D-A31L-08	TCGA-HF-A5NB-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.R78H	0.4833	60.0	0.0	0.0																									PDGFB p.R78H (Missense)		STAD_MUTECT2	TCGA-HF-A5NB-01A-11D-A31L-08	TCGA-HF-A5NB-10A-01D-A31J-08
Biologically Relevant				Microsatellite Stability	Supporting variants		DOCK3 p.P1852Qfs*45 (Frameshift), RNF43 p.G659Vfs*41 (Frameshift), PRDM2 p.E294Kfs*12 (Frameshift), JAK1 p.K142Rfs*26 (Frameshift), DOCK3 p.P1852Sfs*46 (Frameshift), ACVR2A p.K437Rfs*5 (Frameshift), PMS2 p.R151Afs*50 (Frameshift), MSH6 p.N897Ifs*9 (Frameshift), MLH1 p.R497Gfs*11 (Frameshift), RNF43 p.Y457* (Nonsense), ACVR2A p.D96Tfs*54 (Frameshift), MSH3 p.K383Rfs*32 (Frameshift), JAK1 p.R1103Sfs*5 (Frameshift), JAK1 p.K860Nfs*16 (Frameshift), JAK1 p.N339Ifs*3 (Frameshift), MSH6 p.F1104Lfs*11 (Frameshift), DOCK3 p.R776* (Nonsense), ACVR2A p.L7* (Nonsense), RNF43 p.D516Gfs*10 (Frameshift), MLH1 p.X226_splice (Splice Site), RNF43 p.N167Vfs*13 (Frameshift), JAK1 p.G673Vfs*30 (Frameshift), ESRP1 p.N512Tfs*2 (Frameshift), MLH1 p.R659* (Nonsense), POLE p.X2250_splice (Splice Site), MSH2 p.A230Lfs*16 (Frameshift), PMS2 p.D414Tfs*34 (Frameshift), MLH1 p.L155Efs*10 (Frameshift), MSH2 p.Y408* (Nonsense), DOCK3 p.K1976Sfs*185 (Frameshift), RNF43 p.Q254* (Nonsense), PRDM2 p.P987Lfs*54 (Frameshift), PRDM2 p.L1203Ffs*15 (Frameshift), ESRP1 p.E467Gfs*44 (Frameshift), RNF43 p.P594del (Deletion), DOCK3 p.X1861_splice (Splice Site), JAK1 p.P430Rfs*2 (Frameshift), DOCK3 p.F783Lfs*30 (Frameshift), RNF43 p.W159* (Nonsense), RNF43 p.R454Nfs*49 (Frameshift), MSH3 p.N385Qfs*19 (Frameshift), RNF43 p.L311Sfs*108 (Frameshift), ACVR2A p.C85* (Nonsense), RNF43 p.L311Pfs*132 (Frameshift), PRDM2 p.N1426Ifs*3 (Frameshift), JAK1 p.I143Dfs*9 (Frameshift), JAK1 p.L431Vfs*22 (Frameshift), MLH1 p.K255* (Nonsense), ESRP1 p.X657_splice (Splice Site), POLE p.V551Ffs*12 (Frameshift), MLH1 p.K196Nfs*6 (Frameshift), RNF43 p.A430Lfs*72 (Frameshift), RNF43 p.E277* (Nonsense), RNF43 p.I48Yfs*27 (Frameshift), MLH1 p.X103_splice (Splice Site), MLH1 p.Q149* (Nonsense), MSH3 p.X938_splice (Splice Site), RNF43 p.E401* (Nonsense), RNF43 p.R40* (Nonsense), RNF43 p.R330* (Nonsense), MSH3 p.W807* (Nonsense), POLE p.K1550Nfs*12 (Frameshift), RNF43 p.E662Pfs*77 (Frameshift), PRDM2 p.S773Ifs*19 (Frameshift), PRDM2 p.I574Ffs*12 (Frameshift), POLE p.F699Vfs*11 (Frameshift), DOCK3 p.G1834Vfs*63 (Frameshift), MSH2 p.K392Rfs*20 (Frameshift), POLE p.X111_splice (Splice Site), MSH2 p.F19Lfs*45 (Frameshift), ACVR2A p.L383* (Frameshift), POLE p.W243Lfs*20 (Frameshift), PRDM2 p.K1591Nfs*23 (Frameshift), DOCK3 p.G153Vfs*17 (Frameshift)																													Supporting variants: DOCK3 p.P1852Qfs*45 (Frameshift), RNF43 p.G659Vfs*41 (Frameshift), PRDM2 p.E294Kfs*12 (Frameshift), JAK1 p.K142Rfs*26 (Frameshift), DOCK3 p.P1852Sfs*46 (Frameshift), ACVR2A p.K437Rfs*5 (Frameshift), PMS2 p.R151Afs*50 (Frameshift), MSH6 p.N897Ifs*9 (Frameshift), MLH1 p.R497Gfs*11 (Frameshift), RNF43 p.Y457* (Nonsense), ACVR2A p.D96Tfs*54 (Frameshift), MSH3 p.K383Rfs*32 (Frameshift), JAK1 p.R1103Sfs*5 (Frameshift), JAK1 p.K860Nfs*16 (Frameshift), JAK1 p.N339Ifs*3 (Frameshift), MSH6 p.F1104Lfs*11 (Frameshift), DOCK3 p.R776* (Nonsense), ACVR2A p.L7* (Nonsense), RNF43 p.D516Gfs*10 (Frameshift), MLH1 p.X226_splice (Splice Site), RNF43 p.N167Vfs*13 (Frameshift), JAK1 p.G673Vfs*30 (Frameshift), ESRP1 p.N512Tfs*2 (Frameshift), MLH1 p.R659* (Nonsense), POLE p.X2250_splice (Splice Site), MSH2 p.A230Lfs*16 (Frameshift), PMS2 p.D414Tfs*34 (Frameshift), MLH1 p.L155Efs*10 (Frameshift), MSH2 p.Y408* (Nonsense), DOCK3 p.K1976Sfs*185 (Frameshift), RNF43 p.Q254* (Nonsense), PRDM2 p.P987Lfs*54 (Frameshift), PRDM2 p.L1203Ffs*15 (Frameshift), ESRP1 p.E467Gfs*44 (Frameshift), RNF43 p.P594del (Deletion), DOCK3 p.X1861_splice (Splice Site), JAK1 p.P430Rfs*2 (Frameshift), DOCK3 p.F783Lfs*30 (Frameshift), RNF43 p.W159* (Nonsense), RNF43 p.R454Nfs*49 (Frameshift), MSH3 p.N385Qfs*19 (Frameshift), RNF43 p.L311Sfs*108 (Frameshift), ACVR2A p.C85* (Nonsense), RNF43 p.L311Pfs*132 (Frameshift), PRDM2 p.N1426Ifs*3 (Frameshift), JAK1 p.I143Dfs*9 (Frameshift), JAK1 p.L431Vfs*22 (Frameshift), MLH1 p.K255* (Nonsense), ESRP1 p.X657_splice (Splice Site), POLE p.V551Ffs*12 (Frameshift), MLH1 p.K196Nfs*6 (Frameshift), RNF43 p.A430Lfs*72 (Frameshift), RNF43 p.E277* (Nonsense), RNF43 p.I48Yfs*27 (Frameshift), MLH1 p.X103_splice (Splice Site), MLH1 p.Q149* (Nonsense), MSH3 p.X938_splice (Splice Site), RNF43 p.E401* (Nonsense), RNF43 p.R40* (Nonsense), RNF43 p.R330* (Nonsense), MSH3 p.W807* (Nonsense), POLE p.K1550Nfs*12 (Frameshift), RNF43 p.E662Pfs*77 (Frameshift), PRDM2 p.S773Ifs*19 (Frameshift), PRDM2 p.I574Ffs*12 (Frameshift), POLE p.F699Vfs*11 (Frameshift), DOCK3 p.G1834Vfs*63 (Frameshift), MSH2 p.K392Rfs*20 (Frameshift), POLE p.X111_splice (Splice Site), MSH2 p.F19Lfs*45 (Frameshift), ACVR2A p.L383* (Frameshift), POLE p.W243Lfs*20 (Frameshift), PRDM2 p.K1591Nfs*23 (Frameshift), DOCK3 p.G153Vfs*17 (Frameshift)		STAD_MUTECT2		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.504																													COSMIC Signature (version 2) 1 (50%)		STAD_MUTECT2		
